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RÉSUMÉ 
 
La carnitine, un composé endogène présent dans la plupart des tissus animaux, est 
essentielle pour le transport des acides gras activés entre les organelles cellulaires et joue 
donc un rôle important dans le métabolisme des acides gras et dans la production d’énergie 
des cellules. La carnitine lie les acides gras et génère ainsi différentes acylcarnitines de 
longueurs de chaîne variables. La carnitine est également impliquée dans le maintien du 
réservoir cellulaire de coenzyme A libre et dans l’élimination d’acyl-CoAs potentiellement 
toxiques. Chez les mammifères, la carnitine est fournie pour deux tiers par un apport 
alimentaire et pour un tiers par biosynthèse à partir des acides aminés L-lysine et L-
méthionine. Comme la carnitine est présente dans la plupart des tissus à des concentrations 
bien supérieures à celle du plasma, sa distribution depuis ses sites d’absorption et de 
synthèse à travers l’organisme est assurée par des systèmes de transport. Dans de 
nombreuses maladies métaboliques, le métabolisme de la carnitine est fortement perturbé, 
aboutissant à une redistribution du réservoir de carnitine et d’acylcarnitines. La détermination 
individuelle de chaque acylcarnitine dans les fluides biologiques est un procédé approprié 
pour diagnostiquer ces maladies. Le but de cette thèse était de développer des méthodes 
analytiques pour la détermination de la carnitine et des acylcarnitines dans les fluides 
biologiques. Finalement, une des méthodes développées a été utilisée pour le suivi d’une 
étude clinique. 
 
Les connaissances actuelles sur la carnitine et les acylcarnitines, notamment les fonctions 
de la carnitine, sa biosynthèse et son homéostasie, sont passées en revue dans le premier 
chapitre. Des cas de déficiences en carnitine sont également présentés et une description 
des différentes méthodes analytiques utilisées pour la détermination de la carnitine et des 
acylcarnitines complète cette partie introductive. 
 
Le chapitre 2 décrit une méthode d’électrophorèse capillaire développée pour déterminer le 
profil de la carnitine et des acylcarnitines à courte et moyenne chaîne, ceci après une 
extraction en phase solide sur une colonne de silice. Cet essai permet la séparation de la 
carnitine et de cinq acylcarnitines dans des solutions de standard, dans l’urine et dans des 
échantillons d’urine enrichie. Il a été validé pour la détermination de la carnitine et de 
l’acétylcarnitine dans des solutions de standard. Finalement, la carnitine a été quantifiée 
dans des échantillons d’urine et les résultats ont été comparés avec ceux obtenus par un 
essai radio-enzymatique. 
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Le chapitre 3 présente une méthode utilisant la chromatographie liquide à haute 
performance couplée à une détection par spectrométrie de masse en mode MS/MS (HPLC-
MS/MS) pour la détermination de la carnitine et de huit différentes acylcarnitines, incluant les 
acylcarnitines à longue chaîne. Comme la détection est effectuée par spectrométrie de 
masse, une dérivatisation de la carnitine n’est pas nécessaire. Avant d’être injectés dans le 
système, les échantillons ont été soumis à une extraction en phase solide sur une colonne 
échangeuse de cations. La séparation à été obtenue en utilisant un réactif volatil de paires 
d’ions. La validation de la méthode pour la détermination de la carnitine dans des solutions 
de standard et des échantillons d’urine a été effectuée en utilisant un dérivé isotopique 
stable comme standard interne et de l’eau comme matrice de calibration. Les résultats 
obtenus pour la quantification de la carnitine dans des échantillons d’urine ont été comparés 
avec ceux issus d’une méthode radio-enzymatique. L’application à des échantillons d’urine 
provenant de patients souffrant de différentes aciduries organiques à permis de confirmer le 
diagnostic de ces maladies. 
 
L’extension de la méthode HPLC-MS/MS à des échantillons de plasma, après des 
modifications mineures du protocole d’extraction, notamment la précipitation des protéines, 
est rapportée dans le chapitre 4. La butyrobetaine (précurseur direct de la carnitine lors de 
sa biosynthèse) qui, au contraire de l’urine, est présente dans le plasma, a pu être 
déterminée avec la même méthode d’analyse. La quantification de la carnitine, de 
l’acétylcarnitine, de la propionylcarnitine, de l’isovalérylcarnitine, de l’hexanoylcarnitine, de 
l’octanoylcarnitine et de la butyrobetaine a été validée pour des solutions de standard et des 
échantillons de plasma en utilisant une solution aqueuse à 4% d’albumine sérique de bœuf 
comme matrice de calibration. Un échantillon de sérum d’un patient souffrant d’acidurie 
méthylmalonique a pu être identifié comme caractéristique de cette maladie. 
 
Une application pratique de cette méthode HPLC-MS/MS est présentée dans le chapitre 5. 
Une étude clinique à été menée avec sept patients atteints d’insuffisance rénale terminale et 
suivant un traitement de dialyse. La carnitine est efficacement éliminée au cours de la 
dialyse, provoquant ainsi une diminution des taux plasmatiques de carnitine et une 
augmentation relative de ceux des acylcarnitines. Le but de l’étude était d’identifier la 
composition plasmatique en carnitine et en acylcarnitines chez ces patients, tant en 
conditions de base qu’après administration de carnitine à la fin de chaque dialyse. Les 
cinétiques d’extraction de la carnitine et des acylcarnitines pendant la dialyse et leurs 
cinétiques après une administration intraveineuse post-dialyse de carnitine ont été étudiées. 
Une comparaison à été établie entre les conditions de base (sans substitution) et lorsque les 
patients étaient substitués avec deux dosages différents de carnitine. L’administration de 
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carnitine a permis de corriger les faibles taux plasmatiques de carnitine et d’augmenter 
l’extraction des acylcarnitines, suggérant qu’une administration de carnitine aux patients 
sous dialyse pourrait être bénéfique pour l’élimination de groupements acyls potentiellement 
toxiques. 
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ZUSAMMENFASSUNG 
 
Carnitin, eine endogene Substanz die sich in den meisten Geweben der Säugetiere befindet, 
ist essentiell für den Transport von aktivierten Fettsäuren zwischen Zellorganellen, und spielt 
daher eine wichtige Rolle im Fettsäuremetabolismus und in der Energieproduktion einer 
Zelle. Carnitin bindet Fettsaüren und bildet Acylcarnitine mit unterschiedlichen Kettenlängen. 
Weitere wichtige Funktionen von Carnitin sind das Puffern des zellulären freie Coenzym A-
Pools sowie die Beseitigung von potentiell toxischen AcylCoAs. In Säugetieren wird der 
Carnitinbedarf zu zwei Dritteln durch die Nahrung und zu einem Drittel durch Biosynthese 
aus den Aminosäuren L-Lysin und L-Methionin gedeckt. Da der Carnitingehalt in den 
meisten Geweben viel grösser ist als im Plasma, sichern Transportsysteme dessen 
Verteilung vom Absorptions- oder Syntheseort in den gesamten Körper. Bei verschiedenen 
metabolischen Störungen ist das Carnitinmetabolismus stark verändert, so dass der Carnitin- 
und Acylcarnitinpool verschoben ist. Die Bestimmung von einzelnen Acylcarnitinen in 
biologischen Flüssigkeiten ist ein wirksames diagnostisches Mittel zur Erkennung dieser 
Störungen. Ziel dieser Dissertationarbeit war es, analytische Methoden für die Bestimmung 
von Carnitin und Acylcarnitinen in verschiedenen biologischen Flüssigkeiten zu entwickeln. 
Als „follow up“ wurde einer der entwickelten Assays in einer klinischen Studie angewendet.  
 
Das erste Kapitel bietet einen Überblick des gegenwärtigen Wissens über Carnitin und 
Acylcarnitin, inklusiv Carnitinfunktionen, -biosynthese und -homöostase. Fälle von 
Carnitinmangel werden besprochen und eine Beschreibung der verschiedenen zur 
Verfügung stehenden Analysemethoden für die Bestimmung von Carnitin und Acylcarnitinen 
ergänzt diese Einführung. 
 
Kapitel 2 beschreibt die Entwicklung einer Methode zur Profilierung von Carnitin und kurz- 
sowie mittelkettigen Acylcarnitinen mittels Kapillarelektrophorese im Anschluss an eine 
Festphasenextraktion mittels einer Kieselguhrsäule. Diese Methode ermöglicht die Trennung 
von Carnitin und von fünf Acylcarnitinen in Standardlösungen, in Urin sowie in gespiktem 
Urin. Sie wurde für die Bestimmung von Carnitin und Acetylcarnitin in Standardlösungen 
charakterisiert. Carnitin wurde in Urinproben quantifiziert und die Resultate mit 
Konzentrationen verglichen, die durch den radioenzymatischen Assay erhalten wurden. 
 
Im Kapitel 3 wird eine kombinierte Methode aus Hochleistungs-Flüssigchromatographie zur 
Trennung und aus Massenspektrometrie im MS/MS Modus zur anschliessenden Detektion 
(HPLC-MS/MS) für die Bestimmung von Carnitin und acht Acylcarnitinen, inklusiv langkettige 
Acylcarnitine, vorgestellt. Da die Detektion mittels Massenspektrometrie verwendet wird, ist 
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eine Derivatisierung des Carnitins nicht nötig. Die Proben wurden vor Injektion ins System 
zur verbesserten Festphasenextraktion auf einer Kationentauschersäule vorgelegt. Die 
Trennung wurde mittels eines Ionenpaarreagens ermöglicht. Die Validierung der 
Carnitinbestimmung in Standard- und Urinproben wurde mit einem stabilen Isotopenderivat 
als interner Standard und mit Wasser als Kalibrationsmatrix durchgeführt. Diese Resultate 
der Carnitinbestimmung in Urinproben wurden mit denen des radioenzymatischen Assay 
verglichen. Die Anwendung auf Urinproben von Patienten mit verschiedenen organischen 
Acidurien ermöglichte die Bestätigung der entsprechenden metabolischen Störungen. 
 
Die Erweiterung dieser HPLC-MS/MS Methode auf Plasmaproben, nach kleinen 
Modifikationen im Extraktionsprotokoll, inklusiv Proteinfällung, wird im Kapitel 4 beschrieben. 
Butyrobetain, der direkte Carinitinvorläufer in der Biosynthese, der in Gegensatz zum Urin im 
Plasma vorkommt, konnte mit der gleichen Analysenmethode bestimmt werden. Die 
Quantifizierung von Carnitin, Acetylcarnitin, Propionylcarnitin, Isovalerylcarnitin, 
Hexanoylcarnitin, Octanoylcarnitin und Butyrobetain wurde in Standard- und Plasmaproben 
mittels einer wässerigen Lösung mit 4% bovinem Serumalbumin als Kalibrationmatrix 
validiert. Serum eines Patienten mit Methylmaloinsäure Acidurie wurde erfolgreich als 
spezifisch für diese Störung identifiziert.  
 
Ein Beispiel für eine konkrete Anwendung der entwickelten HPLC-MS/MS Methode wird im 
Kapitel 5 dargestellt. Eine klinische Studie wurde mit sieben in der terminalen Phase einer 
renalen Krankheit leidenden und unter Hämodialyse stehenden Patienten durchgeführt. 
Carnitin wird während der Dialyse effizient entfernt, was zu verminderten Carnitinspiegeln 
und zu einer relativen Erhöhung der Acylcarnitine führt. Daher war das Ziel dieser Studie 
eine Untersuchung der Carnitin- und Acylcarnitinenplasmazusammensetzung bei diesen 
Patienten, jeweils unter Basisbedingungen sowie nach Carnitinverabreichung nach jeder 
Dialyse. Die Extraktionskinetik während der Dialyse und die Kinetik der intravenösen 
Carnitingabe nach einer Dialyse wurden studiert. Ein Vergleich der erhaltenen Spiegel wurde 
durchgeführt, wenn Daten ohne Carnitingabe und nach Verabreichung zweier 
unterschiedlicher Carnitindosierungen vorhanden waren. Es konnte gezeigt werden, dass 
durch die Carnitingabe verminderte Carnitinspiegel deutlich verbessert und die Extraktion 
von Acylcarnitinen erhöht werden konnten. Dieser Befund weist darauf hin, dass bei unter 
Dialyse stehenden Patienten Carnitinersatz für die Entfernung von potentiellen toxischen 
Acylgruppen nützlich sein könnte. 
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SUMMARY 
 
Carnitine, an endogenous compound present in most mammalian tissues, is involved in the 
transport of activated fatty acids between cellular organelles and thus plays an important role 
in fatty acid metabolism and in cellular energy production. Carnitine binds fatty acids, 
generating various acylcarnitines with different chain lengths. Carnitine is also implicated in 
the maintenance of the cellular pool of free coenzyme A and in the elimination of potentially 
toxic acyl-CoA. In mammals, carnitine is provided for two thirds by dietary intake and for one 
third by biosynthesis from the amino acids L-lysine and L-methionine. Since carnitine is 
present in most body tissues at much higher concentrations than in plasma, transport 
systems ensure it’s widespread distribution from sites of absorption and synthesis throughout 
the body. In many metabolic disorders, carnitine metabolism is greatly disturbed, leading to a 
redistribution of the carnitine and acylcarnitine pools. The determination of individual 
acylcarnitines in biological fluids is a powerful means to diagnose these disorders. It was the 
aim of this thesis work to develop analytical tools for the determination of carnitine and 
acylcarnitines in biological fluids. Finally, one developed assay was utilized for the follow up 
of a clinical study. 
 
In chapter 1, the current knowledge about carnitine and acylcarnitines, including carnitine 
function, biosynthesis and homeostasis, are reviewed. Cases of carnitine deficiencies are 
discussed, and a description of the different available analytical methods used for carnitine 
and acylcarnitine determination completes this introduction part. 
 
Chapter 2 describes a capillary electrophoresis method developed to profile carnitine, short- 
and medium-chain acylcarnitines, after a solid-phase extraction on a silica column. The 
assay enabled the separation of carnitine and five acylcarnitines in standard solutions, in 
urine and in spiked urines, and was characterized for carnitine and acetylcarnitine in 
standard solutions. Carnitine was quantified in urine samples and the results were compared 
with concentrations obtained using a radio-enzymatic assay. 
 
Chapter 3 presents a high-performance liquid chromatography assay coupled with tandem 
mass spectrometry detection (HPLC-MS/MS) for the detection of carnitine and eight different 
acylcarnitines, including long-chain acylcarnitines. Samples were submitted to a solid-phase 
extraction on a cation-exchange column prior to injection in the system. Since the detection 
is performed with mass spectrometry, a derivatization of carnitine is not necessary. The 
separation was achieved using a volatile ion-pair reagent. The validation for the 
determination of carnitine in both standard and urine samples was performed using a stable 
Summary 
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isotope derivative as the internal standard and water as a calibration matrix. The results 
obtained for the quantification of carnitine in urine samples were compared with those of a 
radio-enzymatic method. Application to urine samples from patients suffering from different 
organic acidurias enabled the diagnosis of these metabolic disorders.  
 
The extension of the HPLC-MS/MS assay to plasma samples, after minor modifications in 
the extraction protocol, including protein precipitation, is reported in chapter 4. Butyrobetaine, 
the direct carnitine biosynthesis precursor is present in plasma, in contrast to urine, and 
could be analyzed during the same analysis. Quantification of carnitine, acetylcarnitine, 
propionylcarnitine, isovalerylcarnitine, hexanoylcarnitine, octanoylcarnitine and butyrobetaine 
were validated for standard solutions and plasma samples using 4% bovine serum albumin 
solution in water as the calibration matrix. Serum from a patient suffering from methylmalonic 
aciduria was successfully identified as characteristic of this disorder. 
 
The concrete use of the developed HPLC-MS/MS method is illustrated in chapter 5. A clinical 
study was conducted with 7 patients suffering from end-stage renal disease undergoing long-
term hemodialysis. As carnitine is efficiently removed during the hemodialysis session, 
leading to reduced carnitine levels with a relative increase of acylcarnitines, the aim of the 
study was to investigate the composition of the plasma carnitine and acylcarnitines pools in 
these patients, in baseline conditions and after they were supplemented with carnitine at the 
end of each hemodialysis session. Extraction kinetics during a hemodialysis session and 
kinetics of intravenous administration of carnitine after a hemodialysis session were studied. 
A comparison was established when patients were given either no supplement or one of two 
different dosages of carnitine. Carnitine supplementation corrected the hypocarnitinemia and 
yielded an increased extraction of acylcarnitines, suggesting that carnitine substitution in 
hemodialysis patients could be useful for the removal of potentially toxic acyl-groups.  
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INTRODUCTION 
 
 
1.1  GENERAL ASPECTS 
 
Carnitine, or 3-hydroxy-4-N-trimethylammino butyrate, is a ubiquitous molecule within 
mammalian tissue, which was first discovered in skeletal muscle extracts in the early 
twentieth century (Gulewitsch and Krimberg, 1905). Its chemical structure C7H15NO3 was 
established in 1927 (Tomita and Sendju, 1927). Carnitine is a small (molecular weight = 
161.2), water soluble, quaternary nitrogen-containing compound (Figure 1) that is present in 
both L- and D- forms, L-carnitine being the biologically active form. In the early 1950’s 
carnitine was shown to be a growth factor for the mealworm Tenebrio molitor and the term 
vitamin BT was assigned to carnitine (Carter et al., 1952).  
 
 
      CH3 
        |  
CH3-N+-CH2-CH-CH2-COO− 
  | | 
 CH3   OH 
 
Figure 1: The structural formula of carnitine 
 
 
Mammalians are able to synthesize carnitine from the amino acids L-methionine and L-
lysine, but approximately two thirds of the human daily requirements come from an 
omnivorous diet. The main dietary source of carnitine is from eating fish and meat, 
particularly red meat, and to a lesser extent from dairy products (Rebouche and Engel, 
1984). Vegetarian diets, although low in carnitine and associated with the lower plasma 
carnitine contents seen in strict vegetarians and lactoovovegetarians, are not a cause of 
carnitine deficiency as the carnitine concentrations remain within normal limits (Lombard et 
al., 1989).  
 
Carnitine is most likely found in all animal species, in numerous organisms and plants 
(Fraenkel, 1954; Panter and Mudd, 1969; Kleber, 1997), in concentrations that vary to a 
great extent from one tissue to another one and from one species to another species. In 
man, a 70 kg healthy male’s total carnitine body content is estimated to be around 21 grams 
(Brass, 1995). Carnitine distribution within the body reflects the needs of each organ towards 
this compound. Skeletal muscle and heart, that are consumers of carnitine, contain more 
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than 95% of the body total carnitine pool and carnitine reaches concentrations of 1570-3010 
nmol/g tissue and 420-840 nmol/g tissue, respectively. Liver, the main site of carnitine 
synthesis, with levels between 570 to 1090 nmol/g tissue, is the next highest carnitine 
containing tissue of the body. The extracellular fluids, including plasma with carnitine levels 
between 36 and 56 µmol/L, contain only about 0.6 % of the total carnitine pool (Engel and 
Rebouche, 1984; Hoppel, 1991). 
 
Carnitine is present as free carnitine and as esterified derivatives, or acylcarnitines, which 
are products of reactions catalyzed by carnitine acyltransferases that utilize acyl-CoA 
(Bremer, 1983; Sandor et al., 1987). Free carnitine is the major carnitine pool representative. 
The proportion of acylcarnitines, with acyl moiety ranging from the short-chain acetyl to the 
long-chain stearoyl (Choi et al., 1977), varies with nutritional conditions, exercise, and 
diseases states. Under normal metabolic conditions, acylcarnitines, which are mainly 
represented by acetylcarnitine, represent a mean value of 22% of the total carnitine pool in 
serum or plasma, 13% in muscle and liver and up to 60% in urine (Choi et al., 1977; Valkner 
and Bieber, 1982; Engel and Rebouche, 1984). Reported plasma concentrations in healthy 
humans are 29-50 µmol/L for free carnitine, 2.5-8.6 µmol/L for acetylcarnitine, 0.18-0.6 
µmol/L for propionylcarnitine, 0.03-0.17 µmol/L for isovalerylcarnitine, 0.02-0.05 µmol/L for 
hexanoylcarnitine, 0.01-0.13 µmol/L for octanoylcarnitine and 2.2-4.9 µmol/L for the long-
chain acylcarnitines (Hoppel, 1991; Minkler and Hoppel, 1993a; Costa et al., 1997; Inoue et 
al., 1999). The relative amounts of acylcarnitine are often expressed as a ratio of 
acylcarnitine to free carnitine. A ratio in plasma greater than 0.4 is indicative of carnitine 
insufficiency (Ahmad, 2001).  
 
Some bacteria, like Pseudomonas aeruginosa and Escherichia coli, use carnitine under 
aerobic conditions as a unique carbon and nitrogen source or, under anaerobic conditions, 
metabolize carnitine to betaines with osmoprotectant properties (Larsen et al., 1987; 
Lucchesi et al., 1995; Kleber, 1997; Rebouche and Seim, 1998). 
 
Carnitine has several direct and indirect roles in mammals and these essential functions are 
reflected by the mechanisms that have evolved to maintain a stable cellular/sub-cellular 
carnitine level: modest rate of endogenous synthesis, absorption from dietary sources, 
efficient conservation by the kidney and mechanisms present in most tissues that establish 
and maintain substantial concentration gradients between intracellular and extracellular 
carnitine pools (Rebouche and Seim, 1998).  
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Beside its main functions, described below, carnitine is also involved in membrane 
stabilization (Fritz and Arrigoni-Martelli, 1993), in the phospholipide metabolism in 
erythrocytes plasma membranes (Arduini et al., 1992) and may acts as an osmolyte (Peluso 
et al., 2000).  
 
 
 
 
1.2  CARNITINE FUNCTIONS 
 
In 1955, Friedman and Frankel showed that carnitine can be reversibly acetylated by acetyl-
coenzyme A (acetyl-CoA) (Friedman and Fraenkel, 1955). In the same year, Fritz showed 
that carnitine stimulates fatty acid oxidation in liver homogenates, a fundamental source of 
cellular energy, particularly in cardiac and skeletal muscles (Fritz, 1955). These seminal 
studies led to the discovery that carnitine is implicated in the transport of activated long-chain 
fatty acids from the cytosol, across the mitochondrial membranes, towards the mitochondrial 
matrix, where β-oxidation takes place.  
 
 
1.2.1  Mitochondrial long-chain fatty acid oxidation  
 
Fatty acid metabolism occurs in the mitochondrial matrix, however, the mitochondrial inner 
membrane is impermeable to fatty acids. Carnitine, by binding fatty acids, is essential 
towards the transport of long-chain fatty acids into the mitochondrial matrix. This process 
involving several enzymes is depicted in Figure 2. 
Cytosolic long-chain fatty acids are first activated by the palmitoyl-CoA synthetase (PCS), 
located in the outer leaflet of the outer mitochondrial membrane, to coenzyme A-derivatives 
(acyl-CoA). Acyl-CoA can cross the outer mitochondrial membrane but need to be converted 
to carnitine derivatives to be able to pass the inner mitochondrial membrane. For this 
purpose, the enzyme carnitine palmitoyltransferase I (CPT) I, located in the inner side of the 
outer mitochondrial membrane, transesterifies the acyl-CoA to the respective acylcarnitines 
(McGarry and Brown, 1997). In this reaction, which is the rate-limiting step in the β-oxidation 
of fatty acids and is inhibited by malonyl-CoA (Drynan et al., 1996), the acyl moiety of the 
long-chain fatty acids is transferred from CoA to the hydroxyl group of carnitine. The long-
chain acylcarnitines are then transported into the mitochondrial matrix by a specific 
transporter, the carnitine-acylcarnitine translocase (CACT) (Pande, 1975), located in the 
inner mitochondrial membrane, which exchanges one long-chain acylcarnitine for one 
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carnitine (Pande and Parvin, 1980). Once in the mitochondrial matrix, the enzyme carnitine 
palmitoyltransferase II (CPT II), located in the inner leaflet of the inner mitochondrial matrix, 
back convert the long-chain acylcarnitines into the respective long-chain acyl-CoAs. The 
released acyl-CoAs can undergo β-oxidation and enter the respiratory chain within the 
matrix. The released carnitine can leave the mitochondrion via the above-mentioned 
translocase or be converted to acylcarnitines. 
 
 
CPT I
Long-chain fatty acid
+ CoASH
Acyl-CoA
Outer
membrane
PCS
Acyl-CoA
Acylcarnitine
+ CoASH
Inner
membrane
CACT
Acylcarnitine
CPT II
Acyl-CoA + carnitine
Cytosol Mitochondrial 
matrix
Acetyl-CoAβ-oxidation
+ carnitine
+ CoA
Acetylcarnitine Acetylcarnitine   +   CoASH
CAT
carnitine
 
 
Figure 2: Schematic representation of mitochondrial long-chain fatty acid metabolism and 
regulation of intramitochondrial acyl-CoA/CoA ratio 
 
 
Carnitine is the substrate for reactions catalyzed by carnitine acyltransferases that convert 
acyl-CoA to the corresponding acylcarnitine, according to the following reversible reaction: 
Acyl-CoA + carnitine  ↔  Acylcarnitine + CoASH 
Three different groups of transferases distinguished by their substrate specificity, their 
cellular localization, their structure and reactivity with inhibitors have been described 
(Solberg, 1974; Bremer, 1983). Carnitine parmitoyltransferases (CPT I and CPT II) use long-
chain acyl-groups as substrates and are found in mitochondria (Miyazawa et al., 1983). 
Carnitine octanoyltransferase (COT) utilizes medium-chain acyl moiety as substrate and is 
found in peroxisomes and microsomes (Miyazawa et al., 1983). Carnitine acetyltransferase 
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(CAT) uses short-chain acyl-groups as a substrate and its localization has been confirmed in 
mitochondria, peroxisomes and microsomes (Edwards et al., 1974; Kahonen, 1976). 
Through the action of acyltransferases, carnitine and acylcarnitines are rapidly 
interconvertible (Brass and Hoppel, 1980; Bremer, 1983). 
 
 
1.2.2  Buffering of the mitochondrial acyl-CoA/CoA ratio  
 
In the mitochondrial matrix, the enzyme CAT converts short-chain acyl-CoAs into the 
corresponding acylcarnitines, using mitochondrial carnitine and liberates free CoA (CoASH) 
(see Figure 2) (Brass and Hoppel, 1980; Bieber, 1988). Experiments conducted with blowfly 
flight muscle (Childress et al., 1967), rat heart (Pearson and Tubbs, 1967), sheep liver 
(Snoswell and Henderson, 1970), frog muscle (Alkonyi et al., 1975) and human skeletal 
muscle (Friolet et al., 1994) suggested that carnitine acts as a buffer for free CoA. Trough the 
action of CAT, carnitine and CoA pools are in close relationship. Brass and Hoppel showed 
that, in rat liver and under different metabolic conditions, the L-carnitine pool reflects the 
coenzyme A pool (Brass and Hoppel, 1980). This reversible exchange allows the cell to 
regulate its levels of free CoA using carnitine as a buffer, and, since carnitine is in most 
tissues in a much higher concentration than CoA, the extramitochondrial 
acetylcarnitine/carnitine ratio will prevent great fluctuations in the mitochondrial acetyl-
CoA/CoA ratio by formation of acyl-CoA (Bremer, 1983; Ramsay and Arduini, 1993). 
 
 
1.2.3  Removal of potentially toxic acyl-groups  
 
Carnitine buffering effect can be extended to the regulation of poorly metabolized and 
potentially toxic acyl-groups, resulting either from xenobiotics (e.g. pivalic acid and valproate) 
(Arrigoni-Martelli and Caso, 2001) or from blockage of a normal metabolic pathway (e.g. 
propionic acid in propionic academia) (Rebouche and Seim, 1998). These acyl-groups are 
converted to CoA-derivatives, thus depleting the cellular pool of free CoA. The subsequent 
transesterification of these acyl-CoAs to the corresponding acylcarnitines, followed by their 
excretion in the urine (Melegh et al., 1987; Duran et al., 1990), replenish the free CoA pool, 
but lead to a carnitine deficiency that can be reversed through carnitine supplementation 
(Holme et al., 1992; Melegh et al., 1993). 
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1.2.4  Fatty acids oxidation in peroxisomes 
 
Carnitine is involved in the transport of products resulting from the peroxisomal β-oxidation, 
from the peroxisome to the mitochondria. In contrast to the mitochondrial β-oxidation, the 
peroxisomal β-oxidation does not require carnitine since the peroxisomal membrane contains 
a direct carrier or a permease for acyl-CoA (Bremer, 1983), and is not as complete as it is in 
the mitochondria. Fatty acids, mainly very long-chain (C>22), are only degraded in shortened 
fatty acids, which then need to be transported into mitochondria for complete oxidation (Ishii 
et al., 1980; Osmundsen et al., 1991; Verhoeven et al., 1998). For this purpose, peroxisomes 
contain CAT and COT (but no CPT) which convert shortened-chain acyl-CoAs into shortened-
chain acylcarnitines, which can be transported to mitochondria (Bieber et al., 1981).  
 
 
 
1.3  CARNITINE BIOSYNTHESIS 
 
Carnitine is synthesized from the amino acids L-methionine and L-lysine, after multiple steps 
involving four enzymes and several cofactors (see Figure 3). The entire biosynthetic pathway 
took a decade of research to be elucidated. In the early sixties it was shown that the injection 
of 14C-butyrobetaine in rats resulted in apparition of radiolabeled carnitine in urine and 
tissues and that methyl-labeled methionine leads to the incorporation of radioactivity into the 
4-N-methyl groups of carnitine (Wolf and Berger, 1961; Bremer, 1962). The biosynthetic 
origin of the carbon-chain and 4-nitrogen atom remained unclear for several years and, in 
1971, it was shown by different investigators that lysine is the carbon chain and nitrogen 
atom donor in the mould Neurospora crassa (Horne et al., 1971; Horne and Broquist, 1973) 
and in rat (Tanphaichitr et al., 1971; Tanphaichitr and Broquist, 1973), with 6-N-
trimethyllysine as intermediate.  
 
In mammalians, free lysine is not methylated, unlike in N. crassa, but the three time 
methylation of lysine is a post-translational event that is catalyzed by a specific protein-
dependant methyltransferase that uses S-adenosyl-L-methionine as methyl group donor 
(Paik and Kim, 1971; 1975). This results in the formation of a protein-linked 6-N-
trimethyllysine (TML). TML is released from the protein-linkage by protein breakdown, which 
is considered to be the rate-limiting step in carnitine biosynthesis (Hoppel and Davis, 1986). 
As more than 65% of the whole-body protein-linked 6-N-trimethyllysine stock is located in 
skeletal muscle, skeletal muscle protein turnover is considered to be important for carnitine 
biosynthesis (Davis and Hoppel, 1983). 
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Figure 3: Pathway of carnitine biosynthesis in mammals 
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The next step is the hydroxylation of TML to 3-hydroxy-6-N-trimethyllysine. This convertion 
involves a 6-N-trimethyllysine hydroxylase, the only mitochondrial enzyme in the carnitine 
pathway, and requires α-ketoglutarate, ascorbate and Fe++ as cofactors (Hulse et al., 1978; 
Sachan and Hoppel, 1980). This enzyme is present in human especially in kidney, but also in 
liver, skeletal muscle, heart and brain, where its activity is about 4 times lower than in kidney 
(Rebouche and Engel, 1980; Stein and Englard, 1982). 
The 3-hydroxy-6-N-trimethyllysine is cleaved by the 3-hydroxy-6-N-trimethyllysine aldolase in 
glycine and 4-trimethylaminobutyraldehyde. The enzyme needs pyroxidal phosphate as 
cofactor and its activity in human is the highest in liver (Rebouche and Engel, 1980). 
Butyrobetaine results from the oxidation of 4-trimethylaminobutyraldehyde by help of the 
cytosolic enzyme 4-trimethylaminobutyraldehyde dehydrogenase with the transfer of a 
hydrogen ion to oxidized nicotinamide adenine dinucleotide (Hulse and Henderson, 1980). 
The activity of this enzyme in human tissues was found to be high in liver and kidney and 
very low in brain, heart and muscle (Rebouche and Engel, 1980). 
According to the measured enzyme’s activities in tissues, the biosynthesis steps from 
protein-linked lysine to butyrobetaine can be performed by most tissues (Rebouche, 1982), 
but skeletal muscle appears to be quantitatively the most important organ (Davis and Hoppel, 
1983; Hoppel and Davis, 1986). 
Finally, γ-butyrobetaine hydroxylase (BBH) catalyzes the stereospecific hydroxylation of 
butyrobetaine to L-carnitine (Englard et al., 1985). BBH is a cytosolic enzyme that requires α-
ketoglutarate, ascorbate and Fe++ (Lindstedt and Lindstedt, 1970), and has a restricted and 
tissue specific expression. In humans, the enzyme is mainly located in liver and kidney, 
perhaps testis and also possibly brain (Rebouche and Engel, 1980). In rat and mouse, the 
BBH is only present in liver (Cox and Hoppel, 1974).  
 
The availability of TML determines the rate of carnitine biosynthesis, which has been 
estimated to be about 1.2 µmol/kg body weight per day in humans (Rebouche, 1992). 
Carnitine biosynthesis accounts for one third to one half of the total carnitine sources when 
an omnivorous diet is consumed. If carnitine food intake is reduced, the biosynthesis of 
carnitine can account for more than 90% of the body requirements, so that a strict vegetarian 
diet is rarely a cause of carnitine deficiency presented in the clinic (Rebouche, 1992). 
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1.4  CARNITINE HOMEOSTASIS 
 
Given the importance of carnitine for mammalian survival, its plasma and tissue levels need 
to be maintained within relatively narrow limits. Carnitine homeostasis is complex, reflecting 
its two sources of supply (diet and synthesis) and its wide distribution within the body. 
The endogenous carnitine pool is maintained by a combination of absorption of carnitine 
from dietary sources, a modest rate of biosynthesis, an extensive but saturable tubular 
reabsorption from the glomerular filtrate and a distribution in most tissues ensured by 
transport and exchange systems that facilitate a high tissues to plasma concentration. 
 
 
1.4.1  Absorption 
 
In rats and humans, approximately 54-87% of dietary carnitine is absorbed (Rebouche and 
Chenard, 1991). Since carnitine is mainly present in animal products, carnitine’s daily intake 
varies greatly with the dietary intake. By way of example, 2 to 12 µmol carnitine per kilogram 
of body weight are provided with an omnivorous diet and less than 0.1 µmol with a strict 
vegetarian one (Rebouche, 1992). By studying carnitine uptake into human intestinal 
mucosal biopsy specimens, Hamilton and colleagues observed that carnitine absorption 
results from a two-component system: a linear absorption, probably representing a passive 
diffusion, and a saturable system suggesting the existence of active transport (Hamilton et 
al., 1986). Rebouche and Chenard investigated the metabolic fate of dietary carnitine in 
humans by administrating an oral tracer dose of labeled carnitine and found that carnitine 
absorption is dependent on the intake amount (Rebouche and Chenard, 1991). Subjects on 
a low-carnitine diet presented a higher bioavailability than subjects under a high-carnitine 
diet. These data suggest that humans do not absorb all of the carnitine they consume and 
further support that a specific active transporter, one that can be saturated even with a 
normal dietary intake, might be involved. In a pharmacokinetic study conducted in healthy 
subjects with oral medicinal doses of 2 and 6 grams of carnitine, Harper et co-workers also 
found a dependency on intake amount in the bioavailability of carnitine (Harper et al., 1988). 
The bioavailability was 16% under the low dosage and 5% under the high dosage, which is 
considerably lower than the bioavailability of dietary carnitine. The authors did not find a 
statistically significant difference in the areas under the plasma carnitine concentration-time 
curves between the two dosages, and suggested that the absorption of carnitine was already 
saturated by the 2 grams dose. The significance of diffusion of carnitine as a mechanism of 
carnitine uptake is presumed to be small under physiological conditions, but may assume 
large importance during therapeutical administration of carnitine (Li et al., 1992).  
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Following oral administration of 2 or 6 grams carnitine in healthy humans, carnitine peak 
plasma concentrations were seen 2.5 to 9 hours after dosing (Harper et al., 1988). By 
studying the postabsorptive fate of injected radioactive-labeled carnitine in rat intestines, 
Gudjonsson and co-workers observed a slow appearance of carnitine in blood and 
suggested that carnitine enters an enterohepatic circulation with passive diffusion into bile 
(Gudjonsson et al., 1985).  Uptake studies of carnitine by perfused rat liver showed that 
carnitine can be taken up by hepatocytes (Kispal et al., 1987). Bile from fed rats was shown 
to be highly esterified (up to 80%), one third of this as long-chain acylcarnitines, and the 
origin of these carnitine esters was associated with a hepatic carnitine metabolism (Hamilton 
and Hahn, 1987). 
 
 
1.4.2  Tissue distribution - carnitine transporters 
 
Carnitine is present in most parts of the body, mainly in skeletal muscle and heart. Since, as 
pointed out before, carnitine biosynthesis in human is restricted to liver and kidney, and two 
thirds of the carnitine needs are provided by diet, this implies the existence of a mechanism 
by which carnitine can be distributed from its place of synthesis or absorption to all tissues 
that rely upon carnitine for their energy supply. Given that carnitine concentration in tissues is 
20 to 50 fold higher than in plasma, carnitine uptake from blood into tissues must take place 
via an active transport process against a concentration gradient.  
 
Experiments of carnitine uptake by different tissues, either using cells or organelles, perfused 
tissues or directly in vivo, have shown the presence of sodium-dependant transporters with 
wide ranges of affinity according to the tissue studied. In liver, a low affinity transport for 
carnitine (high Km value) but a high affinity transport for butyrobetaine (the direct precursor 
to carnitine synthesis) was observed (Christiansen and Bremer, 1976; Kispal et al., 1987). 
This is in agreement with the central role of the liver to deliver carnitine to the body, while 
butyrobetaine enters easily to be converted into carnitine. Heart and skeletal muscles, that 
contain more than 95% of the carnitine pool and might be a storage site for carnitine, present 
both high and low affinity transport of carnitine (Martinuzzi et al., 1991; Georges et al., 2000). 
Kidney, which plays a key role in carnitine homeostasis, with its ability to reabsorb more than 
90 % of carnitine, presents also a dual transport system of carnitine with a high affinity and a 
low affinity transporter (Stieger et al., 1995). 
 
In recent studies, different carnitine transporters have been described. The first ones belong 
to the organic cation transporter family, that function primarily in the elimination of cationic 
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drugs and other xenobiotics, and include the high affinity transporter OCTN2, the low affinity 
transporter OCTN1 and the intermediate affinity transporter OCTN3 (Xuan et al., 2003). 
OCTN2 is strongly expressed in kidney and, to a lesser extent, in heart, placenta, intestine 
and liver, and also transports acetylcarnitine and propionylcarnitine. OCTN2 was also 
reported to be strongly expressed in skeletal muscle (Tamai et al., 1998), but experiments 
conducted in our laboratory demonstrated that it was absent in this tissue (Brooks, 2002). 
OCTN1 has a similar tissue expression profile as OCTN2 does, whereas studies conducted 
in mice revealed a predominant expression in testis for OCTN3 (Tamai et al., 2000), with a 
unique involvement in carnitine-dependent transport in peroxisomes shown in human 
(Lamhonwah et al., 2003). Another lower affinity transporter for carnitine and 
propionylcarnitine (but not for acetylcarnitine), ATB0,+, is a member of the sodium- and 
chloride-coupled amino acid transporters family, and has been described to have a distinct 
tissue distribution, indeed a primary expression in intestinal tract, lung and mammary gland 
(Taylor, 2001).  
 
 
i.  Regulation of tissue distribution 
Tissue distribution and uptake are at least partially controlled by hormones (Bremer, 1983). 
Glucagon and insulin deficiency were reported to reduce plasma carnitine in humans (Genuth 
and Hoppel, 1981). Sex hormones, and thus age, may also influence carnitine distribution.  
Adult female rats have been reported to have lower plasma, heart and muscle carnitine 
concentrations and higher liver levels, thus a significantly higher liver/plasma carnitine 
concentration ratio than adults male rats (Borum, 1978). Nonetheless, the authors did not 
find these differences in rats younger than 50 days of life, suggesting an age-dependency for 
the observed tissue distribution. Plasma carnitine levels were showed to be lower in women 
than in men by about 20% to 25%, but carnitine levels of skeletal muscle presented no sex-
differences (Cederblad, 1976; Opalka et al., 2001). A significant age-dependent decrease of 
carnitine in skeletal muscle was observed in men (but not in women) (Opalka et al., 2001). 
Opalka and colleagues found women increased their carnitine serum levels according to age, 
but not so in men, so that the differences between women and men seem to be minimal after 
menopause, further supporting the influences of sex hormones (Opalka et al., 2001).   
 
 
ii.  Kinetic of exogenous carnitine 
Once carnitine reaches the systemic circulation, it is rapidly distributed into a central volume 
of distribution of approximately 0.2 L/kg, similar to extracellular fluid volume (Uematsu et al., 
1988; Brass et al., 1994). Since carnitine removal from the central compartment occurs either 
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via irreversible elimination into the urine or via uptake by tissues, pharmacokinetic modeling 
using multi-compartmental behavior has been suggested to estimate the distribution of 
carnitine (Welling et al., 1979; Uematsu et al., 1988). For instance, Rebouche and Engel 
used a three-compartment open-system model consisting of extracellular fluid, cardiac and 
skeletal muscles and others tissues, particularly liver and kidney, to quantify the dynamic 
parameters of carnitine metabolism in the dog (Rebouche and Engel, 1983). This approach 
was judged to be applicable for the determination of carnitine fluxes into and out of muscle 
and other tissues, and the estimates of carnitine amount and turnover times obtained by this 
modeling agreed with experimentally measured values. The same model applied in healthy 
humans after intravenous administration of L-[methyl-3H] carnitine, enabled the 
determination of turnover times for these different compartments (Rebouche and Engel, 
1984). The turnover times were found to be 1.1 hour for extracellular fluids, representing the 
initial distribution volume, about 12 hours for the fast equilibrating tissues, more likely 
represented by kidney and liver, and 191 hours for the slow equilibrating tissues, that are 
likely represented by skeletal muscle and heart. The whole body turnover was found to be 66 
days.  
 
 
1.4.3  Metabolism 
 
Carnitine has been shown to be extensively metabolized in microorganisms. Some bacterial 
species can degrade, under aerobic conditions, carnitine to dehydrocarnitine and finally to 
trimethylamine or, when carnitine is the unique source of carbon and nitrogen, to glycine 
(Rebouche and Seim, 1998). Under anaerobic conditions and in the presence of other 
carbon and nitrogen sources, enterobacteria, including E. coli, dehydrate carnitine to 
crotonobetaine that is further reduced to butyrobetaine (Seim et al., 1979).  
 
Unlike microorganisms, mammals were shown to lack the enzymes to degrade carnitine 
(Rebouche et al., 1984; Seim et al., 1985). After oral administration of radioactive-labeled 
carnitine in rats, labeled trimethylamine N-oxide and butyrobetaine were found in urine and 
feces, respectively (Rebouche et al., 1984). These metabolites were not found after 
intravenous administration, nor in germ-free rats receiving oral carnitine (Seim et al., 1985), 
where all of the radioactivity was recovered in the form of carnitine. The authors concluded 
that carnitine degradation in the gastrointestinal tract of the rat is due to the indigenous flora. 
In similar experiments in which humans were administered orally a tracer dose of 
radioactive-labeled carnitine, the major metabolites were found to be labeled-trimethylamine 
oxide, eliminated by urine, and labeled-butyrobetaine, eliminated in feces (Rebouche and 
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Chenard, 1991). The non-absorbed carnitine was almost totally degraded and the formation 
of these metabolites in mammalians was attributed to the bacterial floral in the 
gastrointestinal tract.  
 
Carnitine degradation in mammals is restricted to the non-absorbed carnitine in the intestinal 
tract, whereas absorbed or intravenously administered carnitine and endogenous carnitine 
are mostly eliminated in urine. After intravenous administration of 2 and 6 grams carnitine in 
healthy humans, 70 to 90% of the carnitine dose is recovered unchanged in the urine within 
24 hours (Harper et al., 1988).   
 
 
1.4.4  Elimination – role of kidney 
 
By modulating the plasma carnitine concentration, the kidneys play a pivotal role in the 
establishment and maintenance of carnitine homeostasis in mammals. Carnitine, a water-
soluble non protein-bound compound, is readily filtrated by the renal glomerulus and, to 
prevent excessive loss, is highly efficiently reabsorbed (Engel et al., 1981; Rebouche et al., 
1993). 
 
In healthy humans, 90 to 98 % of the approximately 5.8 mmol of the daily filtered carnitine is 
reabsorbed and only 100 to 300 µmol are excreted in urine (Maebashi et al., 1976; Leschke 
et al., 1984; Rebouche and Seim, 1998). Nonetheless, the rates of carnitine reabsorption and 
excretion are affected by several physiological and pathological factors. By way of example, 
excretion rate is increased by high-fat or high protein diets (Stadler et al., 1993), carnitine 
clearance is also increased during pregnancy (Cederblad et al., 1986) and reabsorption is 
impaired in Fanconi syndrome (Bernardini et al., 1985), a disease characterized by a 
generalized transport defect affecting tubular reabsorption of small molecules, including 
carnitine. At similar plasma carnitine concentrations, vegetarians excrete less carnitine than 
omnivores (Lombard et al., 1989). In a study where strict vegetarians were supplemented 
with carnitine, carnitine clearance was not affected but, at physiological plasma carnitine 
concentrations, carnitine reabsorption was significantly reduced and carnitine excretion 
increased. The authors concluded that the kidney adapts to dietary carnitine intake by 
reducing the efficiency of carnitine reabsorption (Rebouche et al., 1993). 
 
Under normal homeostasis conditions, carnitine is eliminated by excretion in urine, in both 
free and esterified forms, mainly as acetylcarnitine (Chalmers et al., 1984). In urine, the 
acylcarnitines represent 56% of the total carnitine content, whereas in plasma, acylcarnitines 
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account for 22%. This higher acylcarnitine to carnitine ratio in urine in relation to plasma is 
suggested to be the result of a less efficient reabsorption of acylcarnitines or of a renal 
acylation of carnitine followed by leakage of the locally formed acylcarnitine product into 
urine (Wagner et al., 1986; Rebouche and Seim, 1998).  
 
Carnitine is also excreted in milk. Its concentration in human milk was shown to increase 
from 39 to 63 µmol/L the first week post-partum and to be stabilized at 45 µmol/L after one 
month (Borum, 1981). 
 
 
 
 
1.5  CARNITINE DEFICIENCY 
 
Carnitine deficiency can be defined as a plasma or tissue carnitine concentration that is 
below the requirement for the normal function of the organism (Pons and De Vivo, 1995). 
Since carnitine needs depend on several other factors such as age, sex, diet, metabolic 
conditions and tissues dependency on fatty acid oxidation (Rebouche, 1992), the clinical 
consequence of hypocarnitinaemia is determined by the discrepancy between the carnitine 
level and the carnitine requirements. Clinical and biochemical data suggest that tissues 
carnitine content has to fall to less than 10-20% of normal before the biological effect can be 
clinically significant (Stanley, 1987), so that vegetarians, who have low plasma carnitine 
concentrations, do not present the symptoms of a carnitine deficiency (Lombard et al., 1989).  
Given that carnitine plays a key role, not only in fatty acid oxidation, and thus energy 
production, but also in cellular homeostasis of free and acyl-CoA, carnitine deficiency would 
be expected to produce a wide variety of disorders affecting the functions of several organs, 
including liver, skeletal muscle, heart and brain. 
 
Since the first description of human muscle carnitine deficiency syndrome (Engel and 
Angelini, 1973), different forms of carnitine deficiency have been reported. According to their 
different etiologies, such as inherited disorders of metabolism or transport, contracted 
diseases (e.g. liver cirrhosis or HIV infection), therapeutic treatment for totally unrelated 
disorders (valproic acid treatment of epilepsy) or patient with end-stage renal disease 
(ESRD) undergoing hemodialysis, carnitine deficiencies are classified as primary and 
secondary carnitine deficiency. Carnitine deficiency syndromes are due to inherited and 
acquired diseases and carnitine deficiency is the consequence rather than the cause of the 
disease (Kerner and Hoppel, 1998). 
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The most severe clinical symptoms, which might be associated with carnitine deficiency, can 
often be reversed by an oral or intravenous supplementation with carnitine. Carnitine lacks 
toxicity at high dosage, is generally well tolerated and has limited and occasional adverse 
events, mostly gastro-intestinal, such as nausea, vomiting, gastritis and diarrhoea. 
 
 
1.5.1  Primary carnitine deficiency 
 
Primary carnitine deficiency is defined as a decrease in intracellular carnitine content, that is 
associated with impaired fatty acid oxidation, and with no other identifiable systemic illness 
that might deplete tissue carnitine stores (Roe and Coates, 1989). Depending on the tissue 
distribution of the low carnitine level, two different entities of primary carnitine deficiency 
syndromes have been described. A systemic form, characterized by low carnitine levels in 
plasma and in the affected tissue, and a muscular form, with a low carnitine concentration 
restricted to muscle (Engel and Angelini, 1973; Karpati et al., 1975). 
 
 
i.  Systemic carnitine deficiency (SCD) 
Primary systemic carnitine deficiency is characterized by low plasma carnitine 
concentrations, low carnitine levels in the affected tissues (heart, skeletal muscle, liver), both 
usually below 10% of normal (Pons and De Vivo, 1995), and, as the main diagnostic factor, a 
higher than normal excretion of carnitine in the urine (Rodrigues Pereira et al., 1988). The 
defects in this disorder result from an impaired carnitine uptake into cells and are associated 
with a deficient renal carnitine transporter (Treem et al., 1988). Recently, point mutations in 
the gene encoding for the high affinity carnitine transporter OCTN2 have been identified in 
SCD patients (Nezu et al., 1999; Vaz et al., 1999), with a transmission displaying an 
autosomal recessive inheritance pattern (Tein et al., 1990; Lahjouji et al., 2001). The 
detection of SCD is done by the determination of carnitine uptake into cultured patient 
fibroblasts (Tein et al., 1990) and the diagnosis is conclusively made when the uptake is 
negligible. 
SCD, which was first described in 1975 (Karpati et al., 1975), has an onset ranging from 1 
month to 7 years, with a mean of 2 years, and has different types of clinical symptoms 
(Angelini et al., 1992). Progressive cardiomyopathy, the most common form of presentation, 
usually arises at an older age and the low carnitine levels in the heart leads to progressive 
congestive heart failure and death if carnitine substitution is not administered (Waber et al., 
1982; Garavaglia et al., 1991; Stanley et al., 1991). Acute encephalopathy associated with 
hypoketotic hypoglycemia is more commonly seen in younger infants (Pons and De Vivo, 
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1995). Myopathy, manifested with hypotonia, mild motor delay or slowly progressive proximal 
weakness, is rarely present as an isolated form, but is commonly associated with 
cardiomyopathy or encephalopathy (Pons and De Vivo, 1995). The treatment consists of 
daily high doses of carnitine taken orally (100-200 mg/bodyweight), to ensure its absorption, 
possibly through passive diffusion and to reverse or attenuate the clinical symptoms in most 
patients, but without restoring totally the tissues carnitine stores (Angelini et al., 1992).  
 
 
ii.  Muscle carnitine deficiency (MCD)  
This limited form of primary carnitine deficiency is characterized by severely reduced 
carnitine levels in skeletal muscle, only 20% of controls, but normal levels in plasma and 
liver, with no sign of renal carnitine leak (Angelini et al., 1992).  
Although some patients have been shown to have fatty acid oxidation defects, for others no 
definitive biochemical defect has been discovered (Pons and De Vivo, 1995). As the plasma 
level is normal, it has been suggested that MCD might be caused by a defect in the low 
affinity muscle-specific carnitine transporter (Martinuzzi et al., 1991) and that this form of 
disease can be inherited as an autosomal recessive disorder, since parents also had low 
muscle carnitine levels (VanDyke et al., 1975). Studies in cultured myoblasts from a patient 
affected with MCD demonstrated normal carnitine uptake, but an increased carnitine efflux, 
resulting in significantly reduced intracellular carnitine content (Mesmer and Lo, 1990).  
MCD can appear in the first year of life, but usually occurs at late adolescence (Angelini et 
al., 1987; Shapira et al., 1993). Affected patients suffer from progressive muscular weakness 
of varying degrees and some of them from lipid storage myopathy. Carnitine therapy has 
been beneficial on muscle strength in some patients only. Muscle carnitine content was 
increased with variable success, but carnitine stores were rarely replenished (Shapira et al., 
1993). 
 
 
 
1.5.2  Secondary carnitine deficiency 
 
Secondary carnitine deficiency, manifested by decreased plasma or tissue carnitine is 
associated with a wide variety of genetic diseases, or acquired medical conditions or 
iatrogenic factors (Turnbull et al., 1984; Tanphaichitr and Leelahagul, 1993; Pons and De 
Vivo, 1995). 
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i.  Metabolic disorders 
Metabolic disorders are associated with impaired oxidation of acyl-CoA intermediates in the 
mitochondria and are the most characteristic causes of secondary carnitine deficiency. 
These disorders include fatty acid oxidation defects, which are the most frequent, but also 
amino acid oxidation defects, and are characterized by plasma and tissue carnitine levels of 
25 to 50% of normal (Stanley, 1987). The block in the oxidation leads to the accumulation of 
acyl-CoA intermediates at or near the metabolic block. As mentioned earlier, 
transesterification of these acyl-CoAs with carnitine leads to the formation of acylcarnitines 
and to the release of free CoA (Brass and Hoppel, 1980; Bremer, 1983). Acylcarnitines are 
transported out of the mitochondria, out of the cell and finally excreted in the urine (Duran et 
al., 1990; Bohles et al., 1994). As a result, acylcarnitines in urine and blood reflect the 
accumulation of the corresponding acyl-CoA esters in the mitochondrial matrix and a 
characteristic increase of acylcarnitine to carnitine ratio is observed (Chalmers et al., 1984). 
Under normal conditions the plasma acylcarnitine to carnitine ratio is between 0.19 and 0.25, 
whereas ratios above 0.4 are considered abnormal (Penn and Schmidt-Sommerfeld, 1983; 
Golper et al., 1990; Ahmad, 2001). Determination of this ratio and of the acylcarnitine profile 
itself is a valuable means of screening for metabolic disorders (Bohles et al., 1994; Ahmad, 
2001). 
 
Fatty acid oxidation defects, that appear to be inherited in an autosomal recessive fashion, 
can be subdivided into defects of the carnitine cycle for the transport of the long-chain fatty 
acids into the mitochondria and defects of the β-oxidation cycle, that occur within the 
mitochondria (Pons and De Vivo, 1995). Defects of the enzymes involved in the carnitine 
cycle comprise carnitine-acylcarnitine translocase deficiency (Stanley et al., 1992), CPT I 
and CPT II deficiencies (Angelini et al., 1981; Trevisan et al., 1984). Deficiencies due to the 
enzymes involved in the β-oxidation spiral include the 4 acyl-CoA dehydrogenases: the 
short-chain (Turnbull et al., 1984), the medium-chain (MCAD) (Roe et al., 1986), the long-
chain (Hale et al., 1985) and the very long-chain acyl-CoA dehydrogenases (Bertrand et al., 
1993). MCAD deficiency is the most common enzyme deficiency of fatty acid oxidation found 
in the US, UK, and Northern Europe (Angelini et al., 1992) and is characterized by an 
increase of octanoylcarnitine, which can reach plasma concentrations between 1.8 and 28 
µmol/L (Roe et al., 1985; Chace et al., 1997; Zytkovicz et al., 2001). 
 
Block in the oxidation leading to accumulation of abnormal acyl-CoA intermediates at or near 
the metabolic block, associated with low plasma and tissue total carnitine levels, is also seen 
in branched-amino acid disorders (Bohles et al., 1994). Examples of the accumulated 
acylcarnitines in urine are isovalerylcarnitine in isovaleric academia (Roe et al., 1984b) and 
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propionylcarnitine in propionic acidaemia (Roe et al., 1984a) and methylmalonic acidemias 
(Minkler and Hoppel, 1993b). 
 
Carnitine supplementation is given in patients with fatty acid oxidation disorders and other 
organic acidurias to correct the deficiency and to facilitate the removal of accumulating toxic 
acyl intermediates while regenerating mitochondrial free CoA. Increased excretion of 
disease-specific acylcarnitine derivatives in a dose-response relationship has been observed 
(Winter, 2003) 
 
 
ii.  Acquired medical conditions 
Given the role of the liver in carnitine biosynthesis and the importance of the kidney in 
carnitine conservation, acquired metabolic conditions altering carnitine homeostasis might 
occur in patients with diseases of the liver (Krahenbuhl, 1996) or kidney (Leschke et al., 
1984). Decreased carnitine biosynthesis may be associated with pre-maturity or chronic 
renal disease. Diminished carnitine intake may be associated with a low carnitine diet 
(vegetarians) or decreased reabsorption in malabsorption syndromes, such as cystic fibrosis, 
short-gut syndrome or celiac disease (Pons and De Vivo, 1995). Increased requirements and 
reduced body stores may accompany diverse clinical conditions, like pregnancy and extreme 
pre-maturity (Rebouche, 1992). Excessive renal loss of carnitine is seen in Fanconi 
syndrome and renal tubular acidosis (Bernardini et al., 1985; Tanphaichitr and Leelahagul, 
1993; Pons and De Vivo, 1995).  
 
 
iii.  Drug induced 
Several drugs are involved in secondary carnitine deficiency. The branched fatty acid 
valproic acid forms, like natural fatty acids, CoA and carnitine derivatives (Coude et al., 
1983). While investigating the urine of children under chronic valproate therapy with mass 
spectrometry analysis, Millington et al. established the presence of valproylcarnitine in the 
samples (Millington et al., 1985). Chronic therapy with this anti-epileptic drug is associated 
with decreased plasma free carnitine levels and a slight increase of acylcarnitines (Matsuda 
et al., 1986; Coulter, 1991). Excretion of valproylcarnitine constitutes less than 10% of the 
total urinary acylcarnitine pools (Millington et al., 1985), whereas medium-chain 
acylcarnitines, namely hexanoylcarnitine and octanoylcarnitine, have been found to be 
excreted at the same levels as in MCAD deficient patients (Schmidt-Sommerfeld et al., 
1992). Supplementation with carnitine has been shown to normalize plasma carnitine levels 
in patients under valproic treatment (Melegh et al., 1993).  
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Treatments with cisplatin, a cytostatique, or pivalate pro-drugs are associated with an 
increase in renal carnitine excretion (Holme et al., 1992; Heuberger et al., 1998; Brass et al., 
2003). 
 
Possible implication of the carnitine transporter OCTN2 in secondary carnitine deficiency due 
to the therapeutical use of several drugs has been investigated. Ohashi and co-workers 
showed that cationic drugs, such as quinidine, verapamil and valproate, are transported by 
OCTN2 and that quinidine, verapamil and cephaloridine, a zwitterionic drug, have inhibitory 
effect on OCTN2-mediated carnitine transport (Ohashi et al., 1999). Wu and colleagues 
demonstrated that the cationic drugs desipramine and verapamil produce a strong inhibition 
of OCTN2, whereas cimetidine presented a weaker inhibition (Wu et al., 1999). Beta-lactam 
antibiotics having a quaternary nitrogen, like cephaloridine, cefepime and ceflupreman, were 
found to inhibit carnitine transport by OCTN2, in contrast to beta-lactam, without quaternary 
nitrogen, which exhibited no interaction (Ganapathy et al., 2000). OCTN2 has been shown to 
be strongly inhibited by several drugs known to produce carnitine deficiency. The most 
potent blockers were the antibiotic emetine and the ion channel blockers quinidine and 
verapamil (Wagner et al., 2000). The authors did not find a significant inhibition of carnitine 
transport by valproic acid, suggesting that the deficiency induced by valproate therapy is due 
to a different mode of action.  
 
 
iv.  Hemodialysis treatment 
Carnitine homeostasis is grossly disturbed in patients with chronic renal failure (Chen and 
Lincoln, 1977; Leschke et al., 1984; Guarnieri et al., 1987; Wanner et al., 1987). The normal 
route of carnitine renal excretion is lost, which in turn leads, as kidney function further 
deteriorates, to an increase in the plasma content of carnitine and its esters (Chen and 
Lincoln, 1977). Uremic patients have increased plasma levels of both free and total carnitine, 
with a marked relative rise of esterified carnitine translated by a high acylcarnitine to carnitine 
ratio (Rodriguez-Segade et al., 1986b; Wanner et al., 1987). However, significant elevations 
in plasma carnitine concentrations (>100 µmol/L) appear only when creatinine clearance 
decreases below 20 mL/min (Leschke et al., 1984).  
 
In ESRD patients undergoing hemodialysis, the small water-soluble molecules that are 
carnitine and acetylcarnitine are efficiently removed from blood through the dialysis 
membrane (Moorthy et al., 1983; Panzetta et al., 1985). In a study conducted with 12 
patients undergoing long-term hemodialysis, mean extraction coefficients of carnitine and 
acetylcarnitine were reported to be 0.74 and 0.71, respectively (Evans et al., 2000). The 
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acylcarnitine to carnitine ratio was found to be abnormally high before the hemodialysis and 
even higher after the hemodialysis, with values up to 1.9 (Guarnieri et al., 1987; Wanner et 
al., 1987). After termination of hemodialysis, a hyperbolic rise in plasma carnitine, which 
reaches pre-dialysis values within 44 to 48 hours, is observed (Bartel et al., 1981). 
 
Subsequent to chronic hemodialysis therapy, plasma free carnitine was found to decrease 
gradually in accordance with months on hemodialysis, whereas the acylcarnitine to carnitine 
ratio increased in the same time (Sakurauchi et al., 1998). Despite abnormal carnitine 
fractions, the total carnitine plasma concentrations were reported, depending on the study, to 
be normal (Moorthy et al., 1983; Golper et al., 1990), but also decreased (Rodriguez-Segade 
et al., 1986a; b) or elevated (Wanner et al., 1987). Investigations performed on skeletal 
muscle of patients under hemodialysis demonstrated a decrease of the free and total 
carnitine content by about 50% and 10%, respectively, when compared to control values 
(Bellinghieri et al., 1983; Golper et al., 1990), and appeared to be more severe in the longer-
term hemodialysis patients (Savica et al., 1983). Nonetheless, plasma and muscle carnitine 
levels could so far not be correlated (Debska et al., 2000). It has been suggested that to 
correct the low carnitine plasma levels, a net movement out of skeletal muscle into plasma 
would occur during and after hemodialysis, leading to deplete tissues stores, a depleted state 
that would persist as the carnitine uptake by muscle is a very slow process (Moorthy et al., 
1983; Panzetta et al., 1985). 
Even though the dialysis membrane irreversibly eliminates carnitine, weekly carnitine losses 
have been reported to be similar (Leschke et al., 1983), lower (Rumpf et al., 1983) or higher 
(Bohmer et al., 1978) than the renal losses in healthy individuals. It has been suggested that a 
reduced carnitine biosynthesis, as kidney is not functional anymore, a reduced dietary intake 
or an increased requirement might be, together with hemodialysis treatment, responsible for 
the carnitine deficiency observed in hemodialysis patients (Leschke et al., 1983; Guarnieri et 
al., 1987). However, based on a comparison of hemodialysis and renal clearances of 
carnitine, Evans and colleagues considered that a healthy kidney serves to conserve 
carnitine, on the basis of an entire week, more efficiently than does hemodialysis (Evans and 
Fornasini, 2003). 
 
Patients under long-term hemodialysis suffer from many complications, which are similar to 
those observed with carnitine deficiency. Examples of such dialysis-associated symptoms 
include skeletal muscle myopathies and intradialytic cramps (Sakurauchi et al., 1998), 
impaired exercise performance (Hiatt et al., 1992), cardiac dysfunctions, responsible for as 
many as 50% of deaths in hemodialysis patients (Foley et al., 1998) and intradialytic 
complications, such as hypotensive episodes (Riley et al., 1997). 
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Carnitine supplementation has been evaluated in several studies, administered either 
intravenously at the end of each hemodialysis session at typical doses of 10-20 mg/kg 
(Wanner et al., 1987; Ahmad et al., 1990; Golper et al., 1990; Brass et al., 2001; Vesela et 
al., 2001) or orally at higher dosage of 2-4 g/day (Bellinghieri et al., 1983; Sakurauchi et al., 
1998) due to the poor bioavailability of carnitine. 
Treatment is clearly associated with significant increases in plasma concentrations of free 
carnitine and total carnitine (Golper et al., 1990). Although the acyl to free carnitine ratio 
decreases during the treatment, it is still markedly abnormal, even after 6 months of 
supplementation (Golper et al., 1990). Because renal elimination is not functional, the full 
dose is accessible to tissues, so that muscle carnitine content could be increased in 
hemodialysis patients receiving carnitine (Brass, 1995), in contrast to healthy persons treated 
with carnitine (Brass et al., 1994; Wachter et al., 2002). The magnitude of the increase 
appeared to be related to the duration of the treatment (Brass, 1995). A three fold increase in 
muscular carnitine concentration in hemodialysis patients has been observed following 
intravenous supplementation of 2 grams carnitine 3 times weekly for 6 months (Siami et al., 
1991). Carnitine therapy clearly corrects the hypocarnitinemia found in hemodialysis patients 
and the supraphysiological carnitine concentrations achieved might be effective at removing 
metabolic intermediates from the active intramitochondrial coenzyme A pool (Brass et al., 
2001). 
The increased carnitine plasma and tissue levels reached under carnitine supplementation in 
hemodialysis patients have been shown to have positive effects in some patients on the 
following dialysis-related symptoms: the cardiac ejection fraction could be increased (van Es 
et al., 1992), the skeletal muscle mass and the exercise capacity were improved (Siami et 
al., 1991; Hiatt et al., 1992), the incidence of intradialytic hypotension and muscle cramps 
were decreased (Ahmad et al., 1990), chronic anemia was improved either by increasing the 
hematocrit in non erythropoietin treated patients or by enhancing the response to 
erythropoietin and thus decreasing the erythropoietin requirement (Labonia, 1995; Kletzmayr 
et al., 1999; Ahmad, 2001; Vesela et al., 2001) and the global well-being of hemodialysis 
patients was better (Sakurauchi et al., 1998).  
 
In December 1999, the American Food and Drugs Administration granted the approval for 
the use of carnitine for the prevention and treatment of carnitine deficiency in ESRD patients 
who are undergoing hemodialysis (Schreiber, 2002; Bellinghieri et al., 2003). However, 
despite the fact that several clinical syndromes associated with hemodialysis appear to 
respond to intravenous as well as to oral supplementation with carnitine (Brass et al., 2001), 
the approval was specific for the intravenous administration. Indeed, carnitine should not be 
administered orally at high dosage for long periods of time in patients with severely 
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compromised renal function due to the fact that major metabolites formed following oral 
administration will accumulate since they cannot be efficiently remove by the kidneys. As 
already mentioned, unabsorbed carnitine is degraded by intestinal bacteria to butyrobetaine, 
which is eliminated in the feces, and to trimethylamine (TMA) (Rebouche and Chenard, 
1991; Rebouche and Seim, 1998). TMA is efficiently absorbed through the intestinal mucosa, 
further metabolized in the liver to trimethylamine-oxide (TMAO) and eliminated by renal 
excretion (Rebouche and Chenard, 1991). As TMAO is only partially dialyzed, it is not 
normally eliminated in patients with reduced renal function undergoing hemodialysis 
(Schreiber, 2002). When it reaches high concentration in the plasma, TMAO can be back 
converted to TMA, which is potentially toxic (Simenhoff et al., 1977b; Schreiber, 2002). 
Furthermore, TMA accumulation is not desirable since it increases the amount of nitrogenous 
waste to be removed in the dialysis procedure. In addition, the inefficient removal of TMA 
may result in the development of “fishy odor” syndrome (Simenhoff et al., 1977a; Rehman, 
1999). 
 
Due to the lack of homogeneity in individual patient responses to carnitine therapy and the 
inability for the clinicians to predict who will benefit from carnitine supplementation, routine 
carnitine administration to all hemodialysis patients cannot be recommended (Ahmad, 2001; 
Brass et al., 2001). In 2003, the American National Consensus Conference published 
recommendations for the use of carnitine in hemodialysis patients (Eknoyan et al., 2003). 
Four clinical conditions were considered as indications for treatment with carnitine: anaemia, 
intradialytic hypotension, cardiomyopathy and muscle weakness. A low plasma carnitine 
level associated with high acylcarnitine to carnitine ratio is not essential for diagnosis, nor is it 
predictive of clinical response to carnitine therapy, but normal values would exclude 
carnitine-related disorders as a cause of the observed clinical symptoms. The recommended 
dosage is 20 mg/kg body weight, intravenously following each hemodialysis session.  
Owing to the lack of a relationship between plasma carnitine concentrations towards the 
patient’s symptoms, monitoring plasma free carnitine or the acyl to free carnitine ratio during 
the therapy is not justified, but the clinical response to treatment should be evaluated at 3-
months intervals. The therapy should be discontinued if no clinical improvement had 
occurred within 9-12 months (Eknoyan et al., 2003). 
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1.6  CARNITINE AND ACYLCARNITINES DETERMINATION 
 
Numerous analytical methods have been described to determine carnitine and acylcarnitines 
(Figure 4) in foods, chemical and pharmaceutical processes, biological fluids and tissues 
(Lowes and Rose, 1989; Marzo and Curti, 1997; Rashed, 2001). In the first instance, 
techniques enabled the determination of carnitine only (Marquis and Fritz, 1964; Cederblad 
and Lindstedt, 1972), before further developments enabled the determination of various 
carnitine derivatives (i.e. acylcarnitine) (Millington et al., 1989; Minkler and Hoppel, 1993a) 
and the analytical resolution of D- and L-carnitine isomers (De Witt et al., 1994; Mardones et 
al., 1999a). Indeed, the detection of acylcarnitines is of great interest towards interpreting the 
state of the carnitine pool, which is of key importance towards the diagnosis of several 
metabolic disorders. Similarly the determination of carnitine’s enantiomeric purity is important 
prior to its administration in human for therapeutic purposes, as the D-isomer has toxic effect 
on physiological processes. For example, D-carnitine has been shown to produce a 
competitive inhibition of the carnitine acetyltransferase, leading to depletion of the body  
L-carnitine storage (Jung et al., 1993), to inhibit the intestinal L-carnitine uptake (Gross and 
Henderson, 1984), to inhibit in a concentration-dependant manner L-carnitine transport in rat 
kidney brush-border-membrane vesicles (Stieger et al., 1995) and to inhibit OCTN2-
mediated carnitine transport (Tamai et al., 1998; Wu et al., 1999).  
 
 
 
  CH3 
   | 
H3C - N+ - CH2 - CH - CH2 - COO− 
  |         | 
 CH3    R 
 
 
 R    Name R    Name  
     
 
 OH Carnitine OCO(CH2)4CH3 Hexanoylcarnitine 
 H Butyrobetaine OCO(CH2)6CH3 Octanoylcarnitine 
 OCOCH3 Acetylcarnitine OCO(CH2)12CH3 Myristoylcarnitine 
 OCOCH2CH3 Propionylcarnitine OCO(CH2)14CH3 Palmitoylcarnitine 
 OCOC(CH3) Isovalerylcarnitine OCO(CH2)16CH3 Stearoylcarnitine 
 
 
Figure 4: Chemical structures of carnitine, butyrobetaine and acylcarnitines  
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The first carnitine assay described used Tenebrio molitor larvae and was based on larvae 
growth in the presence of the testing material compared with its growth in the presence of a 
known amount of carnitine. Because of its lack of precision, specificity and sensitivity, this 
bioassay was not adequate to quantify carnitine in biological fluids and tissues (Fraenkel, 
1954). 
Chemical methods, based upon the formation of colored complexes between the quaternary 
ammonium group of carnitine and chromophoric compounds, such as bromophenol blue, 
were developed in the late 1950s. These colorimetric assays, although an advancement 
upon the larval approach, still had specificity problems and sensitivity limitations (Friedman, 
1958). 
 
A significant improvement in carnitine determination was made with the enzymatic assay 
developed by Marquis and Fritz (Marquis and Fritz, 1964). The methodology is based upon 
the conversion of the L-isomer of carnitine to acetylcarnitine by the reversible enzyme 
carnitine acetyltransferase using acetyl-CoA as substrate: 
CAT 
L-carnitine + acetyl-CoA    ↔    acetylcarnitine + CoASH 
 
The sulfhydryl groups of the liberated free CoA further react with 5,5’-dithiobis-2-nitrobenzoic 
acid (DTNB) producing a thiophenolate ion which absorbs at 412 nm. This 
spectrophotometric method, developed for rat tissues, needed blank tissue to compensate 
for sulfhydryl groups present in biological tissues and had a vastly improved specificity and 
sensitivity for carnitine.  
 
 
1.6.1  Radioenzymatic assay 
 
The enzymatic assay developed by Marquis and Fritz was further improved by using [14C]-
acetyl-CoA, which leads to labeled acetylcarnitine (Cederblad and Lindstedt, 1972). The un-
reacted, labeled acetyl-CoA is separated from the labeled newly formed acetylcarnitine by 
passing the reaction mixture through an anion-exchange column. Because the reaction has a 
low equilibrium constant and needs to be forced to the formation of acetylcarnitine to get 
linear standard curves, labeled acetyl-CoA has to be in excess and the released CoASH 
needs to be trapped. DTNB was used to render the reaction irreversible (Bohmer et al., 
1974) but, as it was found to slowly inactivate CAT, it was substituted with sodium 
tetrathionate (McGarry and Foster, 1976) or with N-ethylmaleimide (Parvin and Pande, 
1977). Parvin and Pande demonstrated that N-ethylmaleimide is more efficient in preventing 
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the reversal of the CAT reaction because it removes free CoA more rapidly than sodium 
tetrathionate does (Parvin and Pande, 1977). 
 
This assay allows the specific determination of L-carnitine only, but, as acylcarnitines are 
easily hydrolysable in alkaline solutions to carnitine, an appropriate sample preparation 
allows the determination of the different acylcarnitine groups. When samples are treated with 
perchloric acid, two fractions are obtained. The first one, recovered in the supernatant and 
called the acid-soluble fraction, contains free carnitine and short-chain acylcarnitines having 
a chain length up to 10 carbons. The second one, named acid-insoluble fraction, is 
recovered in the pellet and contains acylcarnitines with chain length longer than 10 carbons 
(Hoppel, 1991). Linearities were reported to be 5-50 µmol/L for free carnitine and 5-100 
µmol/L for total carnitine, limit of detection was 1 µmol/L for carnitine, and the inter-day 
variations for free and total carnitine in plasma and in urine samples were below 2.7 %. 
Although the enzymatic assays performed on each fraction, with and without previous 
hydrolysis, enables the determination of free carnitine, short- and medium-chain 
acylcarnitines, long-chain acylcarnitines and total carnitine, the assay is not able to identify 
individual acylcarnitines. 
 
Kerner and Bieber proposed a radioisotopic-exchange method, which enables the 
determination of picomole amounts of individual short-chain acylcarnitines of up to 5 carbon 
atoms (Kerner and Bieber, 1983). A sample containing a pool of carnitine and short-chain 
acylcarnitines is incubated with radioactive-labeled carnitine in the presence of CoASH and 
CAT. As the reaction catalyzed by CAT is easily reversible, an isotopic equilibrium is 
attained, resulting in general labeling of carnitine esters. The produced radioactive-labeled 
carnitine and acylcarnitines are then separated by thin layer chromatography or high-
performance liquid chromatography and the radioactivity of each fraction counted.  
 
Dugan and colleagues exploited the enzymatic conversion by CAT, in the presence of 
CoASH, of urinary short-chain carnitine esters to short-chain acyl-CoAs followed by high-
performance liquid chromatography separation (Dugan et al., 1987). CoA esters were 
quantified by integration of the area under the 254 nm absorption peaks. Limitation of this 
assay is the presence of high free carnitine concentrations because the rate of conversion of 
short-chain acylcarnitines appeared to be reduced.  
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1.6.2  Gas chromatography 
 
Since carnitine and its esters are highly polar, non-volatile compounds, derivatization to 
generate volatile analogues is required prior to gas chromatography (GC) analysis. 
Determination by GC, as described in the methods below, achieves usual detection limits for 
acylcarnitines in the low µmol/L ranges. 
 
Carnitine and its esters are unstable above 1000C and give rise to desmethyl moiety, 
crotonoylbetaine or oxybutyrolactone ring plus trimethylamine. Lewin and coworkers 
exploited this thermal instability to analyzed carnitine by GC (Lewin et al., 1975). In the 
presence of NaOH and NaBH4, carnitine was decomposed at 1600C to oxybutyrolactone and 
then to 4-butyrolactone, which was analyzed as an expression of carnitine.  
 
Procedures for the determination of soluble short-chain acylcarnitines, relying upon alkaline 
hydrolysis of the acylcarnitines and subsequent determination of the released fatty acids, 
have been reported (Choi and Bieber, 1977; Bieber and Lewin, 1981). The main drawback of 
this method is the ambiguity surrounding the origin of the acyl residues in the biological 
matrix, since the liberated fatty acids may arise from acyl-containing compounds other than 
acylcarnitines (Lowes and Rose, 1989). Sample pre-treatment using extraction on a strong 
cation-exchange column could shrink the uncertainty about the origin of the released fatty 
acids to cationic hydrolysable-acyl-containing molecules (Kumps et al., 1994). 
 
However, GC techniques are potentially very useful owing to the possibility of being coupled 
to mass spectrometry (MS) detection, providing not only high sensitivity and selectivity, but 
also structural information. For instance, after derivatization of acylcarnitines to cyclic volatile 
lactones, which kept fatty acid units still bound, GC-MS was applied to the qualitative 
determination of acylcarnitines in urine (Lowes and Rose, 1990) and to the quantitative 
determination in plasma (Costa et al., 1997). Both methods allowed the diagnosis of 
metabolic disorders. The same derivatization technique was recently used to achieve 
enantiomeric separation of D- and L-carnitine on a cyclodextrin chiral stationary phase (Di 
Tullio et al., 2002). A two step derivatization, involving esterification to propyl esters followed 
by nucleophile-assisted thermolytic N-demethylation on the GC column, was used to convert 
the zwitterionic acylcarnitines to their volatile acyl N-demethylcarnitine propyl esters, which 
were then monitored by MS detection (Huang et al., 1991).  
 
 
 
Introduction – carnitine determination 
 49
1.6.3  High-performance liquid chromatography 
 
High-performance liquid chromatography (HPLC) using reversed-phase columns is 
particularly useful to evaluate carnitine and the different acylcarnitines. Because carnitine 
and acylcarnitines have only a weak and non-specific chromophoric absorption at  
λmax = 210 nm due to the carboxyl groups, a pre-column derivatization is required so that the 
usual UV and fluorescence detectors can be coupled with liquid chromatography separation. 
The use of different chromophores reacting either with the carboxyl group or with the 
hydroxyl group of carnitine has been described (see below). In the latter case, acylcarnitine 
profiling will be impossible, as the fatty acid moiety has to be released to free the hydroxyl 
group for derivatization.   
HPLC has however been used for the fractionation of un-derivatized acylcarnitines using a 
step gradient with increasing flow and methanol percentage. Four different fractions, 
detected by non-specific UV-absorption at 210 nm, containing respectively carnitine and 
acetylcarnitine, short-chain acylcarnitines, medium-chain acylcarnitines, and long-chain 
acylcarnitines, respectively, were collected and subsequent quantification using 
radioenzymatic assay was performed. The assay was applied to rat liver tissues (Hoppel et 
al., 1986).  
 
Formation of bromophenacyl esters by reaction with 4’-bromophenacyl trifluoromethane 
sulfonate, known to react with carboxylic acids (Ingalls et al., 1984), is the most used 
derivatization process for carnitine and acylcarnitines determined via UV detection at 254 or 
260 nm. Using this derivative reagent coupled with a separation in a reversed-phase column, 
Minkler and co-workers proposed several methods for carnitine and acylcarnitines analysis. 
The typical linear ranges are 5-1000 µmol/L for carnitine and 2.5-50 µmol/L for acylcarnitines, 
and the limits of detection around 1 µmol/L (Minkler et al., 1984; Minkler et al., 1990; Minkler 
and Hoppel, 1992; 1993a; b; Minkler et al., 1995).  
 
Using isocratic conditions, carnitine, butyrobetaine and betaine standards could be analyzed 
as 4'-bromophenacyl ester derivatives in a 100 x 0.8 cm C18 column within 12 minutes 
(Minkler et al., 1984). 
The separation of carnitine and 11 acylcarnitines in an identical column was achieved within 
60 minutes when using a tertiary gradient containing varying proportions of water, 
acetonitrile, tetrahydrofuran, triethylamine, potassium phosphate, and phosphoric acid 
(Minkler et al., 1990). This assay was applied to urine, spiked urine and urine from patients 
suffering from different metabolic disorders. Isovalerylcarnitine was quantified in the urine of 
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a patient with isovaleric academia using heptanoylcarnitine as an internal standard (Minkler 
et al., 1990). 
The use of a quaternary gradient, containing varying proportions of water, acetonitrile, 
triethylamine and phosphoric acid, enabled to analyze free and total carnitine within 9 
minutes in a 150 x 3.9 mm C8 column (Minkler and Hoppel, 1992). Standards curves were 
established using 4-(N,N-dimethyl-N-ethylammonio)-3-hydroxybutanoate (e-carnitine) as the 
internal standard. Quantification in urine samples was demonstrated to give values that are 
not different from the results obtained using a radioenzymatic assay. By using a shorter 
column (100 x 4.6 mm C8 column) and modifying the gradient, carnitine and 5 short- and 
medium-chain acylcarnitines could be separated in a reduced time of 12 minutes. This 
procedure was applied for the quantification in urine (Minkler and Hoppel, 1993b) and 
plasma samples (Minkler and Hoppel, 1993a) from healthy controls and from patients 
diagnosed with different metabolic disorders, and in human muscle biopsy samples (Minkler 
et al., 1995). Day-to-day variabilities determined in urine samples from patients suffering 
from different metabolic disorders were reported to be below 10% for carnitine and short-
chain acylcarnitines, but up to 26% for medium-chain acylcarnitines (Minkler and Hoppel, 
1993b). Day-to-day variabilities for plasma samples were below 10% for carnitine, 25% for 
acetylcarnitine and 33% for propionylcarnitine (Minkler and Hoppel, 1993a). This method was 
also demonstrated to be suitable, using a 300 x 3.9 mm C18 column, to determine 
butyrobetaine in plasma, urine and liver tissues from rat, but a minor modification of one 
mobile phase constitution was required (Krahenbuhl et al., 1992).  
Other derivatizing reagents used for the determination of carnitine and acylcarnitines with UV 
detection include phenacyl bromide, to form phenacylcarnitine absorbing at 245 nm (van 
Kempen and Odle, 1992) and 4’-bromophenacylbromide (Poorthuis et al., 1993).  
 
Fluorescence detection has been used after pre-column derivatization utilizing different 
fluorescent reagents. Following derivatization of carnitine and acetylcarnitine with a 
fluorescent trifluoromethanesulfonate as the derivatizing agent, fluorometric detection 
showed a 500-fold increase in sensitivity when compared to UV-detection of  
4’-bromophenacyl trifluoromethanesulfonate derivatives, thus enabling the detection of 
acetylcarnitine in dilute human muscle homogenate samples (Minkler et al., 1995). 
Derivatization with 9-anthryldiazomethane (ADAM) and separation in a silica column with 
isocratic elution enabled the determination of carnitine in solution and pharmaceutically 
produced tablets (Yoshida et al., 1988). Acylcarnitine’s profile was obtained in urine from 
healthy human subjects and patients with propionic acidemia, after derivatization with  
3-bromomethyl-6,7-dimethoxy-1-methyl-2(1H)-quinoxalinone. Carnitine and short-chain 
acylcarnitines were determined using different chromatographic conditions (column and 
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gradient) than the ones for medium-and long-chain acylcarnitines, requiring up to 80 minutes 
separation time, and cyclopentanoylcarnitine was used as internal standard (Kamimori et al., 
1994). Determination of carnitine, acetylcarnitine and propionylcarnitine in plasma samples 
after derivatization with 1-aminoanthracene, with a separation performed in 20 minutes in a 
250 x 4.6 mm C18 column under isocratic elution, was reported to get improved quantification 
limits of 5 µmol/L for carnitine, 1 µmol/L for acetylcarnitine and 0.25 µmol/L for 
propionylcarnitine and intra- and inter-day variabilities below 17% and accuracies of 10% 
(Longo et al., 1996). Derivatization with 2-(4-hydrazinocarbonylphenyl)-4,5-diphenylimidazole 
and separation in a reversed-phase column under gradient elution conditions yielded in 
detection limits ranging from 0.2 and 2.0 µmol/L for carnitine, short- and medium-chain 
acylcarnitines in plasma (Kuroda and al., 1996). 
When compared to UV detection, fluorescence detection facilitates enhanced detection and 
quantification limits. This might be useful for the determination of acylcarnitines, which are 
present at lower concentrations than carnitine within the body. However the chromatographic 
conditions appear to be more complicated and the analysis time would be longer. 
 
HPLC was also used to determine the enantiomeric purity of D- and L-carnitine and carnitine 
esters in pharmaceutical preparations. Two different techniques, a direct and an indirect, 
were used to detect the presence of the D-isomer up to 0.05% in a L-isomer preparation. The 
direct method involves the use of a chiral stationary phase, commercially available (Hirota et 
al., 1994) or laboratory-made (D'Acquarica et al., 1999), to separate the D- and L-isomers. 
Detection was performed either by UV or fluorescence after an appropriated derivatization 
(Hirota et al., 1994), or by evaporative light scattering, thus without requiring derivatization 
(D'Acquarica et al., 1999). The indirect method relies on the determination of 
diastereoisomers formed after reaction with a chiral reagent. Diastereoisomers were formed 
by derivatization with a chiral amino compound that has a chromophore for UV detection 
(Kagawa et al., 1999) or a chiral fluorescent compound (Freimuller and Altorfer, 2002), and 
subsequently separated on a reversed-phase column with isocratic elution.  
 
 
1.6.4  Capillary electrophoresis 
 
Because carnitine is a zwitterionic compound, presenting a permanent positive charge under 
acidic conditions (pKa = 3.8), it represents a good candidate for capillary electrophoresis 
(CE) analysis, where separation is based on the migration ability of charged molecules, 
according to their charge to mass ratio when an electric field is applied.  
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CE uses the same detectors as HPLC and the same reagents were used to derivatize free 
and acyl carnitine. After derivatization with the fluorescent ADAM, carnitine and 10 
acylcarnitines, up to palmitoylcarnitine, were separated in a 77 cm x 50 µm I.D. fused-silica 
capillary within 45 minutes using a running buffer containing methanol, as the formed 
derivatives were poorly soluble in water, phosphoric acid and sodium dodecyl sulfate (SDS) 
(Kiessig and Vogt, 1997). A CE method, after derivatization with 4’-bromophenacyl 
trifluoromethane sulfonate, enabling the separation of carnitine and 5 acylcarnitines in less 
than 8 minutes in a 40 cm x 50 µm I.D. fused-silica was developed in our laboratory (Vernez 
et al., 2000) (see Chapter 2). The assay used a binary buffer system containing 
phosphate/phosphoric acid and SDS, had limits of detection for carnitine and acetylcarnitine 
of 3 µmol/L and was applicable to urine samples.  
Indirect UV detection has been investigated on un-derivatized carnitine to overcome the non-
UV absorbance of carnitine (Mardones et al., 1999b). Using quinine as background signal in 
a sulphate buffer, carnitine and 5 acylcarnitines were separated within 20 minutes in a 57 cm 
x 75 µm I.D. fused-silica. The achieved detection limits, ranging from 1.0 to 7.3 µmol/L, 
depending on the compound, are not so good when compared to direct UV-detection 
preceded with a derivatization step, and accuracies were reported to be below 12%.  
 
Determination of the enantiomeric purity of D- and L-carnitine, in ratio up to 1:200 (Vogt et 
al., 1995), by CE was carried out with direct and indirect methods. In contrast to HPLC where 
a chiral stationary phase was used, determination by direct method using CE involved an 
achiral stationary phase in the presence of a chiral selector to separate the stereoisomers. 
After derivatization with the fluorescent 9-fluorenylmethyl chloroformate, reacting on the 
carboxyl group of carnitine, the stereoisomers were separated in a fused-silica capillary using 
a β-cyclodextrine (Mardones et al., 1999a) or a γ-cyclodextrine (Vogt et al., 1995) as the 
chiral selector. Indirect determination was achieved after derivatization with (+) or (-)-1-(9-
fluorenyl)ethyl chloroformate on the carboxyl groups and the formed diastereoisomers were 
separated using a phosphate buffer (De Witt et al., 1994; Vogt et al., 1995). 
 
More recently, CE was used coupled with mass spectrometry to determine free and 
acylcarnitines in urine and plasma samples from healthy humans. (Heinig and Henion, 1999). 
Un-derivatized carnitine and 11 acylcarnitines were separated in less than 10 minutes in a 80 
cm x 75 µm I.D. fused-silica capillary using an optimized mixed organic-aqueous buffer 
containing formic acid and ammonium acetate. As mass spectrometry detection is used, a 
baseline separation is not required, hence a reduced sample time, and better sensitivity is 
achieved. Limits of detection ranged for the different compounds between 0.1 and 1.2 
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µmol/L. Intra- and inter-day variabilities and accuracies performed on plasma samples were 
below 15%. 
 
Capillary electrophoresis generates separations with high resolution, in short analysis time 
and with the consumption of only small amounts of solvent. Nevertheless, organic solvents 
often need to be added to the electrolytes buffer in order to solubilize the more apolar 
derivatized carnitine and acylcarnitines. Because organic solvents tend to evaporate over 
time, the electrolytes buffer needs to be frequently renewed, which renders, according to our 
experience, analytical automation problematic. 
 
 
1.6.5  Mass spectrometry 
 
Given that a clinical diagnosis relies on the unambiguous identification of body fluid 
components, mass spectrometry (MS), due to its ability to provide structural information, is 
an attractive technique used on it’s own or as a detector coupled with a separation 
technique.  
 
The facility to analyze polar, thermal labile and non-volatile molecules, such as carnitine and 
acylcarnitines, was realized with the introduction of mild ionization techniques, such as fast 
atom bombardment (FAB), thermospray and more recently electrospray ionization (ESI) that 
allowed liquid chromatography to interface with mass spectrometry.  
Millington and co-workers pioneered mass spectrometry methods to assay carnitine and 
acylcarnitines, the most successful being the combination of fast atom bombardment 
ionization with tandem quadrupole mass spectrometry (FAB-MS/MS) for analysis of carnitine 
and acylcarnitines as methyl derivatives, after esterification on their carboxylic group, in urine 
and plasma samples (Millington et al., 1989) and dried blood spots (Millington et al., 1990; 
Millington et al., 1991). The methods utilizes the fact that acylcarnitine methyl esters produce 
a characteristic fragment ion at m/z 99, upon collision-induced dissociation, derived from the 
loss of both the quaternary ammonium function (as trimethylamine) and the acyl moiety, and 
that carnitine and acylcarnitines exhibit excellent mass spectra from a FAB ion source 
(Millington et al., 1989). The esterification blocks the acidic function, thereby the formation of 
protonated molecules is enhanced and the sensitivity of detection is improved. Scanning in 
the range of m/z 200-500 in the first quadrupole for precursors of this fragment, the third 
quadrupole being set at m/z 99, produces a profile showing free carnitine and acylcarnitines. 
Quantitation could be achieved by introduction of stable isotope labeled analogues of 
carnitine and acylcarnitines (Kodo et al., 1990). When using butylation instead of methylation 
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for the derivatization procedure, acylcarnitine butyl esters produce a common fragment at 
m/z 85, and amino acids can be determined simultaneously (Chace et al., 1993; Chace et al., 
1997). The widespread application of FAB-MS/MS for acylcarnitine analysis was limited by 
the difficulties in automating sample introduction into the mass spectrometer.  
 
The development of electrospray ionization allowed introduction of the sample into a 
continuously flowing solvent stream and offered a more robust and more sensitive alternative 
to FAB-MS/MS for the profiling of acylcarnitines (Rashed et al., 1994). ESI-MS/MS of 
carnitine and acylcarnitine methyl or butyl esters has been successfully applied in newborn 
screening (Rashed et al., 1995b; Rashed et al., 1997), selective screening (Van Hove et al., 
1993; Chace et al., 1997), post-mortem diagnosis using bile samples (Rashed et al., 1995a) 
and for prenatal diagnosis (Nada et al., 1996; Shigematsu et al., 1996) for many inborn 
errors of metabolism. 
The presence of carnitine biosynthesis precursors, trimethyllysine and butyrobetaine, in 
serum samples has been determined by ESI-MS/MS (Terada et al., 1999). However, 
although butyrobetaine could be successfully measured after methylation, the analysis of 
methylated trimethyllysine suffered from homoarginine interference, which could be 
overcome by propylation and acetylation of the sample instead of methylation.  
 
In the field of screening for metabolic disorders, quantitative analysis is performed using 
stable isotope labeled analogues and yield highly sensitive and reproducible results. Each 
metabolic disorder is associated with primary and secondary markers and for each marker a 
cut-off value is defined. Any value above this threshold is strongly indicative for the presence 
of the suspected disorder. The setting of appropriate cut-off values would minimize false 
negatives without producing an excessive number of false positives. As carnitine and 
acylcarnitine concentrations are variable according to the weight at birth, full-term baby or 
premature baby, and age at collection time, optimal discrimination may require determination 
of cut-off points for these distinct subpopulations (Zytkovicz et al., 2001). 
Rather than using only absolute concentrations of acylcarnitines, diagnosis for metabolic 
disorders relies often on semi-quantitative data based on the ratio between two 
acylcarnitines or between an acylcarnitine and an internal standard. For instance, Rashed 
and coworkers defined isovaleryl academia by an isovalerylcarnitine to acetylcarnitine ratio 
higher than 0.09 (Rashed et al., 1997). Chace and colleagues considered an 
octanoylcarnitine concentration above 0.3 µmol/L combined with an octanoyl- to 
acetylcarnitine ratio above 0.1 as strongly indicative of MCAD deficiency (Chace et al., 1997) 
and that the use of a ratio between two acylcarnitines, instead of the concentrations of one 
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acylcarnitine, could reduced false-positive diagnosis due to general increase in the short-
chain acylcarnitines (Chace et al., 2001b). 
 
Inaccuracies in the measurement of free carnitine (Johnson, 1999) and octanoylcarnitine 
(Chace et al., 2001a) from blood spots by ESI-MS/MS were reported. 
Standard procedure to derivatize carnitine and acylcarnitine to butyl esters implies heating of 
the dried extract in the presence of butanolic HCl at 650C for 15 minutes (Chace et al., 1995; 
Rashed et al., 1995b). If incomplete butylation occurs, under milder conditions for instance, a 
loss of selectivity due to interference from un-derivatized acylcarnitines that give the same 
product ion than butyl esters at m/z 85 can be expected (Chace, 2001). Prolonged butylation 
was demonstrated to produce acylcarnitine hydrolysis, resulting in decreased signal 
intensities for acylcarnitine ions and corresponding increase of the carnitine ion peak 
(Johnson, 1999). Thus, the free carnitine concentrations should be viewed with caution in 
samples with high concentrations of acylcarnitines. Determination of un-derivatized free 
carnitine in healthy newborns was found to give 35% lower concentrations than the one 
obtained after a standard butylation procedure (Schulze et al., 2003). This suggests that it 
would be preferable to perform carnitine ESI-MS/MS analysis without derivatization, a 
process that is realizable (Stevens et al., 2000), but in which sensitivity is somewhat reduced 
for dicarboxylic acylcarnitines when compared to butyl ester analysis (Manning et al., 2001). 
The use of racemic D,L- octanoylcarnitine to establish a calibration curve for blood spot 
analysis was shown to produce overestimation of the octanoylcarnitine content (Chace et al., 
2001a). The authors found that the racemic mixture gave smaller signals than L-
octanoylcarnitine alone, and attributed it to a specific hydrolysis of the D- isomer during the 
sample preparation. 
 
Analysis of free and acyl carnitine butyl esters by ESI-MS/MS for the screening of errors of 
metabolism are mostly performed on dried blood spot samples. However, quantitative 
determination on plasma or serum samples (Vreken et al., 1999), where a clear 
discrimination could be made between controls and affected individuals, was reported to be 
as reliable. The use of butylated urine samples was reported to be suitable for diagnostic 
purposes with analogous criteria than the one used for dried blood spots (Mueller et al., 
2003). Nonetheless, as urine was not submitted to extraction, influences of the matrix on 
signal and ionization suppression had to be overcome by diluting urine samples 10 fold with 
methanol. 
 
ESI-MS/MS presents excellent sensitivity and specificity. Starting from a drop of blood, 
plasma or urine, the whole content of carnitine and its acyl esters can be depicted. Typical 
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linearity ranges obtained for the analysis of the butylated compounds are 5-100 µmol/L for 
carnitine, 2.5-50 µmol/L for acetylcarnitine and 0.2-10 µmol/L for the other acylcarnitines. 
Detection limits are between 0.02 and 0.2 µmol/L (depending on the analyzed acylcarnitine), 
what represent an improvement when compared to the detection limits obtained with HPLC-
UV determination. Reported coefficients of variation for the determination of carnitine and 
acylcarnitine as butyl or methyl esters in blood spot, plasma or serum samples are below 
14% for intra-day assays and below 19% for inter-day assays (Chace et al., 1997; Inoue et 
al., 1999; Chace et al., 2001b; Fingerhut et al., 2001). Similar coefficients of variation were 
reported for the determination of carnitine as butyl ester in urine (Mueller et al., 2003).  
 
Unfortunately, tandem mass spectrometry is unable to distinguish isomeric compounds as 
they have the same precursors and product ions. Based on their differential relative 
abundance of the product ions, valeryl- and isovalerylcarnitine could nonetheless be 
differentiated (Gaskell et al., 1986). A distinction was obtained for the isomeric 
valproylcarnitine and octanoylcarnitine with a prior chromatographic separation (Millington et 
al., 1985). Furthermore, as tandem mass spectrometry is performed on biological samples 
with little sample clean up, the procedure suffers from limitations due to interferences that 
can arise in a biological matrix. 
Nonetheless, because of the automated sample introduction, ESI-MS/MS brought a high-
throughput method of newborn screening and is used in many laboratories as the method of 
choice for the analysis of carnitine and acylcarnitines and screening for metabolic disorders, 
such as fatty acid oxidation defects or organic acidemias. It represents, however, only the 
first stage of making a diagnostic. As the sensitivity depends upon the chosen cut-off, 
confirmation of the diagnosis or follow up require other biochemical/molecular genetic 
techniques (Chace et al., 2001c; Carpenter and Wiley, 2002; Shigematsu et al., 2003).  
 
HPLC-MS/MS determination of carnitine, acetylcarnitine and butyrobetaine has been 
obtained unintentionally, when a reversed-phase assay using an ion-pairing reagent was set 
up to determine acetylcholine concentrations in rat brain (Zhu et al., 2000). The 
chromatogram obtained showed three unexpected extra peaks. As acetylcholine is a 
quaternary ammonium compound, it was supposed that the three peaks were belonging to 
the same class of compounds and subsequent MS/MS experiments yielded to the 
identification of carnitine, acetylcarnitine and butyrobetaine. 
HPLC-MS/MS has been used to investigate carnitine biosynthesis precursors in urine 
samples, previously derivatized to methyl esters, using step gradient ion-pair mobile phase 
(Vaz et al., 2002). Under these conditions, carnitine, butyrobetaine, trimethyllysine and 
hydroxy-trimethyllysine were resolved within 13 minutes. Quantification was performed with 
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stable isotope dilution. The limits of detection from 0.05 to 0.1 µmol/L are similar to  
those obtained by ESI-MS/MS. The imprecision for the determination of carnitine and 
butyrobetaine was below 5% for intra-day assays and below 9% for inter-day assays (Vaz et 
al., 2002).  
In our laboratory, we set up an HPLC-MS/MS method to determine carnitine and 
acylcarnitines in urine and plasma samples. In contrast to most published methods, the 
analytes were not derivatized and the mass spectrometer used was an ion-trap machine. 
The quantification limits achieved were between 0.25 and 5 µmol/L depending on the 
compound (see Chapters 3 and 4) (Vernez et al., 2003). 
 
 
1.6.6  Carnitine extraction 
 
Carnitine determination in pharmaceuticals can be performed directly on an aliquot of the 
dissolved tablets or on an aliquot of the injection or drinkable solution. When carnitine and 
acylcarnitines have to be determined in biological fluids or tissues, a previous appropriate 
extraction procedure is often required. Solid-phase extraction (SPE) on disposable cartridges 
is the most commonly used extraction method for the determination of carnitine and 
acylcarnitines. Several procedures have been described, following a previous protein 
precipitation step with acetonitrile and/or methanol, for both plasma and serum analysis.  
 
SPE on silica column was used to extract carnitine and acylcarnitines from 100 µL plasma, 
after protein precipitation with acetonitrile/methanol (3:1; v/v), or 25 µL urine and elution was 
performed with 4 mL 1% acetic acid in methanol (Minkler and Hoppel, 1993a; b). The 
reported recoveries were 50% for carnitine, 63-68% for short-chain acylcarnitine and 58-67% 
for medium-chain acylcarnitines in urine (Minkler and Hoppel, 1993b). In plasma, the mean 
recoveries were 64% for carnitine, 64-67% for short-chain acylcarnitines and 62-78% for 
medium-chain acylcarnitines (Minkler and Hoppel, 1993a). The use of a more acidic solvent, 
methanol/water/acetic acid (50:45:5), to elute carnitine and acylcarnitines from a silica 
column enabled to reduce the required elution volume to 2 mL and to increase the recoveries 
(Heinig and Henion, 1999). Extraction performed on 2 mL urine showed mean recoveries of 
88% for carnitine, 85-97% for short-chain acylcarnitines and 79-83% for medium-chain 
acylcarnitines. The same protocol applied to 300 µL plasma gave mean recoveries of 75% 
for carnitine, 76-106% for short-chain acylcarnitines and 91% for medium-chain 
acylcarnitines. 
Extraction from 200 µL plasma on a reversed-phase C18 column with methanol elution 
yielded recoveries of 88% for acetylcarnitine, 85% for propionylcarnitne and 80% for 
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octanoylcarnitine (Millington et al., 1989). When a C18 column was combined with an anion-
exchange resin, recoveries obtained for the extraction of 200 µL urine were 52% for 
acetylcarnitine, 68% for propionylcarnitine and 52% for octanoylcarnitine. The association of 
an anion-exchange resin with a cation-exchange column was shown to increase the 
recoveries of low molecular weight acylcarnitine in urine samples (99% for acetylcarnitine 
and 98% for propionylcarnitine) (Millington et al., 1989).  
Strong cation-exchange columns have been used on acidified urine samples, together with 
ammoniac (Kumps et al., 1994) or with pyridine (Kamimori et al., 1994) elution. Elution with 
pyridine gave analytical recoveries higher than 96% for carnitine, short- and medium-chain 
acylcarnitines, whereas long-chain acylcarnitines showed analytical recoveries between 70-
76% (Kamimori et al., 1994). Ammoniac elution gave extraction recoveries between 90 and 
100% for the different acylcarnitines (Kumps et al., 1994).  
Anion-exchange columns have also been used and mean extraction recoveries from 100 µL 
plasmas were reported to be between 82-85% for carnitine, 93-96% for acetylcarnitine and 
85-91% for propionylcarnitine, depending on the concentration tested (Longo et al., 1996). 
 
No matter which SPE column is used, a similar tendency can be observed. Recoveries of 
carnitine and medium-chain acylcarnitines are often of the same magnitude, whereas 
recovery of short-chain acylcarnitines is often increased. The use of specific strong cation-
exchange columns appears to enable increased recoveries for the extraction of carnitine and 
acycarnitines. 
 
Liquid-liquid extraction has been proposed to extract the more hydrophobic and protein-
bound long-chain acylcarnitines from plasma samples. Extraction from 500 µL plasma with 
500 µL ethyl acetate gave recoveries of 66% for palmitoylcarnitine and 47% for 
stearoylcarnitine (Heinig and Henion, 1999). 
 
A simple liquid extraction is also usually applied for ESI-MS/MS analysis of dried blood spots 
on filter paper (Chace et al., 1995; Rashed et al., 1995b; Chace et al., 1997; Fingerhut et al., 
2001).  Carnitine and acylcarnitines are extracted from the spots, corresponding from 3 to 15 
µL whole blood, with 150 to 400 µL methanol. Reported mean recoveries are 93% for 
carnitine, 86-101% for acetylcarnitine, 92-126% medium-chain acylcarnitine and 83-97% for 
long-chain acylcarnitines, depending of the concentrations taken into consideration (Chace et 
al., 1997; Fingerhut et al., 2001). Extraction of 20 µL serum with 1 mL methanol gave similar 
recoveries of 93% for carnitine and 77% for butyrobetaine (Inoue et al., 1999). 
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1.7  AIMS OF THE THESIS 
 
The major objective of this thesis was to develop analytical tools for the quantitative 
determination of endogenous carnitine and acylcarnitines in biological samples. 
 
To obtain the profile of each individual acylcarnitine, in order to be able to detect metabolic 
disorders, for instance, a separation technique is required. HPLC and CE have been 
successfully used, coupled with UV or fluorescent detection. An HPLC method after 
derivatization with 4’-bromophenacyl trifluoromethane sulfonate, based on the assay 
described by Minkler and Hoppel (Minkler and Hoppel, 1993b), was in use in our laboratory. 
Briefly, samples were extracted by solid phase extraction on a silica column and HPLC 
separation took place in a 150 x 4.6 mm C8 reversed-phase column using a quaternary 
gradient over 45 minutes. Limitations of this method were the relative long analysis time and 
the use of large volumes of solvent as the flow was set at 1 mL/min. 
 
Since capillary electrophoresis is adapted to the analysis of charged molecules, such as 
carnitine, and as derivatization with 4’-bromophenacyl trifluoromethane sulfonate enables 
UV-detection, the combination of these two techniques were exploited to set up a new 
method for carnitine and short- and medium-chain acylcarnitines in urine. The objective was 
to get shorter analysis time and reduced consumption of solvent. 
 
When our laboratory received the opportunity to acquire an ion trap mass spectrometer, 
which in itself dictates a restriction in the use of compatible solvents, the method we had 
developed for CE could not be directly transposed, namely, because the SDS used in the 
running buffer is not MS friendly. Additionally, CE analysis proved to be difficult to automate 
as the running buffer has to be renewed every two analyses. Finally, since MS detection, 
owing to its sensitivity, enables the use of small HPLC columns and thus reduced solvent 
volumes, we focused on the development of an HPLC-MS/MS assay. The major advantage 
brought by MS detection is that a derivatization step becomes unnecessary, and the assay 
could be extended to the detection of long-chain acylcarnitines.  
HPLC-MS/MS was first developed to analyze urine samples and then its application was 
extended to plasma, where the precursor to carnitine biosynthesis, butyrobetaine, could also 
be determined.  
 
Different extraction procedures were considered in order to optimize the recovery of carnitine 
and acylcarnitines. For this purpose, many solid phase extraction materials and elution 
Chapter 1 
 60 
buffers were tested as well as liquid-liquid extraction, especially for the determination of long-
chain acylcarnitines. 
In order to achieve the potential of the newly developed assay, it was applied to the follow up 
of a clinical study, where carnitine, acylcarnitines and butyrobetaine plasma content were 
investigated in patients with end-stage renal disease undergoing long-term hemodialysis. 
Profiles of these compounds, extraction kinetics during a hemodialysis session and kinetics 
following intravenous administration of carnitine after a hemodialysis session were 
considered and comparisons were established before and after patients were supplemented 
with two different dosages of carnitine at the end of each hemodialysis session. 
 
The different projects investigated during my thesis were the topic of four publications. These 
publications are presented in chapters 2 to 5 in the form they have been published (chapter 
2, 3 and 4) or submitted (chapter 5) to publication. To facilitate the reading, all the references 
were brought together at the end of this script.   
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2.1  SUMMARY 
 
A capillary electrophoresis method is described for the simultaneous analysis of carnitine and 
short-chain acylcarnitines in aqueous standard solutions and urine samples. Samples were 
worked up using silica gel extraction and derivatization with 4’-bromophenacyl 
trifluoromethanesulfonate. Separation was performed in less than 8 minutes using a binary 
buffer system containing phosphate/phosphoric acid and sodium dodecyl sulfate. 3-(2, 2, 2-
trimethylhydrazinium)-propionate (mildronate) was used as an internal standard. The method 
was developed with aqueous standard solutions and then applied successfully to spiked and 
unspiked human urine samples. The limit of detection for both carnitine and acetylcarnitine is 
3 µmol/L. 
 
 
2.2  INTRODUCTION 
 
Carnitine is an endogenous compound, which is either biosynthesized (from the amino acids 
L-lysine and L-methionine) or taken up by the food (mainly in meat and milk) (Carter et al., 
1995). Carnitine is essential for the transport of fatty acids into the mitochondrial matrix, 
where they are metabolized (β-oxidation for energy production). Fatty acids bind carnitine via 
an ester binding on the hydroxyl group in position 3 of carnitine (see Figure 1), thereby 
generating various acylcarnitines with different chain lengths. Carnitine is also important to 
maintain the cellular pool of free coenzyme A (Friolet et al., 1994). Free (non-esterified) 
carnitine and acetyl-carnitine represent the major constituents of the body fluids and tissue 
carnitine pools in normal subjects. Under pathological conditions, other acylcarnitines can 
accumulate, for instance in inherited or acquired organic acidurias such as propionic or 
isovaleric acidemia. Profiling of the acylcarnitines in body fluids is therefore useful for 
diagnostic purposes. 
 
Existing analytical methods are problematic in that they either do not allow differentiation 
between acylcarnitines (radioenzymatic method) or are time-consuming [high-performance 
liquid chromatography (HPLC method)]. The radioenzymatic assay is strictly enantioselective 
for L-carnitine, but it allows only the determination of the free carnitine, short-chain 
acylcarnitine (difference between total acid-soluble and free carnitine) and long-chain 
acylcarnitines (Hoppel, 1991). HPLC methods have been developed to obtain a profile of 
acylcarnitines (Minkler and Hoppel, 1993a; b; De Witt et al., 1994; Vogt et al., 1995; Longo et 
al., 1996). As carnitine has no specific UV absorption, it has to be derivatized for detection. 
Different chromophores have been described in the literature, reacting either with the 
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carboxyl or the hydroxyl group of carnitine. Examples of such derivatizing agents include 1-
aminoanthracene (Longo et al., 1996), (+)-[1-(9-fluorenyl)-ethyl]-chloroformate [(+)-FLEC] 
(De Witt et al., 1994) and 9-fluorenyl-methylchloroformate (FMOC) (Vogt et al., 1995). 
Minkler and Hoppel used 4’-bromophenacyl trifluoromethanesulfonate which reacts with the 
carboxyl group of carnitine and can be detected at 260 nm (Minkler and Hoppel, 1993a; b). 
 
Capillary electrophoresis (CE) may have several advantages in comparison to HPLC for the 
separation of carnitine and acylcarnitines. The separation time is generally shorter and the 
amount of solvent used smaller, rendering the analysis faster and less expensive. 
Accordingly, CE procedures for the separation of carnitine and acylcarnitine standard 
solutions have been described (De Witt et al., 1994; Vogt et al., 1995; Vogt and Kiessig, 
1996; Kiessig and Vogt, 1997; Mardones et al., 1999a; b). Most recently, also a CE-mass 
spectrometry (MS) method for the separation of carnitine/acylcarnitines in biological fluids 
has been published, but MS is not widely available (Heinig and Henion, 1999). In the present 
paper we describe a CE method to separate acylcarnitines up to C8 in standard solutions and 
in urine, after derivatization of the carboxyl group with 4’-bromophenacyl 
trifluoromethanesulfonate. 
 
 
             CH3 
             |  
H3C - N+ - CH2 - CH - CH2 - COO- 
   |  | 
                         CH3    OR 
 
 
 R Name R Name  
     
 
 H Carnitine COC(CH3)3 Isovalerylcarnitine 
 COCH3 Acetylcarnitine CO(CH2)4CH3 Hexanoylcarnitine 
 COCH2CH3 Propionylcarnitine CO(CH2)6CH3 Octanoylcarnitine 
 
Figure 1: Chemical structures of carnitine and short-chain acylcarnitines analyzed in this study. 
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2.3 EXPERIMENTAL 
 
2.3.1 Chemicals 
 
L-Carnitine was from Fluka (Buchs, Switzerland), and acetylcarnitine, hexanoylcarnitine, 
octanoylcarnitine and sodium dodecyl sulfate (SDS) from Sigma (St. Louis, MO, USA). 
Propionylcarnitine and isovalerylcarnitine were a gift of Sigma-Tau (Zofingen, Switzerland). 
Potassium hydroxide, potassium dihydrogensulfate, sodium dihydrogenphosphate dihydrate, 
silica gel and acetic acid were purchased from Merck (Darmstadt, Germany). Phosphoric 
acid was from Fluka (Buchs, Switzerland). N,N-diisopropylethylamine was from Aldrich 
(Buchs, Switzerland). Methanol and acetonitrile were HPLC grade from Biosolve (The 
Netherlands). 3-(2, 2, 2-trimethylhydrazinium)-propionate (mildronate) was synthesized using 
the methods of Le Berre and Porte (Le Berre and Porte, 1978) and Kosower and Patton 
(Kosower and Patton, 1961) with some modifications. 3-(2, 2, 2-trimethylhydrazinium)-
propionate was used as an internal standard. The derivatizing agent 4’-bromophenacyl 
trifluoromethanesulfonate was synthesized as described elsewhere (Ingalls et al., 1984; 
Minkler and Hoppel, 1992). 
 
 
2.3.2 Standard solutions 
 
A stock 100 mmol/L L-carnitine solution was prepared in water, standardized by a 
spectrophotometric method (Marquis and Fritz, 1964), stored in aliquots at -20 OC and diluted 
with water to the desired concentration just before use. Stock 20 mmol/L solutions of all other 
acylcarnitines were prepared in water (not standardized), stored in aliquots at -20 OC and 
diluted with water to the desired concentration as needed. A 50 µmol/L internal standard 
solution (mildronate) was prepared in water and stored at -20 OC. 
 
 
2.3.3 Sample preparation and derivatization 
 
Carnitine, acylcarnitines and total carnitine were extracted and derivatized according to 
Minkler et al. (Minkler et al., 1995) with minor modifications. Extraction was performed from 
50 µL human urine (undiluted or after dilution up to 10 times) or aqueous standard mixtures. 
A 50-µL volume of aqueous mildronate solution (50 µmol/L) were used as internal standard. 
The samples were dried with an evaporator under reduced pressure at 35 °C. The 
derivatized and dried samples were dissolved with 50 µL acetonitrile-water (80:20, v/v) and 
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injected into the CE system. If necessary, samples were diluted further with the same 
solvent. 
 
 
2.3.4 Capillary electrophoresis conditions 
 
Electrophoresis was carried out on a BioFocus 3000 CE system (Biorad, Hercules, CA, USA) 
equipped with a multi-wavelength detector operating at 260 nm. The separation took place in 
a 40 cm (35.4 cm to detector) x 50 µm I.D fused-silica capillary thermostated at 20 OC. A 
voltage of 18 kV was applied in a constant and cationic mode for a current of about 19 µA. 
Samples were hydro-dynamically injected with pressure for 2 p.s.i. * s (1 p.s.i. =6894.76 Pa). 
 
The capillary was conditioned each morning during 5 min with 0.1 mol/L NaOH, then during 5 
min with water and finally for 30 min with the running buffer. Between runs, a 2 min wash 
with the running buffer was performed. At the end of the day, the capillary was rinsed for 5 
min with 0.1 mol/L NaOH and for another 15 min with water. The optimized running buffer 
(optimized for separation of carnitine and acylcarnitines) was 20 mmol/L NaH2PO4, 20 mol/L 
H3PO4 and 20 mmol/L SDS in acetonitrile-water (50:50, v/v). Fresh buffer was prepared each 
day from a 2 mol/L salt aqueous solution and a 1 mol/L SDS aqueous solution. Both inlet and 
outlet vials were refreshed every two analyses. 
 
 
2.3.5 Radioenzymatic analysis of urine samples 
 
Urine samples of healthy persons were assayed for free and for total carnitine with the 
radioenzymatic method as described by Hoppel (Hoppel, 1991). 
 
 
2.4 RESULTS AND DISCUSSION 
 
2.4.1 Choice of the internal standard 
 
The internal standard has to have a similar behavior in the analytical system as the analytes 
but should not be present in biological samples. Mildronate (Figure 2), an inhibitor of γ-
butyrobetaine hydroxylase, the enzyme catalyzing the last step in carnitine biosynthesis, was 
chosen due to its structural similarity to carnitine (Tsoko et al., 1995; Galland et al., 1998). 
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Pilot studies showed that extraction and derivatization properties of mildronate did not differ 
from carnitine. 
 
 
             CH3 
             |  
H3C - N+ - NH - CH2 - CH2 - COO- 
   |   
                         CH3  
 
Figure 2: Chemical structure of 3-(2, 2, 2-trimethylhydrazinium)-propionate 
(mildronate) which was used as an internal standard 
 
 
2.4.2 Separation of acylcarnitines 
 
Carnitine and acylcarnitines are zwitterionic compounds, which are positively charged in 
acidic solutions (Figure 1). The derivatization with 4’-bromophenacyl 
trifluoromethanesulfonate is performed on the carboxyl group of carnitine/acylcarnitines and 
introduces a permanent positive charge (the charge of the nitrogen in position 4 of carnitine, 
see Figure 1). Therefore, a positive voltage polarity (anode at the inlet) was chosen. As all 
analyzed compounds have the same charge, they were expected to be separated mainly 
according to their molecular mass: the small internal standard shows the fastest migration, 
followed by carnitine and then by the acylcarnitines in the order of increasing chain length of 
the acyl group. The molecular masses of the analytes are quite close, however, requiring the 
use of SDS to widen the separation window. Due to decreased hydrophilicity after 
introduction of an apolar group with derivatization, an organic solvent had to be added to the 
running buffer to solubilize all compounds. Non-aqueous or binary running buffers do not 
only allow analysis of more hydrophobic compounds by solubilization, but also can introduce 
different selectivity (Sarmini and Kenndler, 1997; Valko et al., 1997). Furthermore, the 
interaction between analytes and silanol groups appears to be favorably modified. 
 
Acetonitrile was chosen as an organic solvent, as it had proved its efficiency in solubilizing 
and separating carnitine and acylcarnitines by HPLC (Minkler and Hoppel, 1993b). Different 
concentrations of acetonitrile in the buffer (initially 10 mmol/L NaH2PO4, 10 mmol/L H3PO4 and 
10 mmol/L SDS) were tested. With 30% (v/v) acetonitrile in water, the solubility of the analytes 
was insufficient, resulting in very broad peaks. Fifty and 80% (v/v) acetonitrile in starting buffer 
showed similar separation profiles of carnitine and acylcarnitine standards. A concentration of 
50% (v/v) acetonitrile in starting buffer was chosen as a compromise between solubility of 
carnitine/acylcarnitines and prevention of buffer evaporation during the analysis.  
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The SDS concentration was varied between 10 to 30 mmol/L. In the presence of 10 mmol/L 
SDS, peaks were not well separated, whereas in the presence of 30 mmol/L SDS, the 
migration time increased dramatically. A concentration of 20 mmol/L SDS resulted in an 
acceptable resolution of the analytes with a short running time. Finally, the 
phosphate/phosphoric acid concentration of the starting buffer was adjusted to 20 mmol/L in 
order to sharpen the peaks. 
 
A typical profile of a standard solution of short-chain acylcarnitines is shown in Figure 3. All 
peaks were attributed to the acylcarnitine indicated by injecting each standard alone. As 
expected, the migration order corresponds to the order of the molecular masses. The peak 
attribution was confirmed by the disappearance of the corresponding acylcarnitine peaks and 
the simultaneous increase in the carnitine peak after hydrolysis, by which all acylcarnitines 
are converted into carnitine (Figure 4). Figure 3 demonstrates that the five acylcarnitines 
chosen can be separated from carnitine and internal standard in less than 8 minutes. The 
separation is acceptable for all analytes assayed except isovalerylcarnitine, which could be 
resolved hardly from an interfering peak of the derivatizing agent. 
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Figure 3: Typical electropherogram of carnitine and short-chain acylcarnitines standards. The concentrations are 
100 µmol/L for carnitine/acylcarnitines and 50 µmol/L for the internal standard. The final preparation was diluted 
10 times before injection. Capillary electrophoresis conditions are given in the Experimental section. The peaks 
are: 1 : internal standard, 2 : carnitine, 3 : acetylcarnitine, 4 : propionylcarnitine, 5 : isovalerylcarnitine, 6 : 
hexanoylcarnitine, 7 : octanoylcarnitine and r : peak from the derivatizing agent. 
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Figure 4: Electropherogram of hydrolyzed carnitine and short-chain acylcarnitine standards. The concentrations 
are 100 µmol/L for carnitine/acylcarnitines and 50 µmol/L for the internal standard. The final preparation was 
diluted 10 times before injection. Conditions and peaks as in Figure 3. 
 
 
2.4.3 Method characterization 
 
The optimized method was characterized for carnitine and acetylcarnitine standards. 
The linearity was tested over a concentration range of 5 to 100 µmol/L for both carnitine and 
acetylcarnitine. Regression lines were calculated with the corrected area/migration time 
versus concentration. As shown in the Table 1, a good linearity (r > 0.99) was obtained for 
both compounds. 
 
 
Table 1: Regression data for carnitine and acetylcarnitine standard solutionsa 
            
 
    y = ax + b    Correlation  
            
 
    a   b   r   
            
 
 Carnitine   1.03 ± 0.05 -0.002 ± 0.024  0.999 ± 0.001 
 Acetylcarnitine 1.10 ± 0.06  0.014 ± 0.026  0.999 ± 0.001  
            
 
 a
 The concentration range was 5-100 µmol/L. n = 5 individual determination for every curve. 
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The limit of detection, defined as a signal-to-noise ratio of 3, was established by injecting 
serial dilutions of the corresponding 100 µmol/L standard solutions. For both carnitine and 
acetyl-carnitine the limit of detection was 3 µmol/L. 
 
The inter-day reproducibility performed over 5 days (complete workup of four samples at four 
different concentrations) is shown in Table 2. For both compounds the relative standard 
deviation (RSD) is below 7% for the higher concentrations (25-100 µmol/L) but increases to 
approximately 20% with the lowest concentration (5 µmol/L). The intra-day reproducibility, 
also shown in Table 2, was performed by analyzing three individual samples on the same 
day. The results obtained are similar to the ones obtained for the inter-day assays. 
 
 
Table 2: Reproducibility of the quantification of carnitine and acetylcarnitine standard solutionsa 
 
   
 Corrected Area/Migration time 
 
    
 
Concentration 
(µmol/L) 
Average RSD 
(%) 
n 
Inter-day     
     Carnitine 100 2.092 5.4 5 
 
  50 0.968 2.6 5 
 
  25 0.530 6.6 4 
 
    5 0.110 21.0 4 
     
     Acetylcarnitine  100 
 
2.211 
 
5.0 
 
5 
 
  50 1.137 6.5 5 
 
  25 0.577 5.9 5 
 
    5 0.117 16.1 3 
Intra-day 
    
     Carnitine 100 2.216 1.5 3 
 
  25 0.635 4.6 3 
     
     Acetylcarnitine  100 
 
2.514 
 
6.4 
 
3 
 
  25 0.722 10.2 3 
 
a
 Individual samples of standard solutions were worked up and analyzed on the same or on different days as 
indicated in the Table. 
 
 
2.4.4 Application to urine samples 
 
The next step was to analyze urine spiked with a mixture of the same acylcarnitines (Figure 
5). The separation of the acylcarnitines added proved to be as efficient as for the standard 
solutions in Figure 3. Peak attribution was performed by spiking with individual acylcarnitines 
and by hydrolyzing the spiked urine samples (not shown). An additional peak can be 
observed in urine which elutes just before the internal standard, is not hydrolyzed and does 
not interfere with the analytes of interest.  
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Figure 5: Electropherogram of human urine spiked with 100 µmol/L of each acylcarnitine and 50 µmol/L of 
internal standard. Conditions and peaks are as in Figure 3. u : represents a peak which is observed with urine 
samples but not with standard solutions. 
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Figure 6: Electropherogram of human urine spiked with internal standard (50 µmol/L). The final preparation was 
diluted five times before injection. Conditions and peaks are as in Figure 3. 
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Free and total carnitine were quantified in five urines of healthy persons (Figure 6). The 
urines were appropriately diluted so that their content in free and total carnitine were in the 
calibration range. The results were compared with those of the radioenzymatic method and 
are presented in Table 3. The correlation between the two methods was in an acceptable 
range (r=0.998 for free and 0.959 for total carnitine). On the other hand, the slopes were 
different from one (0.77 for free carnitine and 1.55 for total carnitine), indicating that in urine, 
the free carnitine concentration tends to be over- and the total carnitine concentration 
underestimated by the current CE method. 
 
Additional urine samples contained variable amounts of propionylcarnitine but no other 
acylcarnitines (results not shown). Unfortunately, we did not have access to urine samples of 
patients with organic acidurias. 
 
Table 3: Quantification of free and total carnitine in samples of human urinesa 
 
 
Free carnitine (µmol/L) 
 
  
Total carnitine (µmol/L) 
 
 
Urine sample 
 
CE 
 
 
REA 
 
 
CE 
 
 
REA 
 
 
1 
 
  8.8 
 
10.0 
 
30.4 
 
22.8 
2 27.9 40.0  119  112 
3   7.6 10.5 14.6 16.5 
4 11.0   7.1  137  143 
5  113 144  379  233 
 
a
 Free and total carnitine was determined by capillary electrophoresis (CE) and by the radioenzymatic assay (REA) 
in five human urines. 
 
 
2.5 CONCLUSION 
 
A new CE method was developed to analyze carnitine and acylcarnitines in standard 
aqueous solutions and in human urine samples. Seven compounds (carnitine, different 
acylcarnitines and internal standard) could be separated and identified in less than 8 
minutes. In comparison to similar HPLC methods, analysis of carnitine/acylcarnitines by CE 
is faster and consumes less solvents, rendering CE less expensive. While the current 
method is usable for separation of carnitine and acylcarnitines, the quantification of carnitine 
and acylcarnitines should still be improved. 
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3.1  SUMMARY 
 
A high-performance liquid chromatography – mass spectrometry method has been 
developed for the simultaneous determination of native carnitine and eight acylcarnitines in 
urine. The procedure uses a solid phase extraction on a cation exchange column and the 
separation is performed without derivatization within 17 min on a reversed-phase C8 column 
in the presence of a volatile ion-pairing reagent. The detector was an ion trap mass 
spectrometer and quantification was carried out in the MS/MS mode. Validation was done for 
aqueous standards at ranges between 0.75 and 200 µmol/L, depending on the compound. 
Carnitine was quantified in urine and comparison with a radioenzymatic assay gave a 
satisfactory correlation (R2 = 0.981). The assay could be successfully applied to the 
diagnostic of pathological acylcarnitines profile of metabolic disorders in urines of patients 
suffering from different organic acidurias. 
 
 
3.2  INTRODUCTION 
 
Carnitine is an endogenous compound present in most mammalian tissues, reaching 
particularly high concentrations in skeletal muscle and heart (Bremer, 1983; Friolet et al., 
1994). The most important role of carnitine is the transport of fatty acids into the 
mitochondrial matrix, where they are metabolized via β-oxidation to produce energy (Fritz, 
1955; Bremer, 1983). For this purpose carnitine can be esterified on the hydroxyl group in 
position 3 (see R1 in Figure 1), generating various acylcarnitines with different chain lengths. 
A second function of carnitine is the maintenance of the cellular pool of free (unesterified) 
coenzyme A by the transfer of acyl-groups from acyl-CoAs to carnitine (Brass and Hoppel, 
1980; Bremer, 1983). While free carnitine and acetylcarnitine represent the major 
constituents of the carnitine pool in normal subjects (Bremer, 1983; Friolet et al., 1994), 
analysis of the different acylcarnitines can provide important information about inherited or 
acquired metabolic disorders such as organic acidurias (Minkler and Hoppel, 1993b). 
 
Carnitine determination has been performed with numerous methods. A radioenzymatic 
assay (Hoppel, 1991) allows the specific determination of L-carnitine, whereas high-
performance liquid chromatography (HPLC) and capillary electrophoresis (CE) have been 
used to get enantiomeric separation of D- and L- carnitine (De Witt et al., 1994; Hirota et al., 
1994; Vogt and Kiessig, 1996; Mardones et al., 1999a) and to obtain the acylcarnitine profile 
(Minkler and Hoppel, 1993a; b; Kamimori et al., 1994; Longo et al., 1996; Vernez et al., 
2000). The main drawback of these methods is the need of a derivatization step to introduce 
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a lacking chromophoric group on carnitine and its esters to gain UV or fluorescent 
absorption. Different chromophores have been used, reacting either on the hydroxyl (De Witt 
et al., 1994; Vogt and Kiessig, 1996; Mardones et al., 1999a) or on the carboxyl groups 
(Minkler and Hoppel, 1993a; b; Hirota et al., 1994; Kamimori et al., 1994; Longo et al., 1996; 
Vernez et al., 2000) of carnitine. Concerning capillary electrophoresis, another approach is to 
use indirect UV detection (Mardones et al., 1999b). The acylcarnitine profile can also be 
obtained with gas chromatography (GC) (Kumps et al., 1994). 
 
 
 CH3 
 | 
 R2C - N+ - CH2 - CH - CH2 - COOH 
 | | 
 CH3 OR1 
 
  
R2 R1 Name Transitions (m/z)  
      
 
H3 H Carnitine  162.2 → 103.0 + 60.1 
D3 H Carnitine-d3   165.2 → 103.0 + 63.1 
H3 COCH3 Acetylcarnitine  204.2 → 144.9 + 85.1 
H3 COCH2CH3 Propionylcarnitine  218.2 → 158.8 + 85.1 
H3 COC(CH3)3 Isovalerylcarnitine   246.2 → 186.9 + 85.1 
H3 CO(CH2)4CH3 Hexanoylcarnitine  260.2 → 200.9 + 85.1 
H3 CO(CH2)6CH3 Octanoylcarnitine   288.2 → 229.0 + 85.1 
D3 CO(CH2)6CH3 Octanoylcarnitine-d3  291.2 → 229.0 + 85.1 
H3 CO(CH2)12CH3 Myristoylcarnitine  372.3 → 313.0 + 211.0 
H3 CO(CH2)14CH3 Palmitoylcarnitine  400.4 → 341.1 + 239.1 
H3 CO(CH2)16CH3 Stearoylcarnitine  428.4 → 369.1 + 267.2 
 
Figure 1: Chemical structures of carnitine and the acylcarnitines analyzed and  
MS/MS transitions used for quantification. 
 
 
Mass spectrometry approaches have been introduced first using fast atom bombardment 
tandem mass spectrometry (FAB-MS/MS) (Millington et al., 1989) and then electrospray 
tandem mass spectrometry (ESI-MS/MS). ESI-MS/MS is frequently used for screening 
purposes in newborn blood spots (Chace et al., 1997; Clayton et al., 1998; Inoue et al., 1999; 
Zytkovicz et al., 2001), where acylcarnitines are usually determined after formation of butyl 
(Chace et al., 1997; Clayton et al., 1998; Zytkovicz et al., 2001) or methyl (Inoue et al., 1999) 
esters. This technique allows the determination of amino acids within the same experiment. 
Quantification is performed with help of a triple stage quadrupole using either multiple 
reaction monitoring or precursor ion scans of the common acylcarnitines product m/z 85. 
Mass spectrometry was also used as a detection method after prior separation of carnitine 
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and acylcarnitines by HPLC (Tallarico et al., 1998; Zhu et al., 2000; Vaz et al., 2002), CE 
(Heinig and Henion, 1999; Deng et al., 2001) or GC (Huang et al., 1991; Costa et al., 1997). 
Very recently, a method for the analysis by HPLC-MS/MS of biosynthetic carnitine precursors 
has been published (Vaz et al., 2002). The method uses derivatization with methyl 
chloroformate for the extraction and an ion pair reagent for the HPLC separation. So far, 
quantification of carnitine and acylcarnitines was performed with quadrupole mass 
spectrometers, single or triple, except in one study in which an ion trap method was used 
(Zhu et al., 2000). 
 
Since separation and quantification of carnitine and acylcarnitines in urine has currently not 
been described for ion trap systems, we decided to develop such a method. We describe a 
novel reversed-phase HPLC separation of un-derivatized carnitine and eight biological 
relevant acylcarnitines using an electrospray ion trap mass spectrometer detector. We will 
discuss the application of this system to urine samples of volunteers as well as of patients 
suffering from organic acidurias and describe the problems we were facing for quantification 
with an ion trap system. 
 
 
3.3  EXPERIMENTAL 
 
3.3.1  Chemicals 
 
L-carnitine was from Fluka (Buchs, Switzerland), and acetylcarnitine, hexanoylcarnitine, 
octanoylcarnitine, myristoylcarnitine, palmitoylcarnitine and stearoylcarnitine were from 
Sigma (St. Louis, MO, USA). Propionylcarnitine and isovalerylcarnitine were a gift from 
Sigma-Tau (Zofingen, Switzerland). The deuterated internal standards [2H3]carnitine 
(carnitine-d3) and [2H3]octanoylcarnitine (octanoylcarnitine-d3) were purchased from 
Cambridge Isotope Laboratories (Andover, MA, USA). Methanol and water were of HPLC 
grade from Merck. Other reagents were of analytical grade and purchased either from Fluka 
or from Merck.  
 
 
3.3.2  Preparation of internal standards and standard solutions 
 
Internal standard stock solutions of 1 mmol/L carnitine-d3 and 1 mmol/L octanoylcarnitine-d3 
were prepared in methanol. A mixed internal standard spiking solution was prepared by 
diluting these stock solutions to have respective concentrations of 100 and 20 µmol/L.  
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Standard stock solutions of carnitine and acylcarnitines for calibration were prepared in 
methanol in concentrations between 5 and 20 mmol/L. A mix standard stock solution was 
prepared by diluting the respective stock solutions to obtain a solution containing all 
acylcarnitines of concentrations ranging from 80 to 800 µmol/L. This solution was further 
diluted in methanol to obtain the calibration standard solutions. The carnitine concentration 
was standardized using a spectrophotometric method (Marquis and Fritz, 1964). Carnitine 
contamination due to spontaneous hydrolysis was estimated for each acylcarnitine by 
injecting the individual standard stock solution and measuring the respective peaks area. The 
carnitine content was not found to be relevant in any of them. 
 
 
3.3.3  Urine sample collection 
 
Urine samples were obtained from the chemical laboratory of the University Hospital of 
Basel. One of these urines was used as a quality control sample and to establish calibration 
curves. Patient urines were obtained from the Children Hospital in Basel. 
 
 
3.3.4  Urine sample preparation 
 
Urine pretreatment included dilution, acidification and solid phase extraction. Urine (200 µL) 
was mixed with 50 µL internal standard spiking solution and 50 µL 1 mol/L HCl. For spiked 
urine samples, 50 µL of the appropriate standard stock solution was also added. The volume 
was adjusted to 1 mL with water. The solid-phase extraction was performed as described by 
Kamimori et al. (Kamimori et al., 1994), after some modifications, using disposable cation-
exchange columns (SCX 100 mg, Varian, Harbor City, CA, USA) and a Vac-Elut system 
(Analytichem, Harbor City, CA, USA). After preconditioning with 1 mL methanol, 1 mL water 
and 1 mL of 10 mmol/L aqueous HCl, samples (1 mL) were loaded, washed with 3 mL of 10 
mmol/L aqueous HCl and eluted with 2 mL of 75 mmol/L pyridine in methanol-water (1:1, 
v/v). The eluate was collected in silanised glass tubes an evaporated to dryness at 40 0C 
using a TurboVap evaporator (Zymark, Hopkinton, MA, USA). The residue was dissolved in 1 
mL methanol and reevaporated. The residue was reconstituted in 200 µL methanol-water 
(1:1, v/v) containing both 10 mmol/L heptafluorobutyric acid and 10 mmol/L ammonium 
acetate.  
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3.3.5  HPLC-MS/MS analysis 
 
The HPLC separation was performed on a HP 1100 system (Agilent Technologies, Palo Alto, 
CA, USA) equipped with a heated column compartment. The analytical column was a 
reversed-phase LUNA, C8, 150 x 2.0 mm I.D. (5 µm particles) (Phenomenex, Torrance, CA, 
USA), equipped with a corresponding pre-column MOS, C8, 4.0 x 2.0 mm (Phenomenex). 
The column was maintained at 300C. A gradient elution with two mobile phases was used: 10 
mmol/L heptafluorobutyric acid and 10 mmol/L ammonium acetate in water (A) or in 
methanol (B). The gradient started with 20% B, went up to 90% B between 0.1 min and 4 min 
and was followed by a plateau at 90% B for 14 minutes. The column was then reequilibrated 
for 10 minutes with 20% B. The flow was set at 200 µL/min and the injected sample volume 
was 2 µL. 
 
Mass spectrometry detection was performed on a Finnigan LCQDECA ion trap instrument 
(Finnigan MAT, San Jose, CA, USA) equipped with an electrospray ionization source that 
was run in the positive ion mode (4.0 kV). Sheath gas (N2) pressure was set at 70 arbitrary 
units. The temperature of the heated capillary was kept at 300 0C. Quantitative analysis of 
carnitine and acylcarnitines was monitored in MS-MS mode. For this purpose each of the 
nine peaks chromatographed was associated with a segment. During the analysis time of 
each segment, one precursor ion was stored in the trap and further fragmented with a 
collision energy that allowed a sufficient fragmentation of the selected ion. In the case of 
carnitine and octanoylcarnitine, as their respective deuterated derivative used as internal 
standards are co-eluting, two ions were attributed to their respective segment. The relative 
collision energy was set up at 35% for each compound, the isolation width fixed at 1.8 and 
the product ions were scanned. Automatic gain control was employed using one microscan 
and a maximum injection time of 200 ms. Carnitine-d3 was used as internal standard at a 
concentration of 20 µmol/L for carnitine, acetylcarnitine and propionylcarnitine, whereas 
octanoylcarnitine-d3 was used as internal standard at a concentration of 5 µmol/L for all other 
acylcarnitines. Areas obtained for the two most intense product ions (a common and a 
specific one) were corrected with the respective areas of the internal standard and were used 
for quantification. The observed transitions are given in Figure 1. The HPLC and MS system 
were computer controlled using Xcalibur 1.2 software (Finnigan). The same software was 
also used for all quantitative calculations. Linear regressions were calculated with a 
weighting factor of 1/X. 
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3.3.6  Method validation 
 
Linearity of the developed HPLC-MS/MS method was investigated for carnitine and five 
short- and medium-chain acylcarnitines on aqueous standards. Calibrations (six points) were 
prepared in concentration ranges of 5-200 µmol/L for carnitine, 2.5-100 µmol/L for 
acetylcarnitine and 0.75-30 µmol/L for propionylcarnitine, isovalerylcarnitine, 
hexanoylcarnitine and octanoylcarnitine. Precision and accuracy were determined for 
carnitine, acetyl-, propionyl-, isovaleryl-, hexanoyl- and octanoylcarnitine by running aqueous 
quality controls at three different concentrations covering the calibration range, on the same 
(intra-day) and on different days (inter- day variability). Urine quality controls were run 
simultaneously at two different concentrations, namely a blank (unspiked) urine and the 
same urine after spiking with carnitine, acetyl-, propionyl-, isovaleryl-, hexanoyl- and 
octanoylcarnitine.  
 
 
3.3.7  Urine 
 
Blank and spiked urines were extracted as described above. Carnitine quantitation results of 
quality control urine obtained with an aqueous standard calibration were compared with the 
one obtained with a calibration done with spiked urine. Free carnitine was determined in 15 
different urine samples and the results were compared with radioenzymatic assay. The 
radioenzymatic assay used has been described by Hoppel (Hoppel, 1991). 
 
 
3.4  RESULTS AND DISCUSSION 
 
Carnitine and acylcarnitines belong to a family of compounds with a large span of polarities, 
from the polar carnitine to the quite apolar long-chain acylcarnitines, such as for instance 
stearoylcarnitine. From these characteristics one can easily presume that their simultaneous 
extraction from a biological matrix and their chromatographic separation will be a rather 
delicate task. For instance, it is not possible to use the common C8 or C18 reversed-phase 
material, because carnitine and short-chain acylcarnitines are not properly chromatographied 
under these conditions. So far, the use of reversed-phase HPLC was used after a 
derivatization step that does not only introduce a chromophore group for UV or fluorescence 
detection, but also decreases the polarity of carnitine, enabling thereby its retention on such 
material. To develop our method we used the zwitterionic feature of these analytes for their 
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extraction and exploited the formation of ion-pair for their separation on reversed phase 
material. 
 
 
3.4.1  Optimization of solid-phase extraction  
 
In acidic conditions the carboxylic group of analytes (see Figure 1) is protonated, resulting in 
the presence of permanently positively charged quaternary amines. Under these conditions, 
the choice of a cation exchange column for the extraction is particularly well suited. 
According to the literature, ammonia (Kumps et al., 1994) and pyridine (Kamimori et al., 
1994) were evaluated to displace carnitine and its esters from the column. The entire 
extraction process was investigated using [14C]-carnitine and [14C]-palmitoylcarnitine, a 
hydrophilic and a lipophilic representant of the analyte family. As we were facing hydrolysis 
of acylcarnitines during the extraction process when using ammonia, what was absolutely not 
desired, we changed to pyridine. The minimal effective concentration able to displace in a 
satisfactory way both analytes was found to be at 75 mmol/L pyridine in a water-methanol 
(1:1, v/v) mixture. Recovery for [14C]-carnitine was 75 and 73% for [14C]-palmitoylcarnitine. 
Silanised glass tubes were used to collect the eluate in order to prevent interactions of 
positively charged carnitines with the hydroxyl groups of glass. It was impossible to 
resolubilize the dried eluate using the starting HPLC mobile phase, since with 20% methanol 
the long-chain acylcarnitines could not be brought into solution. We, therefore, used a water-
methanol (1:1, v/v) mixture, containing 10 mmol/L heptafluorobutyric acid and 10 mmol/L 
ammonium acetate.  
 
 
3.4.2  Analysis of carnitine and acylcarnitines by HPLC-MS/MS 
 
For the HPLC separation we investigated different volatile ion-pairing agents, in order to 
mask the positive charges on the nitrogen atom and to increase the interactions of the polar 
compounds with reversed-phase material. While the addition of trifluoroacetic acid was not 
successful (carnitine was still not retained by the C8 column), heptafluorobutyric acid at an 
optimal concentration of 10 mmol/L showed enough ion-pairing interactions in order to get 
retention of carnitine and acetylcarnitine. The pH of the eluant was fixed to 3.2 with 10 
mmol/L ammonium acetate, as a more acidic mobile phase was not required to increase the 
number of positive charge and in order to protect the column material. With this composition 
of the mobile phase and using a gradient, from 20 to 90% organic solvent, to increase the 
elution strength, we could elute stearoylcarnitine within 17 min. A typical chromatogram 
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obtained under the developed conditions, recorded in MS mode, shows a good baseline 
separation of carnitine and eight acylcarnitines (see Figure 2). With higher concentrations of 
heptafluorobutyric acid, as described in the literature for the determination of acetylcholine 
and related quaternary amines such as carnitine and acetylcarnitine (Zhu et al., 2000) or, 
most recently, for the determination of carnitine and carnitine precursors (Vaz et al., 2002), 
the retention times of long-chain acylcarnitines increases without any further benefit for the 
retention of carnitine and acetylcarnitine. As samples had to be solubilized in a water-
methanol (1:1, v/v) mixture, their elution strengths were higher than the one of the mobile 
phase and we were facing peak broadening, especially for carnitine and acetylcarnitine. By 
reducing the injection volume from 10 to 2 µL, the resulting peak sharpening compensated 
for the water-methanol (1:1, v/v) mixture, and we did not lose to much sensitivity, since the 
number of scans through the peaks was still sufficient. 
 
Figure 2: Total ion current trace of a mixed standard containing: 1, carnitine (80 µmol/L; 160 pmol injected);  
2, acetylcarnitine (40 µmol/L; 80 pmol injected); 3, propionylcarnitine (12 µmol/L; 24 pmol injected);  
4, isovalerylcarnitine (12 µmol/L; 24 pmol injected); 5, hexanoylcarnitine (12 µmol/L; 24 pmol injected);  
6, octanoylcarnitine (12 µmol/L; 24 pmol injected); 7, myristoylcarnitine (8 µmol/L; 16 pmol injected);  
8, palmitoylcarnitine (8 µmol/L; 16 pmol injected); 9, stearoylcarnitine (8 µmol/L; 16 pmol injected). 
 
 
The electrospray ionization process shows a predominant protonated molecular ion of  
[M + H]+ for all analyzed compounds (data not shown). The formation of these positively 
charged molecular ions may also be supported by the presence of heptafluorobutyric acid in 
the mobile phase. These peaks were selected as precursor ions to undergo collision induced 
dissociation in the ion trap and produce the MS/MS data. The fragmentation pattern of these 
ions follows a similar process, namely loss of the trimethylamine moiety (see Figure 3).  
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Figure 3: Product ion spectra (MS/MS) of analyzed compounds with relative collision energy of 35% and an 
isolation width of 1.8. 
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While the corresponding m/z 60 ion is seen for carnitine and acetylcarnitine, only the 
complementary ions [M+H – N(CH3)3]+, that are compound-specific, are seen for all the other 
acylcarnitines. In addition for short- and medium-chain acylcarnitines, a common fragment at 
m/z 85 is present, corresponding to a rearrangement of the butyric acid chain (+CH2-CH=CH-
COOH), as suggested in the literature (Tallarico et al., 1998; Heinig and Henion, 1999). This 
common fragment ion is the most intense for the short-chain acylcarnitines, whereas the 
specific fragment ion [M+H – N(CH3)3]+ is the most intense for the medium-chain 
acylcarnitines. With a chain length larger than six carbons, the fragmentation process 
produces the specific ion (due to the loss of trimethylamine), and a less intense ion 
corresponding to the fatty acid moiety itself (R1 in Figure 1). 
 
 
3.4.3  Method validation 
 
Quantification was carried out in MS/MS mode using two product ions, a common and a 
specific one, as in the fragmentation patterns these two ions were of relative intensities 
between 40 to 90%. This way we could gain selectivity. Although carnitine exhibits a lower 
electrospray sensitivity than the acylcarnitines, the resulting increase in the limit of 
quantification does not disturb its determination in biological matrix, since the urine 
concentrations of carnitine are usually higher than that of acylcarnitines. We did not perform 
any quantification experiments on long-chain acylcarnitines because they are usually not 
present in urine (Hoppel, 1991). 
 
The linearity of the method was evaluated for carnitine and five short- and medium-chain 
acylcarnitines on aqueous standards. Ranges were 5-200 µmol/L for carnitine, 2.5-100 
µmol/L for acetylcarnitine and 0.75-30 µmol/L for propionylcarnitine, isovalerylcarnitine, 
hexanoylcarnitine and octanoylcarnitine. Limits of quantification (LOQs) were determined as 
the lowest concentration with a relative deviation of replicate runs of less than 20%. They 
correspond to 5 µmol/L for carnitine, 2.5 µmol/L for acetylcarnitine and 0.75 µmol/L for 
propionylcarnitine, isovalerylcarnitine, hexanoylcarnitine and octanoylcarnitine, respectively, 
and were chosen as the lowest concentration of the respective calibration standards. For 
quantification, areas of the 2 most intense product ions were used after division by the 
respective areas of the selected internal standard. The linearity of the method was validated 
by recalculating the aqueous calibration standard concentrations (n=6) with the obtained 
linear regression. Results for carnitine are given in Table 1. With precisions smaller than 8% 
and accuracies of 99.2 ± 9.3% we found these results within acceptable limits. Precision and 
accuracy data for intra- and inter-day assays on aqueous quality controls were performed at 
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three different concentrations, covering the concentration range of the calibration standards 
used. For intra-day analysis, the precision was between 1.2 and 8.0% for carnitine and 
acylcarnitines, whereas the values for inter-day precision were between 2.7 and 14.6%. 
Results for carnitine are presented in Table 2. 
 
 
 
Table 1: Accuracy and precision for the determination of carnitine in calibration standards 
   
 
Added Found 
concentration concentration     SD        Precision (%)        Accuracy (%) 
(µmol/L)  (µmol/L)        
   
  
    5      5.8 0.4 7.2 116.5 
  10      9.8 0.6 5.7   98.0 
  20    17.8 1.3 7.1   89.2 
  50    46.9 3.5 7.4   93.7 
100  100.4 4.5 4.5   99.6 
200  204.2 3.5 1.7   97.9 
   
 n = 6 determinations 
 
 
 
 
Table 2: Intra- and inter-day variability of free carnitine in aqueous standard and in urine 
    
    
 Inter-day assay (n=12)  Intra-day assay (n=7) 
    
    
 Low  Medium High Low Medium High 
       
  
Standard quality control  
   Added concentration (µmol/L)   5     80 150    15    80 150 
   Found concentration (µmol/L) 13.6     78.3 150.9    14.7    86.0 150.3 
   Precision (%)   5.3       8.1 10.9      1.2      2.7     2.7 
   Accuracy (%) 91.0     97.8 100.6    98.0  107.5 100.2 
  
Inter-day assay (n=4) 
  
Intra-day assay (n=8) 
 
       
       
 Unspiked Spiked   Unspiked Spiked  
       
       
Urine quality control 
   Added concentration (µmol/L)   0    50      0   60  
   Found concentration (µmol/L) 63.7  111.5    63.8 127.6  
   Precision (%)   6.0      4.0      1.8     6.1  
   Accuracy (%)  nd    95.7      nd 106.3  
       
       nd: not determined. 
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3.4.4  Application to urine 
 
A chromatogram obtained for a urine sample is shown in Figure 4A. We see a typical urine 
profile with predominant peaks of carnitine (peak 1) and acetylcarnitine (peak 2). Depending 
on the urine concentration, propionylcarnitine (peak 3) and isovalerylcarnitine (peak 4) can 
also occasionally been seen. In contrast to standards where the method could easily be 
validated with acceptable intra- and inter-day precisions and accuracies for all compounds, 
we were facing more difficulties using urine, where only the quantification of carnitine was 
validated.  
 
 
Figure 4: Total ion current trace. A: Control urine. B: Medium chain acyl-CoA dehydrogenase deficiency (MCAD). 
C: Methylmalonic aciduria (MMA). D: Isovaleric academia (IVA). The samples were extracted and analyzed as 
described in the Materials and methods section. Peaks are: 1, carnitine; 2, acetylcarnitine; 3, propionylcarnitine; 
4,isovalerylcarnitine; 5, hexanoylcarnitine; 6, octanoylcarnitine. 
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As already mentioned, carnitine and acylcarnitines are endogenous compounds, rendering it 
impossible to get carnitine-free urine. The presence of endogenous carnitine and 
acylcarnitines makes it difficult to use urine as a matrix for calibration standards. To facilitate 
the determination of carnitine in urine, we therefore investigated the possibility of using a 
calibration curve performed with aqueous calibration standards instead of spiked urine. As 
compared to calibration standards in urine, aqueous calibration standards yielded similar 
results, with deviations of 5.6 or 3.0% for non-spiked or spiked urine, respectively (n = 8 
determinations for each condition). These results indicated that urine could be substituted 
with water to prepare the calibration standards. Further experiments showed also that the 
calibration curves of standards undergoing extraction and HPLC-MS/MS were not different to 
curves of standards undergoing HPLC-MS/MS only (results not shown), as the use of an 
internal standard compensates for any extraction loss. Intra- and inter-day variabilities for 
unspiked and spiked urine quality controls are shown in Table 2 and are, with precisions 
smaller than 6.1%, as good as for standard quality controls.  
 
The quantification of free carnitine in 15 urines was finally compared with the standard 
radioenzymatic method (Figure 5) and a linear relationship is observed (R2 = 0.981). 
However, the concentrations found with the HPLC-MS/MS method were approximately 10% 
lower than the ones obtained with the radioenzymatic assay and there was a positive 
intercept on the x-axis. Taking into consideration the quantification of carnitine in calibration 
standards (Table 1) and the recovery of carnitine added to urine (Table 2), the problem 
appears to be more likely due to the radioenzymatic assays than to the HPLC-MS/MS assay.  
For acylcarnitines, the intra-day precisions were below 15% except for octanoylcarnitine, 
which had a variability of 40%. As for carnitine, the inter-day variabilities for acylcarnitines 
were higher than intra-day, with variabilities in the range of 20% for most of them. The use of 
only two internal standards for quantification of all analytes is probably associated with an 
increased variability, as observed also by others (Vaz et al., 2002). Better results might be 
observed with a deuterated derivative for each analyzed acylcarnitine, since the suppression 
effects would be the same for each compound and its internal standard, as they will enter the 
trap under the same conditions of ion trap gating and HPLC mobile phase composition.  
 
Figure 4B-D displays urine HPLC chromatograms from patients suffering from different 
metabolic disorders. Figure 4B is from a patient with medium-chain acyl-CoA dehydrogenase 
(MCAD) deficiency. As expected with this metabolic disorder (Chace et al., 1997), the peaks 
for octanoylcarnitine and hexanoylcarnitine are increased (peak 6 and 5, respectively) and 
the ratio octanoylcarnitine/acetylcarnitine is higher than 0.1. Figure 4C depicts a 
chromatogram of a patient suffering from methylmalonic acidemia (MMA) where the 
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propionylcarnitine peak (peak 3) is more than 8 fold increased when compared with a control 
urine (Zytkovicz et al., 2001). Figure 4D shows a urine of a patient with isovaleric acidemia 
(IVA). As expected, the isovalerylcarnitine peak (peak 4) is increased.  
 
 
Figure 5: Correlation between the quantification of free carnitine in urine, using a radioenzymatic method (REA) 
and HPLC-MS/MS. The relationship is characterized by the following equation y = 0.909 x – 7.32  (R2 = 0.9806). 
 
 
3.5  CONCLUSION 
 
In this paper we presented a reversed-phase HPLC separation of un-derivatized carnitine 
and eight acylcarnitines with ion trap mass spectrometry detection. The method is based on 
the detection of common and specific daughter ions produced by collision-induced 
dissociation of the molecular cation. This method could be applied successfully to the 
identification and quantification of carnitine and acylcarnitines. The application to patient 
urines proved that the developed HPLC-MS/MS method is capable to identify metabolic 
disorders and can therefore be used for diagnostic purposes in a non-invasive way. The 
application of this method to plasma and tissue samples and the extension towards 
quantification of long-chain acylcarnitines is currently investigated.  
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4.1 SUMMARY  
 
A high-performance liquid chromatography-mass spectrometry method was developed for 
the determination of carnitine, its biosynthetic precursor butyrobetaine and eight 
acylcarnitines in plasma. The procedure includes a solid-phase extraction for carnitine, short- 
and medium-chain acylcarnitines and a liquid-liquid extraction for protein-bound long-chain 
acylcarnitines, followed by separation on a reversed-phase column in the presence of a 
volatile ion-pairing reagent. Detection was carried out using an ion-trap mass spectometer 
run in the MS/MS mode. The choice of the matrix for calibrators used for quantification of 
these endogenous compounds was also investigated. Validation was performed for standard 
quality controls diluted with 4% bovine serum albumin solution and for spiked plasma quality 
control samples at concentrations between 0.5 and 80 µmol/L, depending on the compound. 
Intra- and inter-day precisions for the determination of carnitine were below 3.4% and 
accuracies between 95.2 and 109.0%. Application of the method for the diagnosis of 
pathological acylcarnitine profiles of metabolic disorders in a patient suffering from 
methylmalonic aciduria is presented. The method allows quantification of carnitine, 
butyrobetaine, acetylcarnitine and propionylcarnitine and semi quantitative analysis of 
medium- and long-chain acylcarnitines. In comparison to other methods, no derivatization 
step is needed. 
 
 
4.2 INTRODUCTION 
 
Carnitine (3-hydroxy-4-N-trimethylaminobutyrate) is a small, ubiquitous molecule in 
mammalian tissues, mainly located in skeletal muscle and heart (Bremer, 1983; Friolet et al., 
1994). Carnitine has a critical role in energy metabolism, as it is an essential factor for 
transport of fatty acids into the mitochondrial matrix, where they are metabolized via 
β-oxidation (Bremer, 1983). Fatty acids bind carnitine by the formation of an ester on the 
hydroxyl group in position 3 (see R1 in Figure 1), generating various acylcarnitines with 
different chain lengths. Carnitine is also involved in the maintenance of the cellular pool of 
unesterified coenzyme A (CoA), by the transfer of acyl-groups from acyl-CoAs to carnitine 
(Brass and Hoppel, 1980). In normal subjects, carnitine and acetylcarnitine represent the 
major constituents of the body fluid and tissue carnitine pools (Bremer, 1983; Friolet et al., 
1994). Under pathological conditions such as acquired or inherited metabolic disorders, other 
acylcarnitines can accumulate (Minkler and Hoppel, 1993b). For diagnostic purposes, 
profiling of the acylcarnitines in body fluids is therefore beneficial. 
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Several methods have been developed for the determination of carnitine and acylcarnitines. 
Beside the radioenzymatic method (Hoppel, 1991), high-performance liquid chromatography 
(HPLC) (Minkler and Hoppel, 1993a; De Witt et al., 1994; Kamimori et al., 1994; Longo et al., 
1996) and capillary electrophoresis (CE) (Vogt and Kiessig, 1996; Mardones et al., 1999a; 
Vernez et al., 2000) have been used for enantiomeric separation of D- and L-carnitine and to 
obtain acylcarnitine profiles. Due to the lack of a chromophoric group, detection is performed 
by UV or fluorescence, after derivatization with different chromophores. 
 
 
 CH3 
 | 
 R2C - N+ - CH2 - CH - CH2 - COOH 
 | | 
 CH3 R1 
 
  
R2 R1 Name Transitions (m/z)  
      
 
H3 OH Carnitine  162.2 → 103.0 + 60.1 
D3 OH Carnitine-d3   165.2 → 103.0 + 63.1 
H3 H Butyrobetaine  146.2 →   87.0 + 60.1 
H3 OCOCH3 Acetylcarnitine  204.2 → 144.9 + 85.1 
H3 OCOCH2CH3 Propionylcarnitine  218.2 → 158.8 + 85.1 
H3 OCOC(CH3)3 Isovalerylcarnitine   246.2 → 186.9 + 85.1 
H3 OCO(CH2)4CH3 Hexanoylcarnitine  260.2 → 200.9 + 85.1 
H3 OCO(CH2)6CH3 Octanoylcarnitine   288.2 → 229.0 + 85.1 
D3 OCO(CH2)6CH3 Octanoylcarnitine-d3  291.2 → 229.0 + 85.1 
H3 OCO(CH2)12CH3 Myristoylcarnitine  372.3 → 313.0 + 211.0 
H3 OCO(CH2)14CH3 Palmitoylcarnitine  400.4 → 341.1 + 239.1 
D3 OCO(CH2)14CH3 Palmitoylcarnitine-d3  400.4 → 341.1 + 239.1 
H3 OCO(CH2)16CH3 Stearoylcarnitine  428.4 → 369.1 + 267.2 
 
Figure 1: Chemical structures of carnitine, butyrobetaine and the acylcarnitines analyzed  
and MS/MS transitions used for quantification. 
 
 
In order to improve detection and identification of acylcarnitines, methods using mass 
spectrometry were developed. Fast atom bombardment tandem mass spectrometry (FAB-
MS/MS) was used first for the determination of carnitine and acylcarnitines as methyl esters 
(Millington et al., 1989), followed by electrospray tandem mass spectrometry (ESI-MS/MS) of 
their methyl or butyl esters (Chace et al., 1997; Inoue et al., 1999; Zytkovicz et al., 2001). 
Although this technique became the method of choice for the determination of carnitine and 
acylcarnitines in the field of newborn screening (Hardy et al., 2001; Carpenter and Wiley, 
2002), the results should be interpreted with caution, since the derivatization with butanol 
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might be only partial and hydrolysis of acylcarnitines could occur (Johnson, 1999; Ho et al., 
2003). 
 
In the present paper, we describe the adaptation and validation of our previously developed 
HPLC-MS/MS method in urine (Vernez et al., 2003) for the determination of carnitine, 
butyrobetaine and acylcarnitines in plasma. 
 
 
4.3 EXPERIMENTAL 
 
4.3.1 Chemicals 
 
L-carnitine was obtained from Fluka (Buchs, Switzerland), butyrobetaine (4-
trimethylaminobutyrate), acetylcarnitine, hexanoylcarnitine, octanoylcarnitine, 
myristoylcarnitine, palmitoylcarnitine, stearoylcarnitine and bovine serum albumin were from 
Sigma (St. Louis, MO, USA). Propionylcarnitine and isovalerylcarnitine were a gift from 
Sigma-Tau (Zofingen, Switzerland). The deuterated internal standards carnitine-d3, 
octanoylcarnitine-d3 and palmitoylcarnitine-d3 were purchased from Cambridge Isotope 
Laboratories (Andover, MA, USA). Methanol, ethyl acetate and water were of HPLC grade 
from Merck (Darmstadt, Germany). Other reagents were of analytical grade and purchased 
either from Fluka or from Merck. 
 
 
4.3.2 Instrumentation 
 
The HPLC separation system consisted of a HP 1100 series (Agilent Technologies, Palo 
Alto, CA, USA) including a heated column compartment. The analytical column was a 
reversed-phase LUNA C8, 150 X 2.0 mm, 3 µm (Phenomenex, Torrance, CA, USA), 
equipped with the corresponding pre-column. Mass spectrometry detection was performed 
on a Finnigan LCQDECA ion trap instrument (Finnigan MAT, San Jose, CA, USA) equipped 
with an electrospray ionization source. The HPLC and MS systems were run using the 
Xcalibur 1.2 software (Finnigan). 
 
4.3.3 Standard and internal standard solutions 
 
Standard stock solutions were prepared by dissolving the respective compound in water to 
obtain concentrations ranging from 5 to 20 mmol/L. These stock solutions were further 
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diluted with water to get three solutions: a 320 µmol/L carnitine solution, a mixed solution 
containing butyrobetaine, acetylcarnitine, propionylcarnitine, isovalerylcarnitine, 
hexanoylcarnitine and octanoylcarnitine at individual concentrations of 80 µmol/L and a 
solution containing 500 µmol/L of myristoylcarnitine, palmitoylcarnitine and stearoylcarnitine.  
After appropriate dilution with water, 3 sets of standard spiking solutions, ranging from 40 to 
320 µmol/L for carnitine, from 2 to 80 µmol/L for butyrobetaine and short- and medium-chain 
acylcarnitines, and from 0.25 to 10 µmol/L for the long-chain acylcarnitines were obtained. 
The carnitine concentration was standardized using a spectrophotometric method (Marquis 
and Fritz, 1964). The contamination with carnitine of the solutions containing acylcarnitines 
(due to spontaneous hydrolysis) was estimated by injecting the individual standard stock 
solution and measuring the respective peak areas. However, the carnitine content was not 
relevant in any of the solutions. 
 
Internal standard stock solutions containing either 5 mmol/L carnitine-d3, 1 mmol/L 
octanoylcarnitine-d3, or 1 mmol/L palmitoylcarnitine-d3 were prepared in methanol. A mixed 
internal standard-spiking solution was prepared by diluting the carnitine-d3 and 
octanoylcarnitine-d3 stock solutions with water to yield concentrations of 80 and 20 µmol/L, 
respectively. A palmitoylcarnitine-d3 spiking solution of 1 µmol/L was prepared by dilution of 
the stock solution with water. 
 
 
4.3.4 Plasma sample collection 
 
Plasma samples were obtained either from the chemical laboratory or from the blood 
collection center of the University Hospital, Basel. Plasma calibrators and plasma quality 
samples were prepared from 3 different plasma pools. Patient serum was obtained from the 
University Children’s Hospital, Basel. 
 
 
4.3.5 Sample preparation 
 
Carnitine, butyrobetaine and short- and medium-chain acylcarnitines were extracted from 
plasma by solid phase extraction after a protein precipitation step. Two hundred µL plasma 
or bovine serum albumin 4% in water (for calibrators and standard quality controls) were 
mixed with 50 µL internal standard spiking solution, 50 µL of each standard spiking solution 
(calibrators and standard quality controls) or 100 µL water (unspiked plasma samples) and 
acidified with 70 µL HCl (1 mol/L). Proteins were precipitated with 1 mL acetonitrile-methanol 
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(3:1, v/v). After vigorous mixing and centrifugation, 1200 µL of the supernatant was applied 
on a disposable cation-exchange column, according to a previously published protocol 
(Vernez et al., 2003). The only alteration to the published procedure was the modified 
washing step, which was done with 20 mmol/L HCl -methanol (1:1, v/v). An aliquot of 2 µL of 
the reconstituted sample was injected into the HPLC-MS/MS system. 
 
Myristoyl-, palmitoyl- and stearoyl-carnitine were extracted using a separate liquid-liquid 
extraction procedure. To 200 µL plasma or bovine serum albumin 4% in water (for calibrators 
and standard quality controls), 50 µL internal standard spiking solution and 50 µL standard 
spiking solution (calibrators and standard quality controls) or water (unspiked plasma 
samples) were added. Extraction was performed by adding 1 mL ethyl-acetate and shaking 
for 5 minutes. The organic layer was removed and the aqueous residues were extracted a 
second time with 1 mL ethyl-acetate. The combined organic layers were evaporated under 
nitrogen at 30oC. The evaporated residues were reconstituted in 50 µL methanol-water (1:1, 
v/v), containing 10 mmol/L heptafluorobutyric acid and 10 mmol/L ammonium acetate. The 
HPLC-MS/MS analysis was performed on 10 µL of the reconstituted samples. 
  
 
4.3.6 Chromatographic conditions 
 
The HPLC-MS/MS system was run as previously described (Vernez et al., 2003). Briefly, the 
separation was carried out using a binary gradient with a volatile ion-pair reagent, which 
consisted of 10 mmol/L heptafluorobutyric acid and 10 mmol/L ammonium acetate in water 
(A) or in methanol (B) at a flow rate of 200 µL/min. The gradient started at 20% B, went up to 
90% B within 4 min, and then stayed at a plateau at 90% B for another 14 min. For detection, 
analytes were ionized by positive ion (4.0 kV) electrospray and the selected ions were 
monitored in the MS/MS mode. Each compound was associated with a segment, except for 
butyrobetaine, which was in the same segment as carnitine. As the internal standards are 
stable isotopes from analyzed compounds, they were in the same segment as their 
respective analyte.  
 
Carnitine-d3 was used as internal standard at a concentration of 20 µmol/L for the 
determination of carnitine, butyrobetaine, acetylcarnitine and propionylcarnitine. 
Octanoylcarnitine-d3 was used as internal standard at a concentration of 5 µmol/L for the 
determination of all medium-chain acylcarnitines. Palmitoylcarnitine-d3 served as the internal 
standard for the long-chain acylcarnitines at a concentration of 1 µmol/L. Areas obtained for 
the 2 most intense product ions (a common and a specific one) were corrected with the 
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respective areas of the internal standard and were used for quantification. The observed 
transitions are given in Figure 1. The Xcalibur 1.2 software was used for quantification of the 
analytes. Linear regressions of the calibration curves were calculated with a weighting factor 
of 1/X. 
 
 
4.3.7 Validation procedure 
 
The linearity of the method was investigated using the sample preparation procedure 
described above for carnitine, five short- and medium-chain acylcarnitines, and the long-
chain palmitoylcarnitine. Calibration curves (six points) were prepared in concentration 
ranges of 10-80 µmol/L for carnitine, 0.5-20 µmol/L for butyrobetaine, acetylcarnitine, 
propionylcarnitine, isovalerylcarnitine, hexanoylcarnitine and octanoylcarnitine and 0.25-10 
µmol/L for palmitoylcarnitine. Precision and accuracy were determined by running standard 
quality controls at 3 different concentrations covering the calibration range (2 concentrations 
for palmitoylcarnitine), on the same (intra-day) and on different days (inter-day variability). 
Pooled plasma quality controls were run simultaneously at 3 different concentrations (in 
double), namely a blank (unspiked) plasma and the same plasma after spiking with 2 
different concentrations. To investigate the method under clinical conditions a plasma sample 
of a patient suffering from methylmalonic aciduria (MMA) was analyzed. This disease is 
caused by defects of the cobalamine-dependent enzyme methylmalonyl-CoA mutase.  
 
 
4.4 RESULTS AND DISCUSSION 
 
4.4.1 Extraction procedure 
 
In a previous paper (Vernez et al., 2003) we discussed in detail the difficulties facing the 
extraction of the compounds of the carnitine family. The difficulties originate from the 
zwitterionic nature of carnitine and from the different length of the acyl-group regarding the 
acylcarnitines, leading to a wide range of polarities. After introducing a protein precipitation 
step, the solid phase extraction developed for urine samples could be successfully applied to 
plasma samples for the determination of carnitine, butyrobetaine and short- and medium-
chain acylcarnitines. However, a different protocol had to be developed for the extraction of 
long-chain acylcarnitines in plasma, as they are bound to plasma proteins (Marzo et al., 
1991). We therefore investigated liquid-liquid extraction (Heinig and Henion, 1999) to extract 
these compounds efficiently. Several solvents were tested and the entire extraction process 
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was investigated using 14C-palmitoylcarnitine dissolved in 200 µL plasma. Hexane, ether, 
chloroform and dichloromethane gave extraction recoveries below 10%, whereas 2 mL ethyl 
acetate gave a recovery of 40%, which could not be improved further by other solvents. 
Since ethyl-acetate turned out to be to lipophilic to extract medium- and short-chain 
acylcarnitines, the solid phase extraction could be performed also on the liquid-liquid 
extraction residue, resulting in the same efficiency as for non-extracted plasma (data not 
shown). Nevertheless, under routine conditions, we preferred to use a different aliquot to 
extract carnitine and short- and medium- chain acylcarnitines, because these two extraction 
procedures were usually not performed on the same day. 
 
 
4.4.2 HPLC-MS/MS separation 
 
Carnitine, the carnitine precursor butyrobetaine and 8 acylcarnitines could be separated in 
less than 16 minutes (see Figure 2). As for the extraction procedure, the separation of these 
compounds in plasma could be performed using the same conditions as for urine (Vernez et 
al., 2003). In comparison to the method developed for urine, the plasma method was worked 
out also for the determination of butyrobetaine and long-chain acylcarnitines. In comparison 
to carnitine, butyrobetaine has no hydroxyl group in position 3 (see R1 in Figure 1). We 
therefore expected its elution close to carnitine, but with a higher retention time, as it is less 
hydrophilic than carnitine and should be retained better on the reversed-phase column. 
Figure 2 shows that butyrobetaine is indeed eluted after carnitine, but the two compounds 
are not baseline separated, which is not disturbing when using mass spectrometry for 
detection. The mass spectrometer was set so that butyrobetaine and carnitine were in the 
same analysis segment. The presence of 3 compounds in the same segment (carnitine, 
butyrobetaine and deuterated carnitine) did still allow a sufficient number of scans through 
each peak to obtain sufficient sensitivity and precision.  
 
 
4.4.3 Matrix used for calibrators 
 
The presence of endogenous carnitine and acylcarnitines in biological fluids renders it 
difficult to use plasma as a matrix for calibrators, as it is difficult to get carnitine-free plasma. 
To investigate, whether water could be used as a calibration matrix instead of plasma, we 
compared the results using a calibration performed with standards in water with a calibration 
performed with spiked plasma. Values resulting from the calibration in water were 10 to 20% 
higher than those obtained with plasma. The use of plasma prepared differently (citrate 
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instead of heparin), or obtained from different patients, or the use of bovine serum albumin 
4% in water, to better mimic the plasma matrix, resulted in a similar calibration as obtained 
with water. A plasma pool was therefore dialyzed using a 6-8000 Da cut off membrane 
(Longo et al., 1996), and used as a calibration matrix. The results were identical to those in 
the presence of 4% bovine serum albumin. Matrix effect and ion suppression were further 
evaluated using the post-column infusion technique (Bonfiglio et al., 1999). Carnitine and the 
different acylcarnitines were continuously infused, one by one, and dialyzed plasma samples 
were injected into the system. No suppression area could be observed for any compound 
when dialyzed plasma was injected. The experiment could not be performed using non-
dialyzed plasma, since the endogenous carnitine and acylcarnitines in plasma interfered with 
the infused compounds.  
 
Taking into consideration all the experiments mentioned above, we decided that the use of a 
calibration in the presence of 4% bovine serum albumin (see sample preparation in the 
Method section) was the best alternative to the use of plasma as a calibration matrix. This is 
in accordance to Hoppel (Hoppel, 1991) who also adds a bovine serum albumin solution to 
the aqueous calibrators for the radioenzymatic determination of carnitine. The obtained 
accuracies for carnitine in plasma controls, which were between 95.2 and 109.0% (see 
section below), supported us in our choice. These values are in the same range as the 
values obtained with plasma as a matrix for calibration (95.4 to 100.4%). 
 
 
Figure 2: Total ion current trace of a mixed standard containing (in pmol on column): 1, carnitine (80);  
2, butyrobetaine (40); 3, acetylcarnitine (40); 4, propionylcarnitine (40); 5, isovalerylcarnitine (40);  
6, hexanoylcarnitine (40); 7, octanoylcarnitine (40); 8, myristoylcarnitine (24); 9, palmitoylcarnitine (24);  
10, stearoylcarnitine (24). 
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4.4.4 Quantification in standard and plasma quality controls 
 
Quantification was carried out in the MS-MS mode using two product ions (Vernez et al., 
2003). The linearity of the method including extraction was evaluated between 10 and 80 
µmol/L for carnitine, between 0.5 and 20 µmol/L for butyrobetaine, acetylcarnitine, 
propionylcarnitine, isovalerylcarnitine, hexanoylcarnitine and octanoylcarnitine, and between 
0.25 and 10 µmol/L for palmitoylcarnitine. 
 
The recalculated calibrator concentrations with the obtained linear regression (n = 6) were 
used to validate the linearity. The results for carnitine show accuracies of 100.0 ± 0.4% and 
precisions smaller than 2.4% (Table 1). Butyrobetaine and short- and medium-chain 
acylcarnitines had precisions between 0.9 and 10.3% and accuracies between 80 and 126%, 
except for octanoylcarnitine with accuracies between 70 and 150%.  
 
 
Table 1: Validation of the linearity of the method for carnitine in calibration  
standards by recalculation of the calibrator concentrations  
   
 
Added Found  
concentration  concentration       SD          Precision (%)        Accuracy (%) 
(µmol/L)   (µmol/L)       
   
  
  10    10.0 0.2 1.9 100.1 
  30    30.1 0.7 2.4 100.3 
  40    39.9 0.3 0.8   99.7 
  50    49.7 1.2 2.3   99.4 
  60    60.2 0.4 0.7 100.4 
  80    80.1 1.0 1.2 100.1 
   
 n = 6 determinations 
 
 
Precision and accuracy data for intra- and inter-day variabilities on standard quality controls 
were obtained at three different concentrations, covering the calibration ranges used for 
carnitine, butyrobetaine, short- and medium-chain acylcarnitines (Table 2) and at two 
different concentrations for palmitoylcarnitine. For intra-day analysis, the precisions were 
between 1.4 and 10.1% (18.6% for palmitoylcarnitine), whereas the values for inter-day 
precisions varied between 1.0 and 11.0% (22.5% for palmitoylcarnitine). Accuracies were 
between 85.5% (78 and 68% for the low concentration of propionylcarnitine and 
octanoylcarnitine, respectively) and 104.8% for intra-day analysis, and between 80.4% (77 
and 68% for the low concentration of propionylcarnitine and octanoylcarnitine, respectively) 
and 108.4% (119% for palmitoylcarnitine) for inter-day assays. 
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Table 2: Intra- and inter-day variabilities of standards quality controls for free carnitine 
and short- and medium-chain acylcarnitines 
 
         
 
 
 C1 AC BB PC IVC HC OC 
Concentration ranges (µmol/L) 10-80 0.5-20 0.5-20 0.5-20 0.5-20 0.5-20 0.5-20 
Concentration  (µmol/L)        
    QC2 low 15 1.5 1.5 1.5 1.5 1.5 1.5 
    QC medium 35 8.0 8.0 8.0 8.0 8.0 8.0 
    QC high 55   15   15   15   15   15   15 
         
         
Inter-day  (n=5)        
    QC low Precision (%) 4.0 4.0       2.7 2.4 6.3     11.0 3.5 
 Accuracy (%) 95.9 89.7   103.3 77.3 85.4     80.4 67.6 
    QC medium Precision (%) 1.0 4.2       2.0 3.5 2.7       3.8 3.4 
 Accuracy (%) 102.1 84.7     92.2 81.6 101.6   108.4 95.7 
    QC high Precision (%) 1.9 5.4       2.5 4.0 2.7       6.8 1.9 
 Accuracy (%) 100.1 92.4     92.4 95.4 96.4   102.3 98.4 
         
         
Intra-day  (n=5)        
    QC low Precision (%) 2.6 3.6       1.4 2.8 3.6       2.5 5.7 
 Accuracy (%) 97.1 85.5   104.8 77.8 87.1     94.1 68.3 
    QC medium Precision (%) 1.8 5.3       2.9 1.6 2.5       2.8 1.6 
 Accuracy (%) 102.2 92.2     93.4 78.4 98.3     99.8 96.3 
    QC high Precision (%) 1.8 3.1       1.5 10.1 5.6       3.3 1.8 
 Accuracy (%) 102.0 99.1     95.0 102.9 95.1     94.5 100.6 
         
1
 C = carnitine, AC = acetylcarnitine, BB = butyrobetaine, PC = propionylcarnitine, IVC = isovalerylcarnitine,  
  HC = hexanoylcarnitine, OC = octanoylcarnitine 
2
 QC = quality control 
 
 
Table 3: Intra- and inter-day variabilities of plasma quality controls for free carnitine and 
short- and medium-chain acylcarnitines 
 
         
  C1 AC BB PC IVC HC OC 
         
         
Concentration ranges (µmol/L) 10-80 0.5-20 0.5-20 0.5-20 0.5-20 0.5-20 0.5-20 
Concentration  (µmol/L)        
   QC2 unspiked    0    0    0    0    0    0    0 
   QC low  15 1.5 1.5 1.5 1.5 1.5 1.5 
   QC medium  35 8.0 8.0 8.0 8.0 8.0 8.0 
         
         
Inter-day  (n=10)        
   QC unspiked Precision (%)     3.4 13.4       11.9       3.2 nd3        nd nd 
 Accuracy (%)      nd nd          nd        nd nd        nd nd 
   QC low Precision (%)     3.0 4.6         6.9       7.3 13.7     20.5 9.74 
 Accuracy (%)   97.6 124.6     119.3     70.5 100.0     60.5 58.24 
   QC medium Precision (%)     2.8 8.8         7.3       8.2 7.8     25.3 32.6 
 Accuracy (%) 109.0 107.6     105.6     96.8 129.9     88.3 73.8 
         
         
Intra-day  (n=10)        
   QC unspiked Precision (%)     2.9 4.0         8.1         nd nd        nd nd 
 Accuracy (%)     nd  nd          nd         nd nd        nd nd 
   QC low Precision (%)     2.2 9.5         6.5        7.4 2.8       3.6 1.0 
 Accuracy (%)   95.2 77.0       93.9    114.9 114.8     97.6 60.0 
   QC medium Precision (%)    2.2 7.9         6.0        4.6 7.9       5.6 3.5 
 Accuracy (%)   98.3 109.2     106.2    101.3 121.3   116.3 102.1 
         
1
 C = carnitine, AC = acetylcarnitine, BB = butyrobetaine, PC = propionylcarnitine, IVC = isovalerylcarnitine,  
  HC = hexanoylcarnitine, OC = octanoylcarnitine 
2
 QC = quality control 
3
 nd: not determined 
4
 n = 6 
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Precision and accuracy data for intra- and inter-day assays on plasma quality controls were 
obtained at three different concentrations, a blank plasma (unspiked) and 2 different 
concentrations covering the respective calibration ranges (Table 3). Mean inter-day 
concentrations measured in blank plasma were 34.3 µmol/L for carnitine, 5.35 µmol/L for 
acetylcarnitine, 0.76 µmol/L for butyrobetaine, and 0.65 µmol/L for propionylcarnitine, 
whereas isovalerylcarnitine, hexanoylcarnitine, and octanoylcarnitine were below the 
quantification limits. Precisions were between 1.0 and 9.5% for intra-day analysis of 
carnitine, short- and medium-chain acylcarnitines, and between 2.8 and 13.7% (except 25 
and 33% for hexanoylcarnitine and octanoylcarnitine, respectively) for inter-day assays. For 
intra-day analysis, the accuracies were between 77.0% (60% for octanoylcarnitine) and 
116.3% (121% for isovalerylcarnitine). The values for inter-day precisions were between 
70.3% (61 and 58% for hexanoylcarnitine and octanoylcarnitine, respectively) and 129.9%. 
The long-chain acylcarnitines (myristoylcarnitine, palmitoylcarnitine and stearoylcarnitine) 
were determined only qualitatively (see Figure 3), but not quantified. 
 
All the most relevant compounds, namely carnitine, butyrobetaine, acetylcarnitine and 
propionylcarnitine exhibit acceptable precisions and accuracies for intra- and inter-day 
assays in standards and in plasma quality controls. Medium chain acylcarnitines present 
more imprecision, especially at low concentrations in plasma quality controls. This could be 
explained by the fact that medium chain acylcarnitines are partially bound to plasma protein 
(Marzo et al., 1991) and that their extraction could have been affected by the protein 
precipitation step. Since the method will be used primarily for the diagnosis of patients with 
metabolic disorders, semi-quantitative determination of medium- and long-chain 
acylcarnitines is sufficient (see below). 
 
 
4.4.5 Application to a serum sample from a patient with a metabolic disorder 
 
Figure 3 represents on the panel A a chromatogram obtained from a plasma of a healthy 
person. This shows the typical carnitine profile with predominant peaks of carnitine (peak 1) 
and acetylcarnitine (peak 3). Butyrobetaine (peak 2) and other acylcarnitines can also be 
detected.  The panel B of Figure 3 depicts a chromatogram of a serum from a patient 
suffering from methylmalonic academia (MMA). As expected, the propionylcarnitine level 
(peak 4) is clearly increased in this plasma. 
HPLC-MS/MS analysis of plasma samples 
 103 
 
 
 
 
 
Figure 3: Total ion current trace of a control plasma (A) and serum of a patient with methylmalonic aciduria (B). 
The samples were extracted and analyzed as described in the Experimental section. The traces obtained for 
carnitine and for short- and medium-chain acylcarnitines were combined with the ones obtained for long-chain 
acylcarnitines (2 different traces resulting from 2 different injections): 1, carnitine; 2, butyrobetaine;  
3, acetylcarnitine; 4, propionylcarnitine; 5, isovalerylcarnitine; 8, myristoylcarnitine; 9, palmitoylcarnitine;  
10, stearoylcarnitine. The inserts show an expended view of final parts of the respective chromatograms. As 
expected, the patient has an increased peak for propionylcarnitine. 
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4.5 CONCLUSION 
 
In the present paper we present the application of a reversed-phase high-performance liquid 
chromatography with MS/MS detection for the determination of carnitine, its biosynthetic 
precursor butyrobetaine, and eight short-, medium- and long-chain acylcarnitines. The 
method could successfully be validated for standards and plasma quality controls, using a 
bovine serum albumin 4% in water as a calibration matrix. A metabolic disorder with a 
pathological acylcarnitine profile could be successfully diagnosed. 
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5.1  SUMMARY 
 
Background: The current study was performed to investigate the kinetics of carnitine, 
individual acylcarnitines and butyrobetaine in patients on hemodialysis. 
Methods: Seven stable long-term hemodialysis patients were studied under basal conditions 
(no carnitine supplementation) and 3 weeks after i.v. supplementation with L-carnitine (10 or 
20 mg/kg body weight) after each hemodialysis session. The kinetic studies included serial 
determinations of carnitine and metabolites just before, during or between hemodialysis 
sessions. Analysis was performed by HPLC-MS/MS. 
Results: Before hemodialysis, the plasma concentrations were (µmol/L) 15.1 ± 1.4 for 
carnitine, 5.9 ± 1.7 for acetylcarnitine, 0.66 ± 0.13 for propionylcarnitine and 0.96 ± 0.25 for 
butyrobetaine (basal conditions), and 147 ± 68 for carnitine, 73 ± 35 for acetylcarnitine, 6.3 ± 
3.3 for propionylcarnitine and 2.6 ± 0.8 for butyrobetaine (carnitine 20 mg/kg). During 
hemodialysis, the plasma concentrations dropped by approximately 80% for all compounds 
determined, with extraction coefficients ranging from 0.81 to 0.87. In patients supplemented 
with 20 mg/kg carnitine, the amount of carnitine removed by hemodialysis equaled 56% of 
the administered dose, consisting of 3.08 mmol carnitine, 1.47 mmol acetylcarnitine and 
0.070 mmol propionylcarnitine. Between the hemodialysis sessions, carnitine, acylcarnitines 
and butyrobetaine reached steady state concentrations within 1 day both under basal 
conditions and after supplementation. 
Conclusions: Patients on hemodialysis have reduced carnitine, acylcarnitine and 
butyrobetaine plasma levels, which can be normalized or increased by supplementing 
carnitine. Propionylcarnitine is an important constituent of the acylcarnitine pool, which can 
be removed by hemodialysis. Removal of potentially toxic acyl-groups may represent a 
mechanism for the beneficial effect of carnitine in these patients. 
 
 
5.2  INTRODUCTION 
 
Carnitine (L-3-hydroxy-4-N-trimethylaminobutyrate) is an endogenous compound present in 
most mammalian tissues, which is ingested by the diet and produced endogenously by 
biosynthesis. Carnitine is an essential factor for transport of long-chain fatty acids into the 
mitochondrial matrix, where they are metabolized via β-oxidation (Fritz, 1955; Bremer, 1983). 
By reacting with activated fatty acids, carnitine can generate various acylcarnitines with 
different chain lengths. By accepting acyl-groups from acyl-CoAs, carnitine is also involved 
in the regulation of the cellular pool of free coenzyme A (CoASH), thus acting as a buffer 
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(Brass and Hoppel, 1980; Bieber et al., 1982). This buffer effect may be important for the 
detoxification and elimination of potentially toxic acyl-groups, originating from exposure to 
xenobiotics or from blockage of metabolic pathways. In contrast to acyl-CoAs, the 
corresponding acylcarnitines can be excreted in the urine (Bremer, 1983; Roe et al., 1983). 
 
In healthy subjects, carnitine and acetylcarnitine represent the major constituents of the body 
fluid and tissue carnitine pools (Bremer, 1983; Friolet et al., 1994). Skeletal muscle contains 
more than 95% of the total carnitine body stores, and the tissue concentrations are 
considerably higher than the concentration in plasma (Friolet et al., 1994), necessitating 
active transporter into tissues. Kidneys play a crucial role in carnitine homeostasis, since 
they reabsorb more than 90% of the filtered carnitine (Krahenbuhl and Reichen, 1997), so 
that the plasma levels of free carnitine are maintained at 37±8 µmol/L (Hoppel, 1991). 
 
Since carnitine is a small molecule (molecular weight = 161.2), and not protein-bound, it is 
efficiently removed from blood through the dialyzer membrane (Evans, 2003). Patients with 
end-stage renal disease undergoing long-term hemodialysis have therefore reduced carnitine 
plasma (Bellinghieri et al., 1983; Rodriguez-Segade et al., 1986a; Wanner et al., 1990; Hiatt 
et al., 1992; Evans et al., 2000) and muscle levels (Bellinghieri et al., 1983; Hiatt et al., 
1992), and may suffer from complications similar to those observed in patients with carnitine 
deficiency, e.g. skeletal muscle weakness and pain, intradialytic cramps and hypotensive 
episodes or impaired exercise performance (Bellinghieri et al., 2003; Evans, 2003). Relative 
to the decreased carnitine, acylcarnitines are increased, so that the acylcarnitine to total 
carnitine ratio (free carnitine plus acylcarnitines) is higher than in healthy subjects 
(Rodriguez-Segade et al., 1986a; Wanner et al., 1990; Hiatt et al., 1992; Evans et al., 2000). 
Supplementation with carnitine, either orally or intravenously, at the end of hemodialysis has 
been shown to increase the carnitine plasma concentration (Bellinghieri et al., 1983; Wanner 
et al., 1990; Siami et al., 1991; Evans et al., 2000) and carnitine skeletal muscle 
concentration (Bellinghieri et al., 1983; Siami et al., 1991). Despite the fact that carnitine 
supplementation is clearly associated with an increase in carnitine plasma and tissue levels, 
carnitine administration has been shown to be associated with clinical improvement of 
muscular symptoms only in some (Bellinghieri et al., 1983; Ahmad et al., 1990; Sakurauchi et 
al., 1998) but not in all studies or patients (Hurot et al., 2002). In several studies, the 
metabolism of carnitine in patients on long-term hemodialysis has been investigated. Most of 
them were restricted to the observation of free and acylcarnitines (Leschke et al., 1983; 
Rumpf et al., 1983; Panzetta et al., 1985), but in some studies, the acylcarnitines were 
differentiated (Jackson and Lee, 1996; Evans et al., 2000). In one recent study, the plasma 
concentration of carnitine, acetylcarnitine and total carnitine was investigated in patients on 
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hemodialysis before and after intravenous supplementation of different doses of carnitine 
(Evans et al., 2000). 
 
In the current study, we investigated the composition of the plasma carnitine, acylcarnitine 
and butyrobetaine pools in patients on long-term hemodialysis under baseline conditions and 
during intravenous supplementation with two different doses of carnitine. The kinetics of 
carnitine, individual acylcarnitines and butyrobetaine were evaluated during and between 
hemodialysis sessions. The analytical method utilized was HPLC-MS/MS (Vernez et al., 
2003), which allows the quantification of all analytes mentioned above. We were particularly 
interested to answer the question which acylcarnitines other than acetylcarnitine accumulate 
in the plasma of patients on long-term hemodialysis and how the plasma butyrobetaine pool 
is influenced by the administration of carnitine. 
 
 
5.3  EXPERIMENTAL 
 
The study was approved by the Ethics Committee of the Cantons of Basel and patients 
provided written informed consent before the start of the study. 
 
 
5.3.1  Study population 
 
Patients aged between 20 and 80 years were recruited at the dialysis center of the University 
Hospital of Basel. Enrolment requirements included treatment with hemodialysis three times 
a week for more than 6 months and the absence of acute illnesses. Patients already 
supplemented with carnitine, either orally or intravenously, were also excluded from the 
study. 
Seven patients, 3 women and 4 men, with a mean age of 59 years (see details in Table 1) 
were included. They underwent 3 hemodialysis sessions per week with a duration of 240 
minutes and a dialysate flow of 0.5 L/min. A HF 80 dialysis membrane (Fresenius, Bad 
Homburg, Germany), the most commonly used membrane in our dialysis center, was utilized 
for all patients.  
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Table 1: Characterization of the patients that completing the study. Patients 1, 5 and 7 were 
recruited for intra- and inter-dialysis kinetics (see Table 2) 
 
 
 
5.3.2  Study design 
 
The study was performed over 7 weeks (21 hemodialysis sessions) and included three 
different observation periods. During the first week (hemodialysis sessions 1, 2 and 3), 
patients were studied under baseline conditions (no carnitine supplementation). During the 
three next weeks (hemodialysis sessions 4-12), all patients were supplemented after each 
hemodialysis session with 10 mg/kg body weight carnitine i.v. (low carnitine supplementation). 
During the last three weeks (hemodialysis sessions 13-21), carnitine supplementation was 
increased to 20 mg/kg body weight carnitine i.v. (high carnitine supplementation). Carnitine 
(Carnitene sigma-tau®, Sigma-Tau Pharma AG, Zofingen, Switzerland) was administered by 
slow injection using the venous line installed for hemodialysis, just before it was removed at 
the end of the hemodialysis session. After the administration of carnitine, the line was flushed 
with saline. Blood samples were collected in 2 mL heparinized tubes which were centrifuged 
and the plasma was removed and stored in polystyrene tubes at -200C until analysis. 
 
 
5.3.3  Steady state carnitine and acylcarnitines profiles between hemodialysis sessions 
 
To establish the carnitine and acylcarnitine profiles over the entire study period, blood 
collections were performed in all patients twice under baseline conditions (before 
hemodialysis sessions 1 and 3), thrice under low carnitine supplementation (before 
hemodialysis sessions 6, 9 and 12) and thrice under high carnitine supplementation (before 
hemodialysis sessions 15, 18 and 21). Thus, the first blood samples collections under the 
 
 
Patient 
 
 
Sex 
 
Age 
(year) 
 
Urine 
production  
per day (ml) 
 
 
Target 
weight  
(kg) 
 
Dialysis  
blood flow  
rate (L/min) 
 
Carnitine  
dose (mmol) 
for 10 mg/kg 
 
1 
 
female 
 
46 
 
0 
 
59.0 
 
0.30 
 
3.663 
2 male 75 200 83.5 nr2 5.17 
3 male 38 50 66.0 nr 4.08 
4 female 60 0 76.0 nr 4.69 
5 female 59 0 72.51 0.30 4.39 
6 male 57 650 75.5 nr 4.69 
7 male 76 800 74.5 0.30 4.65 
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respective supplementation conditions were performed after 3 administrations of the 
respective carnitine dosage. All samples were withdrawn immediately before the respective 
hemodialysis session was started. 
 
 
5.3.4  Carnitine and acylcarnitines kinetics during hemodialysis sessions (intra-dialysis) 
 
Intra-dialysis kinetics of carnitine was studied in 3 patients (patients 1, 5 and 7) under 
baseline conditions (session 3), after 3 weeks of low carnitine supplementation (session 12) 
and after 3 weeks of high carnitine supplementation (session 21). Blood samples were 
collected before hemodialysis was started, during and at the end of hemodialysis. During 
hemodialysis, arterial blood (blood entering in the dialysis system), venous blood (blood 
leaving the dialysis system) and 10 mL dialysate were collected at 10, 30, 60, 120 and 180 
minutes after beginning hemodialysis. The arterial blood was obtained just before the venous 
one, and the dialysate was collected just after the blood samples had been obtained. 
 
 
5.3.5 Carnitine and acylcarnitines kinetics between two hemodialysis sessions (inter- 
          dialysis) 
 
Inter-dialysis kinetics of carnitine were studied on 3 patients (patients 1, 5 and 7) under 
baseline conditions (between sessions 2 and 3) and at the end of the study (between 
sessions 20 and 21, after 3 weeks of treatment with 20 mg/kg carnitine). Blood samples were 
collected before the start of hemodialysis, immediately after hemodialysis had been 
completed (for session 20, just before carnitine was administered) and 5, 10, 15, 20, 30, 45 
minutes and 1, 2, 4, 6, 20 and 44 hours after carnitine had been administered. At the end of 
hemodialysis, the venous line was kept open during 6 hours for the collection of blood. The 
20 hours blood sample was performed by venopuncture, and the 44 hours collection time 
point corresponded to the beginning of the next hemodialysis session. Patients received a 
vegetarian meal between the blood collections at 1 and 2 hours. 
 
 
5.3.6  Analysis of carnitine and acylcarnitines 
 
Carnitine, the different acylcarnitines and butyrobetaine present in plasma and dialysate 
samples were analyzed by high-performance liquid chromatography - tandem mass 
spectrometry (HPLC-MS/MS) according to a method published previously for urine and 
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adapted for plasma (Vernez et al., 2003). Briefly, samples were subjected to a solid phase 
extraction on a cation-exchange column and separation was performed using a reversed-
phase column in the presence of a volatile ion-pairing reagent. Detection was carried out 
using an ion-trap mass spectrometer run in the MS/MS mode. The method linearity was 
between 10-80 µmol/L for carnitine and 0.5-20 µmol/L for acetylcarnitine, propionylcarnitine, 
isovalerylcarnitine and butyrobetaine. Inter-day and intra-day plasma quality controls had 
precisions ranging from 2.2 to 13.7% and accuracies between 70.5 and 129.9%, for both 
carnitine and acylcarnitines.  
Plasma samples having high carnitine and acetylcarnitine levels were diluted up to 40 fold 
with a 4% bovine serum albumin solution in water before analysis in order to reach the 
calibration range. Modified calibration ranges for carnitine (between 5-60 µmol/L) were used 
for the analysis of samples containing a low carnitine concentration. 
The acylcarnitine concentration used to calculate total carnitine (sum of free and 
acylcarnitine) and the acylcarnitine to total carnitine ratios was obtained by summing the 
concentration of each individual acylcarnitine. 
 
 
5.3.7  Statistics and pharmacokinetic analysis 
 
Data are presented as mean ± SEM unless stated otherwise. Kinetics of carnitine, 
acylcarnitine and butyrobetaine in the inter-dialysis period were analyzed under baseline 
conditions (between hemodialysis sessions 2 and 3) and after 3 weeks of supplementation 
with 20 mg/kg body weight carnitine (between hemodialysis sessions 20 and 21). The area 
under the curve from time zero to 44 hours (AUC0-44) was determined with the linear 
trapezoidal rule using TopFit software (Tanswell and Koup, 1993). The baseline corrected 
AUC was calculated by subtracting the AUC obtained under baseline conditions from the 
corresponding AUC after carnitine substitution. 
The intra-dialysis period was evaluated under baseline conditions (hemodialysis session 3), 
after 3 weeks treatment with 10 mg/kg body weight carnitine (hemodialysis session 12) and 
after 3 weeks supplementation with 20 mg/kg body weight carnitine (hemodialysis session 
21). The extraction coefficient (E) was calculated as follows:  
 
E = Cpre – Cpost   (1) 
 Cpre 
where Cpre is the concentration of the analyte in arterial blood (entering the dialysis system) 
at the start of hemodialysis and Cpost the concentration in the arterial blood at the end of 
hemodialysis.  
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Alternatively, E was calculated as: 
 
E’ = Cart – Cven   (2) 
 Cart 
where Cart is the arterial and Cven the venous concentration at a given time point. Since the 
values for E and the average of E’ (average of several determinations during hemodialysis) 
were not different, E is given in Table 2 and was used for the following calculations. 
The clearance by hemodialysis was calculated as: 
 
Clh = Q x E    (3) 
Where Q is the hemodialysis blood flow (Table 1) and E the extraction coefficient (equation 
1). 
The amount of carnitine and acylcarnitines eliminated by hemodialysis (Ah) was calculated as 
follows: 
   Ah = AUCart; 0-240 x Clh   (4) 
with AUCart; 0-240 being the area under the curve in arterial blood from time zero until 
completion of hemodialysis after 240 minutes. 
 
 
5.4  RESULTS 
 
Using a sensitive HPLC-MS/MS method, we investigated the intra- and inter-dialysis kinetics 
of carnitine in patients with chronic renal failure treated by hemodialysis under baseline 
conditions and during treatment with different amounts of intravenous carnitine. Under 
baseline conditions, all patients had lower free carnitine plasma concentrations as compared 
to patients without renal disease (Hoppel, 1991; Krahenbuhl and Reichen, 1997), ranging 
from 12.8 to 16.4 µmol/L. The acylcarnitine to carnitine ratio was 0.42 ± 0.09 (range 0.33 and 
0.59), a value which is higher than observed in healthy persons (Hoppel, 1991; Krahenbuhl 
and Reichen, 1997). Acetylcarnitine was the prominent short-chain acylcarnitine, but 
propionylcarnitine was also detectable in 4 patients and isovalerylcarnitine in one patient. 
The carnitine precursor butyrobetaine could be found in the plasma of all patients at a 
concentration of 0.96 ± 0.25 µmol/L (range 0.66 – 1.30 µmol/L). 
 
 
5.4.1  Carnitine and acylcarnitines profiles 
 
The evolution of the carnitine and acylcarnitine pools over the entire study is depicted in 
Figure 1. After 1 week of supplementation with 10 mg/kg carnitine (low dosage) at the end of 
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each hemodialysis session, the carnitine pre-dialysis concentration increased in all patients 
between 130 to 440 % as compared to baseline (mean plasma concentration 40.4 ± 16.1 
µmol/L, range 21.1 – 70.8). The acetylcarnitine concentration increased from 5.9 ± 1.7 to 
18.0 ± 9.1 µmol/L, propionylcarnitine from 0.66 ± 0.13 to 1.20 ± 0.63 µmol/L and 
butyrobetaine from 0.96 ± 0.25 to 1.78 ± 0.72 µmol/L. Propionylcarnitine was detectable in 
the plasma of 2 patients and isovalerylcarnitine in 1 patient. After 3 weeks of low dosage 
carnitine supplementation, the carnitine, acetylcarnitine and propionylcarnitine plasma levels 
had further increased in most patients, while the isovalerylcarnitine and butyrobetaine levels 
remained constant. After one week of carnitine supplementation at low dosage, the 
acylcarnitine to carnitine ration had reached a value of 0.46 ± 0.11, which dropped to 0.41 ± 
0.07 at the end of the low carnitine supplementation period.  
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Figure 1: Pre-dialysis plasma concentrations of carnitine, acylcarnitines and butyrobetaine. Values are 
expressed as mean ± standard error, n = 7 patients. Analysis was performed by HPLC-MS/MS as described 
in Methods. A: carnitine ( ) and acetylcarnitine (ο). B: propionylcarnitine (x), isovalerylcarnitine (+) and 
butyrobetaine (∆). 
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After one week of supplementation with 20 mg/kg carnitine (high dosage) at the end of each 
hemodialysis, the carnitine plasma concentration showed a further increase by a factor of 
1.94 ± 0.51 (range 1.28 to 2.62), reaching values between 46 and 186 µmol/L. Similar to 
carnitine, acetylcarnitine increased by a factor of 2.17 ± 0.49 (range 1.30 to 2.74), 
propionylcarnitine by a factor of 2.75 ± 0.96 (range 1.56 to 3.98), and butyrobetaine by a 
factor of 1.39 ± 0.23 (1.09 to 1.68). Isovalerylcarnitine appeared in the plasma of 2 more 
patients. At the end of the study, after 3 weeks of high dose carnitine supplementation, 6 
patients showed further increases in their carnitine levels, reaching concentrations between 
78-229 µmol/L. In contrast, patient number 4 showed a constant carnitine plasma 
concentration at 48 µmol/L over the entire 3 weeks of high dose carnitine supplementation. 
Further increases were also observed for acetylcarnitine, propionylcarnitine and 
isovalerylcarnitine, reaching plasma concentrations of 72.5 ± 35.0 µmol/L, 6.30 ± 3.30 µmol/L 
and 0.92 ± 0.26 µmol/L, respectively. The mean plasma concentration of butyrobetaine 
reached 2.58 ± 0.85 µmol/L at the end of the high supplementation period. After one week of 
carnitine supplementation at high dosage, the acylcarnitine to carnitine ratio had reached a 
value of 0.48 ± 0.13, which increased to 0.52 ± 0.10 at the end of the high carnitine 
supplementation period. 
 
 
5.4.2  Intra-dialysis kinetics 
 
The plasma concentration time curves for carnitine, acylcarnitines and butyrobetaine are 
given in Figure 2. As known from previous studies (Evans et al., 2000), carnitine and 
acetylcarnitine can be removed efficiently by hemodialysis. As could be expected, this is also 
the case for propionylcarnitine and butyrobetaine (see Figures 2B and 2C). For carnitine, 
acylcarnitines and butyrobetaine, new steady state plasma concentrations are reached after 
2 to 3 hours of hemodialysis. This steady state concentration is 50 to 80% lower for all 
analytes than the respective pre-dialysis plasma concentrations, indicating an efficient 
removal by hemodialysis. 
The kinetic analysis of the plasma concentration-time curves during hemodialysis allowed the 
calculation of the extraction (E) by hemodialysis, hemodialytic clearance (Clh) and the 
amount of analytes removed by hemodialysis (Ah) (see Table 2). These calculations show 
that supplementation with carnitine is associated with a dose-dependent removal of acyl-
groups by hemodialysis. 
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Figure 2: Kinetics of carnitine, acylcarnitines and butyrobetaine during hemodialysis (intra-dialysis). Values are 
expressed as mean ± standard error, n = 3 patients. Analysis was performed by HPLC-MS/MS as described in 
Methods. A: Baseline conditions (hemodialysis session 3), B: During supplementation with 10 mg/kg body 
weight carnitine (hemodialysis session 12), C: During supplementation with 20 mg/kg body weight carnitine 
(hemodialysis session 21). Symbols are: carnitine ( ), acetylcarnitine (ο), propionylcarnitine (x) and 
butyrobetaine (∆). 
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Table 2: Kinetics for carnitine, acylcarnitines and butyrobetaine during and between hemodialysis 
sessions. Values are expressed as mean ± standard error, n = 3 patients. Kinetic calculations were 
performed as described in Methods. 
 
 
     Carnitine  Acetylcarnitine Propionylcarnitine Butyrobetaine 
  
 
Intra-dialysis  
No substitution 
AUCart; 0-240min (µmol/L x h)  24.9 ± 2.60 7.65 ± 1.06         nd2  2.123 
CLh (L/h)   10.5 ± 0.15 12.4 ± 1.21         nd  10.73 
E     0.585 ± 0.008 0.689 ± 0.067         nd  0.5943 
Ah1 (mmol)   0.264 ± 0.031 0.098 ± 0.008         nd  0.0233 
 
10 mg/kg carnitine 
AUCart; 0-240min (µmol/L x h)  64.25 ± 3.31 25.14 ± 0.76       2.863 3.45 ± 0.154 
CLh (L/h)   13.52 ± 0.83 14.32 ± 0.67      11.033 14.07 ± 0.46 
E     0.751 ± 0.046 0.795 ± 0.037      0.6133 0.782 ± 0.0254 
Ah1 (mmol)   0.920 ± 0.091 0.387 ± 0.002      0.0473 0.049 ± 0.0044 
 
20 mg/kg carnitine 
AUCart; 0-240min (µmol/L x h)  189.8 ± 33.7 90.79 ± 23.82 4.92 ± 0.21 3.37 ± 0.42 
CLh (L/h)   14.50 ± 0.41 15.32 ± 0.31 14.00 ± 1.51 14.42 ± 0.27 
E     0.806 ± 0.023 0.851 ± 0.017 0.778 ± 0.084 0.801 ± 0.015 
Ah1 (mmol)   3.077 ± 0.282 1.473 ± 0.270 0.070 ± 0.010 0.052 ± 0.008 
 
 
 
Inter-dialysis  
 
AUC0-44h (µmol/L x h) – no substitution 537.8 ± 49.8 201.9 ± 28.9       nd  45.0 ± 10.4 
AUC0-44h (µmol/L x h) – 20 mg/kg carnitine 9228 ± 1475 2691 ± 569 240.8 ± 52.6 107.6 ± 26.5 
Baseline-corrected AUC0-44h (µmol/L x h) 8691 ± 1494 2489 ± 558 240.8 ± 52.6 62.6 ± 16.6 
 
1: Amount excreted in urine of patient 7 is included 
2: nd: could not be determined 
3: n=1 
4: n=2 
 
 
5.4.3  Inter-dialysis kinetics 
 
At the end of hemodialysis, the plasma levels of all analytes were reduced by 50-80% as 
compared to pre-dialysis values (see Figure 2). When carnitine was not supplemented, 
carnitine, acetylcarnitine and butyrobetaine plasma concentrations started to increase 
already 5 minutes after the end of hemodialysis (Figure 3A). This increase was more marked 
during the first 6 hours after hemodialysis, and steady-state concentrations were reached 
after 8 to 24 hours.  
In patients supplemented with 20 mg/kg carnitine, the plasma carnitine concentration 
reached 1340 ± 550 µmol/L 5 minutes after intravenous administration of carnitine (see 
Figure 3B). After having reached the peak concentration, the plasma carnitine concentration 
decreased with a half-life of approximately 2 hours, reaching steady state concentrations 8 to 
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24 hours after injection. After intravenous administration of carnitine, the plasma 
concentrations of acetylcarnitine, propionylcarnitine and butyrobetaine increased rapidly, 
reaching steady state concentration after 8 hours (see Figure 3B). In patient number 1, 
isovalerylcarnitine was also detected and showed a similar kinetic behavior as the other 
acylcarnitines. 
The AUCs for the inter-dialysis period obtained without carnitine supplementation and after 3 
weeks of supplementation with 20 mg/kg are given in Table 2. In comparison to baseline, the 
AUCs increased by a factor of 17.7 ± 7.0 for carnitine, 13.5 ± 5.4 for acetylcarnitne and 2.4 ± 
0.3 for butyrobetaine during supplementation with carnitine. 
 
 
 
Figure 3: Kinetics of carnitine and acylcarnitines between two hemodialysis sessions (inter-dialysis). Values are 
expressed as mean ± standard error, n = 3 patients. Analysis was performed by HPLC-MS/MS as described in 
Methods. A: Baseline conditions between hemodialysis sessions 2 and 3 (no carnitine supplementation), B: 
Supplementation with 20 mg/kg body weight carnitine between hemodialysis sessions 20 and 21. Symbols are: 
carnitine ( ); acetylcarnitine (ο), propionylcarnitine (x) and butyrobetaine (∆). 
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5.5  DISCUSSION 
 
Our study demonstrates that patients on long-term hemodialysis have reduced plasma 
carnitine concentrations before and after hemodialysis, that carnitine, acylcarnitines and 
butyrobetaine are removed by hemodialysis and that the plasma carnitine and butyrobetaine 
levels can be increased to physiological or even supraphysiological levels by 
supplementation of carnitine following each hemodialysis session.  
 
Under baseline conditions, all patients investigated were carnitine-deficient with a mean 
plasma free carnitine concentration of 15.0 ± 1.4 µmol/L, which is well below the normal 
range of 37±8 µmol/L (Hoppel, 1991). The acylcarnitine to free carnitine ratio was 0.42 ± 
0.09, indicating a redistribution of the plasma carnitine pool towards acylcarnitines (Hoppel, 
1991; Krahenbuhl and Reichen, 1997). Acylcarnitines were mainly represented by 
acetylcarnitine, as reported in other studies (Bellinghieri et al., 1983; Jackson and Lee, 1996; 
Evans et al., 2000). Interestingly, propionylcarnitine could be detected in 4 patients with 
plasma concentrations ranging between 0.53 and 0.82 µmol/L. Propionylcarnitine has also 
been detected in plasma of healthy persons, but at lower concentrations as compared to the 
patients in our study (Minkler and Hoppel, 1993a; Inoue et al., 1999). In addition, still under 
baseline conditions, isovalerylcarnitine was present in a single patient at a level of 0.86 
µmol/L, also a higher concentration than the 0.11 ± 0.06 µmol/L reported in healthy sportive 
subjects (Inoue et al., 1999). Since acylcarnitines are formed from the respective acyl-CoAs 
(Brass and Hoppel, 1980; Bieber et al., 1982; Bremer, 1983), it can be assumed that the 
tissue concentrations of propionyl-CoA and isovaleryl-CoA are increased at least in some 
patients on long-term hemodialysis. Depending on the metabolic situation, the plasma 
carnitine profile can reflect both the carnitine pool of the liver (Sandor et al., 1990) or of 
skeletal muscle (Friolet et al., 1994). In the case of propionate, the plasma carnitine profile 
primarily reflects the liver carnitine and coenzyme A pools, because propionate degradation 
is located in liver mitochondria (Frenkel and Kitchens, 1975). It is well known that propionate 
and other short- and medium chain fatty acids can impair mitochondrial function, in particular 
mitochondrial β-oxidation (Brass et al., 1986; Brass and Beyerinck, 1988). This inhibition may 
explain increased plasma concentrations of free fatty acids in patients on long-term 
hemodialysis (Maeda et al., 1989), and suggests that removal of acyl-groups may be 
potentially beneficial for this group of patients. Since the administration of exogenous 
carnitine is not only associated with an increase in free carnitine, but also in the respective 
acylcarnitine fractions, and since acylcarnitines are removed efficiently by hemodialysis, 
carnitine supplementation is associated with an increased removal of acyl-groups by 
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hemodialysis (see Table 2). In support of our hypothesis suggesting a beneficial effect of 
carnitine on mitochondrial metabolism, carnitine supplementation has been associated with a 
drop in the plasma free fatty acid concentration in patients on long-term hemodialysis 
(Maeda et al., 1989) and with an increase in cardiac fatty acid metabolism (Sakurabayashi et 
al., 1999). In addition, beneficial results on hepatic mitochondrial function have also been 
reported in patients suffering from methylmalonic aciduria who were treated with high doses 
of carnitine (Roe et al., 1983). The administration of carnitine to patients on long-term 
hemodialysis may therefore act in two ways, namely by increasing the low carnitine levels in 
skeletal muscle (Bellinghieri et al., 1983; Spagnoli et al., 1990; Siami et al., 1991) and by 
eliminating potentially toxic acyl-groups mainly from liver. 
 
Butyrobetaine, the direct carnitine biosynthesis precursor (Vaz and Wanders, 2002), was 
present in all patients at concentrations between 0.66 and 1.30 µmol/L under baseline 
conditions. These values are below reported mean butyrobetaine plasma concentrations in 
healthy persons of 1.80 µmol/L determined by tandem mass spectrometry (Inoue et al., 
1999) or 4.66 µmol/L determined by an enzymatic assay (Sandor et al., 1988). Similar to 
carnitine, butyrobetaine is stored mainly in skeletal muscle (Krahenbuhl et al., 2000; Vaz and 
Wanders, 2002). In order to be converted to carnitine, butyrobetaine has to be transported 
from skeletal muscle into the blood and then into liver, kidney or testes, where butyrobetaine 
hydroxylase is expressed and carnitine can be synthesized (Vaz and Wanders, 2002). Since 
butyrobetaine can be removed by hemodialysis (see Table 2), patients on long-term 
hemodialysis have lower butyrobetaine plasma concentrations than healthy subjects. 
Considering that butyrobetaine is taken up actively by tissues and that the Km value of this 
transport is in the range of 5 µmol/L (Berardi et al., 1998), it can be assumed that transport 
into tissues shows an almost linear relationship with the plasma concentrations, suggesting 
that patients on hemodialysis have reduced tissue butyrobetaine concentrations. Impaired 
carnitine biosynthesis may therefore contribute to the low carnitine plasma and tissue 
concentrations (Bellinghieri et al., 1983; Rodriguez-Segade et al., 1986a; Wanner et al., 
1990; Hiatt et al., 1992; Evans et al., 2000) in patients on long-term hemodialysis. In support 
of this hypothesis, patients on long-term hemodialysis have lower plasma and tissue 
concentrations of carnitine as compared to healthy subjects despite hemodialysis removes 
less carnitine than renal excretion in healthy subjects (Leschke et al., 1983; Rumpf et al., 
1983). Our study supports the hypothesis that carnitine biosynthesis is reduced in patients on 
long-term hemodialysis and offers a possible mechanism for this assumption. 
 
Interestingly, supplementation of carnitine in patients on long-term hemodialysis is not only 
associated with an increase in plasma carnitine and acylcarnitines, but also in butyrobetaine 
Chapter 5 
 122 
(see Figure 1). How carnitine enters skeletal muscle is so far not completely clear, but it has 
to be an active transport, since the tissue concentrations are much higher than the plasma 
carnitine concentration (Bremer, 1983; Friolet et al., 1994). One possible transporter is 
OCTN2, a sodium-dependent carnitine transporter with a high expression in the kidney 
(Tamai et al., 1998). In humans, mRNA expression of OCTN2 is also high (Tamai et al., 
1998), whereas rats have a low expression of OCTN2 in skeletal muscle (Spaniol et al., 
2001). In the rat, a potential-driven transport of carnitine into skeletal muscle plasma 
membrane vesicles has been described with different substrate specificities than OCTN2, 
suggesting additional carnitine transporters (Berardi et al., 2000). The observed increase in 
the plasma butyrobetaine concentration during carnitine supplementation (see Figure 1) 
suggests the possibility that uptake of carnitine into and release of butyrobetaine from 
skeletal muscle are related with each other, possibly by an exchange mechanism similar to 
the carnitine-acylcarnitine translocase in the inner mitochondrial membrane (Indiveri et al., 
1997). In support of the existence of such an exchange mechanism, the administration of 
butyrobetaine to rats was associated with a decrease in skeletal muscle carnitine and 
increases in the carnitine plasma concentration and renal excretion (Sartorelli et al., 1989). 
 
In conclusion, our study shows that carnitine, short-chain acylcarnitines and butyrobetaine 
are removed efficiently by hemodialysis and that supplementation with exogenous carnitine 
increases the plasma concentrations of carnitine itself, but also of acylcarnitines and 
butyrobetaine in patients on long-term hemodialysis. Removal of potentially toxic acyl-groups 
as acylcarnitines by hemodialysis may explain some of the beneficial effects associated with 
the administration of carnitine in this group of patients. The increase in the plasma 
butyrobetaine concentration after carnitine supplementation may be explained by an 
exchange between carnitine and butyrobetaine across the skeletal muscle plasma 
membrane. 
 
 
Acknowledgements 
We would like to thank the entire team of the dialysis center of the University Hospital of 
Basel, who helped us to conduct this study. This work was supported by a grant of the Swiss 
National Science Foundation to S.K. (3100-59812-03/1). 
 
  
  
 
 
 
C H A P T E R  
 6 
 
 
Conclusion 
 125 
CONCLUSION 
 
Using capillary electrophoresis and high-performance liquid chromatography, we developed 
new analytical methods for the determination of endogenous carnitine, acylcarnitines and 
butyrobetaine in biological fluids. 
 
Despite the fact that carnitine is a good candidate for capillary electrophoresis analysis, this 
technique had not been widely exploited to analyze carnitine and its esters when we started 
to set up our method. Most of the available assays focused on the determination of the D- 
and L-isomers of carnitine. Some of them enabled nonetheless the separation of carnitine 
and acylcarnitines, but required up to 25 minutes to separate the medium-chain 
acylcarnitines. Our developed capillary electrophoresis assay enables the separation of 
carnitine and six short- and medium-chain acylcarnitines in standard solutions and in urine 
samples in a short analysis time, namely within 8 minutes. When setting up the assay, we did 
not include the analysis of long-chain acylcarnitines because they are usually not present in 
urine. However, further investigations, for instance increasing the SDS concentration to 
widen the detection windows and increasing the acetonitrile percentage in the running buffer 
to facilitate their solubility, would probably enable the extension of this assay towards long-
chain acylcarnitines. The detection limits of 3 µmol/L achieved for carnitine and 
acetylcarnitine are in the same range as the detection limits obtained by most HPLC and CE 
methods for the determination of these compounds and were sufficient for the quantification 
of carnitine in urine samples. Relative standard deviations of corrected area/migration time 
for intra- and inter-day assays in standard solutions were below 10% and reached 21% at the 
quantification limits.  
 
Analysis of endogenous compounds renders it impossible to obtain a biological matrix that is 
free of the substance to quantitate. Nevertheless, most published methods for the 
determination of carnitine and acylcarnitines use pooled plasma or urine samples, to which 
increasing amounts of analytes are added, as a calibration matrix (Chace et al., 1997; 
Vreken et al., 1999; Stevens et al., 2000). Because the samples to analyze may have less 
carnitine and acylcarnitines than the pooled matrix samples used for the calibration, and thus 
be out of the calibration ranges, we considered the use of water as a matrix to establish our 
quantitative data. The quantification of carnitine in urine using water or spiked urine as the 
calibration matrix yielded similar results (see chapter 3). Because of the presence of plasma 
proteins, the use of water as a calibration matrix appears to be less obvious when analyzing 
plasma samples. A solution of 4% bovine serum albumin in water as the calibration matrix 
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turned out to be suitable for the quantification of endogenous carnitine, acylcarnitines and 
butyrobetaine in plasma samples (see chapter 5). 
 
Mass spectrometry has been proven in the last years to be a powerful tool for the 
determination of carnitine and acylcarnitines, especially for the screening of metabolic 
disorders in newborns. ESI-MS/MS analysis, combined with a simple methanol extraction of 
dried blood spots samples and the absence of a chromatographic separation is used in 
screening programs. Nonetheless, because of possible matrix interferences, particularly 
when working with complex matrix such as urine, the use of previous adapted extraction and 
separation is recommended to get reliable results. 
 
The HPLC-MS/MS method that we have developed here enables the determination of 
carnitine and acylcarnitines, including long-chain acylcarnitines, in aqueous standards, urine 
and plasma samples in a short analysis time of 17 minutes. The separation of these 
compounds, which have a large span of polarities, on a reversed-phase column was 
achieved by the addition of an ion-pairing reagent into the mobile phases and has the 
advantage that pre-column derivatization is not necessary. More interestingly, butyrobetaine, 
the direct carnitine biosynthesis precursor, can be determined during the same analysis.  
 
The assay exhibits sufficient sensitivity, precision and accuracy to quantify carnitine, short-
chain acylcarnitines and butyrobetaine in urine and plasma samples. The precision for these 
determinations (below 10%) is similar to those obtained with other MS/MS assays.  
Medium-chain acylcarnitines could not be determined with enough sensitivity to enable their 
determination in plasma and urine samples, but could be quantified in aqueous standard 
solutions, in spiked urine and spiked plasma samples with precision similar to those obtained 
for short-chain acylcarnitines. As presented in chapter 3, this assay allows the identification, 
in a non-invasive way, of medium-chain acylcarnitines in urine samples from patients 
suffering from MCAD deficiency, thus enabling the diagnosis of metabolic disorders.  
In order to apply the developed assay for the quantitative determination of long-chain 
acylcarnitines in plasma, further investigations would be necessary, principally to improve the 
recovery of 40% we achieved with liquid-liquid extraction. Unfortunately we did not have 
access to plasma samples from patients having increased long-chain acylcarnitines to 
assess the ability of our plasma assay for the qualitative identification of pathological profile. 
But, as long-chain acylcarnitines could be determined in spiked plasma samples, we can 
reasonably presume, that such qualitative determinations are possible. 
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The qualitative detection of metabolic disorders using the developed HPLC-MS/MS method 
was shown to be feasible. Nonetheless, an access to more samples from patients with 
abnormal carnitine metabolism should be provided and a comparative study with the other 
methods used for screening should be performed before our assay can be used in a routine 
manner for the quantitative detection of metabolic disorders. 
 
Our quantitative results were produced using an ion trap mass spectrometer in selected-
reaction monitoring mode. As it is known that triple quadrupole mass spectrometers display 
improved sensitivity in selected-reaction monitoring mode, it would be interesting to compare 
the detection limits which could be achieved when using such a mass spectrometer coupled 
with our HPLC separation. This could be a way of increasing sensitivity towards the 
determination of medium- and long-chain acylcarnitines in plasma samples.  
 
As described in chapter 5, the developed HPLC-MS/MS method could successfully be used 
for the quantitative determination of carnitine, short-chain acylcarnitines and butyrobetaine 
profiles in the plasma of patients under hemodialysis. The effects of the dialysis process on 
the plasma concentrations of these compounds could be evaluated. Additionally, the 
distribution of the plasma acylcarnitine pools in these patients and the outcome of carnitine 
supplementation on carnitine, acylcarnitines and butyrobetaine plasma levels could be 
assessed. 
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